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The techniques of hypophysial portal blood collection and
radioimmunoassay were used to examine the relationships between and
the relative importance of corticotrophin-releasing hormone (CRH),
vasopressin (AVP) and oxytocin (OT) in stimulating the secretion of
adrenocorticotrophin (ACTH) in vivo. Factors affecting synthesis
of pro-opiomelanocortin (POMCT, the precursor for ACTH, were
examined by measuring the content of POMC mRNA in the anterior
pituitary gland by Northern blot analysis.
After adrenalectomy, there is an increase in the release of CRH
and AVP into portal blood and an increase in the synthesis and
secretion of ACTH. Dexamethasone injection decreased the release
of AVP into portal blood collected 3h after the injection, but had
no effect on the release of CRH. The responsiveness of the
pituitary to CRH, however, was reduced by dexamethasone injection.
These results suggest that glucocorticoids act both at the
hypothalamus and at the pituitary gland to control ACTH secretion.
Increased secretion and synthesis of ACTH was found to occur after a
5 min period of ether stress. Ether stress resulted in a prolonged
increase in plasma ACTH and corticosterone concentrations which was
followed after 6h by an increase in the content of POMC mRNA in the
anterior pituitary gland.
Electrical stimulation of the paraventricular nuclei (PVN)
significantly increased the release of CRH but not AVP into portal
blood. The increase in CRH release was correlated with a
significant increase in the peripheral plasma concentration of ACTH
and corticosterone in rats in which the pituitary stalk was
intact. However, PVN stimulation had no effect on the content of
POMC mRNA in the anterior pituitary gland. Stimulation of the
amygdala and the hippocampus decreased the release of CRH but not
AVP into portal blood. These results suggest that the PVN is an
important central node involved in the regulation of ACTH and
thereby glucocorticoid release. Electrical stimulation of the
median eminence did not increase the release of CRH, AVP or OT into
portal blood possibly due to inhibiting effects which might involve
antidromic and/or recurrent colateral stimulation. Infusion of
naloxone before electrical stimulation of the median eminence did
not increase the release of AVP or of OT into portal blood.
The content of immunoreactive AVP in hypophysial portal blood
from homozygous Brattleboro rats was approximately 50% of that in
Long Evans rats. Analysis by high performance liquid
chromatography showed that the AVP in portal blood from Brattleboro
rat co-eluted with synthetic AVP. There was no significant
difference in the CRH or OT concentrations in portal blood between
Long Evans and Brattleboro rats. ACTH and corticosterone
concentrations in plasma were lower in heterozygous Brattleboro rats
compared with those in Long Evans rats. The POMC mRNA content in
the anterior pituitary gland in Brattleboro rats is 2-fold higher
than in Long Evans rats. The presence of AVP in the portal blood
of homozygous Brattleboro rats suggest that there may be some
processing and release of AVP from the defective
AVP-neurophysin-glycopeptide precursor in the external layer of the
median eminence.
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Adrenocorticotrophin (ACTH) is secreted from the anterior
pituitary and is under the control of a feedforward system which
involves various components of the central nervous system. These
components influence endocrine neurones in the hypothalamus which
secrete corticotropin-releasing hormone (CRH), arginine vasopressin
(AVP) and oxytocin into hypophysial portal blood. These
neurohormones are transported to the anterior pituitary where they
stimulate the release of ACTH and e-endorphin. ACTH stimulates the
secretion of glucocorticoids from the adrenal cortex. The
brain-hypothalamic-pituitary components of this system are modulated
by the negative feedback of glucocorticoids. The neuroendocrine
control of ACTH secretion will be discussed in this chapter.
1.1 Corticotrophin releasing factors
In 1948 Geoffrey Harris hypothesised that stress induced
activation of the central nervous system is transduced from a neural
into a humoral signal in the hypothalamus. Harris proposed that
nervous stimuli may cause the liberation of a releasing factor into
the capillary sinusoids of the median eminence, the releasing factor
would then be transported via the hypophysial portal vessels to
excite the anterior pituitary gland. More specific experimental
evidence for the existence of a corticotrophin releasing factor
(CRF) was obtained by Saffran & Schally (1955) and by Guillemin and
Rosenberg (1955); however, their efforts to isolate and
characterise the CRH were hampered by the lack of a CRF assay with
sufficient accuracy and sensitivity and by the presence of
vasopressin and catecholamines in hypothalamic extracts that had the
ability to release ACTH. In 1970, Portanova & Sayers devised a
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simple in vitro adenohypophysial cell dispersion technique for the
measurement of CRF activity. An _jjn vitro assay system was used by
Vale et al. (1981) and culminated in the isolation and
characterisation of a 41 amino acid peptide from ovine hypothalamus
that was found to stimulate ACTH and 6-endorphin secretion from
primary cultures of anterior pituitary cells. Subsequently, the
structures of rat (Rivier et al., 1983a) carp (Ling et al., 1984)
and bovine CRH (Esch et al., 1984) have also been established and a
structure proposed for human CRH on the basis of the sequence of the
human CRH genome (Shibahara et al., 1983). Ovine and rat CRH
differ by seven residues (Fig 1.1) while rat and human CRH are
identical. Additionally, two other peptides show homologies with
ovine CRH (Pallai et al., 1983); sauvagine, a 40-residue peptide
found in frog skin and urotensin, a 41-residue peptide isolated from
teleost urophyses. Comparative studies on the respective ability
of these peptides to release ACTH have indicated that ovine CRH,
urotensin and sauvagine exhibit equivalent potencies on rat
corticotrophs (Rivier et al., 1983b).
The addition of increasing doses of ovine CRH to rat anterior
pituitary cell cultures causes a dose-dependent increase in ACTH
secretion (Rivier et al., 1983b). The action of CRH is mediated by
cyclic AMP, and dexamethasone inhibits both the release of ACTH and
the increase in pituitary cyclic AMP which are stimulated by CRH
(Bilazikjian & Vale, 1983). Ovine CRH also stimulates secretion of
other pro-opiomelanocortin (POMC) derived peptides from the anterior
pituitary (Vale et al., 1983a). The presence of CRH in hypophysial
portal plasma at concentrations sufficient to stimulate secretion of
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1984). Exposure of rat anterior pituitary cells to ovine CRH for
eight days results in an increase in ACTH content (cellular plus
medium) of the cultures, suggesting CRH can elevate ACTH synthesis
as well as release (Vale et al., 1983a). In addition, the finding
that long-term treatment with ovine CRH increases POMC mRNA levels
(Bruhn et al., 1984; Sutton et al., 1985) supports the hypothesis
that CRH may regulate POMC gene expression.
1.1.1 Interaction between CRH and other ACTH secretagogues
The current concensus is that regulation of ACTH secretion is
under multifactorial control. A variety of studies have indicated
that the action of CRH on ACTH release can be modulated by
glucocorticoids, catecholamines, neurohypophysial peptides and other
substances. This hypothesis is supported by the observation that
immunoneutralisation with antisera to ovine CRH did not abolish
stress induced increases in ACTH secretion (Linton et al., 1983;
Rivier & Vale, 1983a). The ability of AVP and, to a lesser extent,
oxytocin (OT), which are themselves weak ACTH secretagogues, to
potentiate the effect of CRH at the pituitary level has been
observed many times (Antoni et al., 1983; Gillies et al., 1982;
Vale et al., 1983). AVP and OT each have a synergistic action with
CRH as shown by further elevation of ACTH secretion at plateau
concentrations of CRH following the addition of AVP or OT. This
synergistic effect is observed at concentrations of AVP and OT that
are in the range of those found in portal blood (Horn et al.,
1985). AVP and OT in portal blood are release from nerve terminals
that project to the primary plexus of the portal vessels from
neurones which, as is the case for CRH neurones, are located mainly
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in the parvocellular region of the paraventricular nucleus (PVN)
(Fig 1.2). The exact mechanisms involved in this potentiation are
not fully understood. Although AVP does not appear to act on or by
way of CRH receptors and does not by itself alter cyclic AMP
accumulation in the anterior pituitary, it potentiates 4-fold the
stimulation of cyclic AMP synthesis by CRH. This suggests that AVP
may enhance the efficiency of coupling between the CRH receptor and
adenylate cyclase (Giguere & Labrie, 1982a).
The catecholamines, adrenaline, noradrenaline and the
8-adrenergic agonist isoprenaline have a smaller but still
significant ACTH secretagogue activity relative to CRH (Vale et al.,
1983; Rivier & Vale, 1985a). Simultaneous exposure of the
pituitary gland to catecholamine and ovine CRH results in additive
effects on ACTH secretion. In the case of adrenaline, this
interaction takes place at concentrations of catecholamines reached
in portal blood during stress (Gibbs, 1985) and may represent a
physiological mechanism of ACTH secretion. Studies carried out
with the aid of anti-CRH and anti-AVP sera and ganglionic blocking
agents have shown that all three factors, CRH, AVP and
catecholamines mediate stress-induced ACTH release, although of the
three factors, CRH is the most potent (Rivier & Vale, 1983a; Linton
et al., 1983). The interaction between catecholaminergic and CRH
neurones is further complicated in that immunocytochemical studies
have shown CRH immunoreactivity in the PVN increased after
adrenaline synthesis had been blocked by a specific inhibitor of
PNMT, suggesting that the adrenergic neurones that densely innervate
CRH neurones in the PVN inhibit CRH release (Mezey et al., 1984).
Angiotensin II has also been shown to be a weak ACTH
Figure 1.2 Schematic diagram of a sagittal section of the
hypothalamus
Sagittal section of the hypothalamus illustrating the major
neurones involved in the control of ACTH release. Ascending
adrenergic projections may inhibit CRF release by actions on the
cell body, but probably release ACTH by a direct action on anterior
pituitary cells. For clarity, other modulating neurones
(GABAergic, opioid and noradrenergic) are not shown nor are the
controlling inputs from the limbic or other areas of the CNS.
Vasopressin and oxytocin, as well as being released from terminals
on the portal vessels, may also be released laterally from fibres in
the supraoptic-hypophysial tract. (PVN = paraventricular nucleus;
ME = median eminence, with the primary plexus of the hypophysial
portal vessels; Pit = pituitary gland).
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secretagogue (Rivier & Vale, 1983b; Spinedi & Negro-Vilar, 1984)
and also enhances slightly the ACTH response to CRH (Rivier & Vale,
1983b). Angiotensin II immunoreactivity is found in PVN neurones
that project to the external layer of the median eminence and the
median eminence content of angiotensin II increases after
adrenalectomy. However, pharmacological blockade of receptors to
angiotensin II did not affect basal or stress induced concentrations
of ACTH and corticosterone (Buckner et al., 1986) and there have
been no reports of angiotensin II release into hypophysial portal
blood.
Somatostatin (SS) is present in hypophysial portal blood in
significant concentrations (Sheward et al., 1984) and, therefore, a
possible interaction between SS and CRH on ACTH secretion has been
investigated. Richardson (1983) has observed that SS significantly
inhibits CRH induced ACTH release from mouse pituitary tumour cells,
however, the doses necessary to achieve this inhibition are far
higher than reported to be present in portal blood.
A variety of in vitro studies indicate that the stimulatory
effect of CRH on the corticotrophs is inhibited by glucocortoicds
via feedback inhibition, a process classically considered to be both
time- and concentration-dependent (Keller-Wood & Dallman, 1984).
This effect appears to be near maximum if cells are incubated with
dexamethasone for 4h, but only partial if dexamethasone is added at
the same time as ovine CRH. Increasing doses of steroids shift the
dose-response curves to ovine CRH to the right and reduce the
maximum stimulated ACTH release (Vale et al., 1983a). In vitro,
CRH can still stimulate some ACTH secretion even at maximally
effective concentrations of glucocorticoids. This correlates with
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studies j_n vivo showing that stress
secretion) is capable of increasing
in the presence of high circulating
(Plotsky & Vale, 1984).
(which presumably increases CRH
plasma ACTH concentrations even
corticosterone concentrations
1.1.2 Control of CRH release
1.1.2.1 Neurotransmitter effects
Understanding the central neurotransmitters involved in
controlling CRH release has been complicated by the multiple
hypothalamic factors which regulate ACTH secretion and by the
necessity to use bioassays to determine CRH activity which often did
not discriminate between these multiple factors. However,
development of a sensitive radioimmunoassay for CRH has reduced
these problems. A general summary of the data accumulated suggests
that CRH release is facilitated by central cholinergic and
serotonergic neurones and is inhibited by adrenaline, GABA, morphine
and e-endorphin (Rivier <& Plotsky, 1986). The role of
noradrenaline is more controversial in that noradrenaline has been
generally thought to inhibit the secretion of bioactive CRH
(Berkenbosch et al., 1981; Weiner & Ganong, 1978;) but studies in
the rat and in man suggest that noradrenaline facilitates CRH
release (Hary et al., 1984; Rivier & Plotsky, 1986).
More direct evidence on the effect of neurotransmitters has been
provided by measurements of CRH release into portal blood.
Information gained from studies on neurotransmitter release into
portal blood is not free from artefact, as apart from anaesthesia
and surgical stress, pharmacological agents injected systemically
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or into cerebral ventricles could exert indirect effects on
neurotransmitter release. With this in mind, the facilitatory role
of the serotonergic system has been demonstrated by Gibbs & Vale
(1983) who reported that blockade of re-uptake of serotonin into
presynaptic terminals with fluoxetine significantly increased the
release of AVP and CRH into portal blood. Plotsky has reported
preliminary results that indicate acetylcholine is associated with a
3-fold elevation of CRH release into portal blood while
noradrenaline caused a decrease in portal blood CRH
concentrations. Administration of B-endorphin significantly
reduced portal CRH concentrations while intracerebroventricular
injection of naloxone increased 2.5-fold the CRH concentration in
portal blood, suggesting that opiates may act as autoregulatory
agents to limit CRH secretion (Rivier & Plotsky, 1986).
Vasopressin administration has been found to decrease secretion of
CRH into portal blood in a dose-dependent fashion (Plotsky et al.,
1985), suggesting that endogenous AVP has an inhibitory influence at
the central level while acting at the pituitary level to potentiate
the ACTH releasing activity of CRH.
1.1.2.2 Differential release and action of CRF, AVP and QT
ACTH secretion is controlled by multiple factors and flexibility
of the neural regulation of ACTH secretion has been studied by the
direct measurement of the various releasing factors into portal
blood in response to various stimuli. Haemorrhage is associated
with increased portal blood concentrations of CRH, AVP, OT and
adrenaline (Poltsky et al., 1985b; Plotsky & Vale, 1984). The
ACTH secretory response to haemorrhage is attenuated by
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pre-treatment with either CRH antiserum, AVP antagonists or
ganglionic blockers (Plotsky, 1985a; Plotsky et al., 1985b),
suggesting that the regulation of haemorrhage-induced secretion is
multifactorial in nature and that CRH acts as the predominant
regulatory agent. Insulin-induced hypoglycemia is frequently used
to test the integrity of the hypothalamic-adrenocortical system.
In the fasted rat, the ACTH response to insulin-induced
hypoglycaemia is abolished by anti-CRH serum, attenuated by
administration of a AVP antagonist and moderately reduced by
ganglionic blockade (Plotsky et al., 1985c). However,
insulin-induced hypoglycemia is accompanied by a significant
increase in AVP but not CRH or OT concentrations in portal blood
(Plotsky et al., 1985c) suggesting that in this situation, CRH plays
a permissive role which is necessary for an effective ACTH response
to the less potent ACTH secretagogue, AVP.
The apparent differential effects of CRH and AVP are made more
complex by the recent findings that 44% of immunoreactive CRH
terminals in the external layer of the median eminence of the rat
also stain strongly for AVP and AVP-neurophysin and that after
adrenalectomy virtually all CRH positive terminals were also
positive for AVP and AVP-neurophysin. Co-localisation of CRH, AVP
and AVP-neurophysin in many neurosecretory vesicles in nerve
terminals of the median eminence has also been demonstrated by
electron microscopy (Whitnall et al., 1985).
1.1.2.3 CRH receptors
Specific, high-affinity receptors for CRH have been localised in
the anterior and intermediate lobes of the rat and human pituitary
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g1 and (de Souza et a 1., 1985a). CRH receptors in the anterior
pituitary parallel the distribution of corticotrophs in the anterior
pituitary, whereas receptors in the intermediate lobe are
distributed homogeneously. The CRH receptors appear to be coupled
to the adenylate cyclase system (Giguere et a 1., 1982b; Labrie et
al., 1983). After adrenalectomy there is a decrease in the CRH
receptor concentration in the rat anterior pituitary gland which is
associated with a comparable decrease in maximal CRH-stimulated
adenylate cyclase activity and sensitivity to CRH. These decreases
in receptor density and adenylate cyclase activity are presumably
due to down-regulation of the CRH receptor and can be prevented by
treatment with dexamethasone (Wynn et al., 1985). CRH receptors
are also present in the cerebral cortex and parts of the limbic
system in rat brain and these receptors appear to be unaffected by
adrenalectomy (de Souza et al., 1985b).
Specific CRH receptors have also been found in monkey adrenal
medulla and sympathetic ganglia. In the adrenal medulla, these
receptors are coupled to adenylate cyclase and stimulate the
secretion of catecholamines and met-enkephalin. This supports the
view that CRH has a paracrine action in peripheral tissues (Udelsman
et al., 1986).
1.1.3 Extra pituitary actions of CRH
Intracerebroventricular administration of ovine CRH in vivo has
provided evidence that CRH may have an extra pituitary site of
action. Mean arterial pressure and heart rate increased after
intraventricular administration of ovine CRH (Fisher et al., 1982)
as did plasma concentrations of adrenaline, noradrenaline, glucagon
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and glucose (Brown et al., 1982). Behavioural activation was also
observed (Britton et al., 1982; Sutton et al., 1982).
In vivo, CRH has also been shown to influence the secretion of
other pituitary hormones by interactions with various transmitters
at the hypothalamic level. Intracerebral injection of ovine CRH on
the morning of pro-oestrus attenuates the LH and GnRH surge (Rivier
& Plotsky, 1986) suggesting CRH may have an inhibitory effect on
central release of GnRH. In the rat, intracerebral injection of
ovine CRH decreased plasma growth hormone concentrations and this
was reversed by immunoneutralisation with anti-SS serum (Katakami et
al., 1985; Rivier & Vale, 1985b).
The character of pituitary and extra pituitary actions of CRH is
consistent with the concept of CRH as a peptide primarily concerned
with the physiological changes that help the animal respond to
stress and may explain the deleterious action of stress on
reproductive functions.
1.2 Adrenocorticotrophin and related peptides
1.2.1 Biosynthesis
The primary structure of ACTH was first determined in 1954 and
found to be a peptide hormone comprising 39 amino acids with a
molecular weight of 4.5K (Bell, 1954). Pulse chase studies
demonstrate that ACTH is synthesised as part of a larger precursor
with a Mr of 31K which is processed to 4.5K Mr ACTH through
intermediate forms (Mains & Eipper, 1976). Translation of
pituitary mRNA in a cell-free system followed by immunoprecipitation
yielded the initial precursor of ACTH with Mr of 35K (Nakanishi et
al., 1976). Further cell-free translation studies showed that the
ACTH precursor encoded by pituitary mRNA also contained b-endorphin
(Nakanishi et al., 1977a). b-endorphin had previously been shown
to be derived from b-lipotropin (b-LPH) (Li & Chung, 1976) and their
data showed that there is thus a common precursor for both ACTH and
b-LPH. The structure of the ACTH/b-LPH precursor
pro-opiomelanocortin (POMC), was finally determined from the
nucleotide sequence of cloned DNA complementary to the mRNA coding
for the precursor (Nakanishi et al., 1979) (Fig. 1.3). The
precursor is enzymatically processed to give ACTH, which can be
further processed to aMSH and corticotropin-1ike intermediate
peptide (CLIP) and b-LPH which can be further processed to produce
b-endorphin and y-LPH. b-endorphin could theoretically be further
processed to methionine-enkephalin but there is no evidence to
support the view that POMC is a source of enkephalin. POMC is
glycosylated and its products can be further modified by
glycosylation, phosphorylation, sulphation, N-terminal acetylation
and C-terminal cleavage (Liotta & Krieger, 1983; Hollt, 1985b;
Jenks et al., 1986).
Post-translational patterns of processing POMC are tissue
specific. In the anterior pituitary, POMC is cleaved to form
mainly ACTH, b-LPH and N-terminal peptide, b-LPH is processed to a
limited extent to form y-LPH and b-endorphin (Fig. 1.4). In the
intermediate lobe of the pituitary, ACTH is processed to form a-MSH
and CLIP, N-terminal peptide is converted to some extent to y-MSH
and the remaining amino terminal portion. The conversion of b-LPH
to y-LPH and b-endorphin is almost complete and further processing
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Fig. 1.4 Schematic representation of
tissue specific processing of
the ACTH-g-LPH precursor"
Processing of pro-ACTH-e-LPH in the anterior
pituitary (A) and in the neurointermediate
pituitary and extrapituitary tissues (B).
Dotted lines represent limited processing.
From Imura et al., (1983).
8-MSH from y-LPH (Imura et al., 1983).
There is widespread distribution of POMC fibres throughout the
brain, most of which are presumed to derive from cell bodies in the
arcuate nucleus. Hypothalamic nuclei, in particular the PVN,
receive an especially dense innervation of POMC-containing fibres as
does the median eminence. Several of the hind and mid brain nuclei
and the periaqueductal 9r^y are also densely innervated with POMC
containing fibres (Liotta & Krieger, 1983). The processing
patterns of POMC in the brain have been shown to be similar to those
in the intermediate lobe of the pituitary gland (Imura et al.,
1982). The physiological significance of POMC yielding multiple
bioactive hormones may be that they perform co-ordinated modulatory
functions in the central nervous system and peripheral tissues in
response to stress.
In summary, ACTH and B-endorphin are derivatives of a 31K
glycosylated precursor protein, POMC which undergoes
post-translational processing. Post translational processing and
modification is tissue specific and serve as important regulatory
mechanisms. Acetylation, which is catalysed by acetyltransferase,
is an important regulatory mechanism. For example, in the
intermediate lobe of the frog, dopamine inhibits acetylation
resulting in the presence of inactive (des-acetyl-a-MSH) and active
B-endorphin. In the uninhibited state all the a-MSH is acetylated
and, therefore, active. Since N-acetylated B-endorphin is
inactive, this mechanism could operate to provide a switch from a
potent melantrophic signal to an opioid signal (Jenks et al., 1986).
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1.2.2 Regulation of POMC synthesis
Recent evidence indicates that factors known to alter secretion
of POMC peptide hormones may also alter POMC biosynthesis via
modulation of POMC mRNA levels. Differential regulation of POMC
release and synthesis occurs in the anterior and intermediate lobes
of the pituitary gland. Removal of glucocorticoids by
adrenalectomy increased POMC mRNA significantly in the anterior
pituitary gland and POMC mRNA was reduced by treatment with
dexamethasone (Herbert et al., 1981). Glucocorticoids have been
shown to exercise their action at the level of transcription,
changes in transcription rates of POMC were visible 10-15 min after
adrenalectomy (Eberwine & Roberts, 1984). Long-term treatment with
CRH results in increased POMC mRNA content in the anterior pituitary
gland (Bruhn et al., 1984). Glucocorticoids or CRH have little or
no effect on POMC mRNA content in the intermediate lobe.
POMC gene expression in the intermediate lobe can be altered by
dopamine, blockade of the dopamine receptor by haloperidol
increased, while a dopamine agonist, ergocryptine, decreased the
content of POMC mRNA in the intermediate lobe of the pituitary gland
(Chen et al., 1983). The mechanism of action is unclear but may be
mediated by cyclic AMP.
POMC gene expression is also affected by other factors such as
oestrogen which decreases both content of POMC mRNA and rate of POMC
transcription in the medial basal hypothalamus in ovariectomised
rats. Presumably the main site of action of oestrogen is the
arcuate nucleus as that is where, in the hypothalamus, the cell
bodies of POMC-containing neurones are concentrated (Roberts et al.,
1986).
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1.2.3 Function and mechanism of action of POMC derived peptides
ACTH, released from the anterior pituitary gland, has its main
endocrine action on the adrenal gland where it stimulates the
secretion and synthesis of glucocorticoids and to a lesser extent
mineralo corticoids. ACTH also stimulates cell growth and division
in the zona fasciculata and reticularis. These actions are
produced by ACTH binding to receptors in the plasmalemma which
results in the production of cyclic AMP (Sayers et al., 1974) which,
in turn, activates cAMP-dependant protein kinases. Activated
kinase may phosphorylate a cholesterol esterase which accelerates
the conversion of cholesterol fatty acid esters in lipid droplets of
adrenocorticoid cells to free cholesterol. Cholesterol in the
cellular part of free cholesterol may also be derived from plasma.
Cyclic AMP is believed to induce the synthesis of a labile protein
which accelerates the conversion of cholesterol to pregnenolene (the
rate limiting step in glucocorticoid synthesis) possibly by
transporting cholesterol to its site of chain cleavage on the
mitochondrial P450 system. Once pregnenolene is formed, the
subsequent steroid conversions follow at a rapid rate. Activation
of protein kinase also promotes cell division. In addition to
2
cyclic AMP, Ca is involved in the mechanism of action of ACTH.
The physiological functions of other POMC derivatives are not
clear. MSH stimulates melanocytes in lower vertebrates and
possibly under pathological conditions in man, y-MSH has been
reported to potentiate the adrenal response to ACTH (Al-Dujaili et
al., 1981) and b-MSH has been reported to stimulate aldosterone but
not corticosterone production (Matsuoko et al., 1981). The role,
if any, of s-endorphin in acupuncture has been widely discussed, but
is yet to be proven (Clement-Jones, 1982) and studies on the role of
8-endorphin in affective disorders and schizophrenia are
inconclusive (Berger et al., 1986). Studies in genetically obese
mice suggest that CLIP-like peptide may stimulate insulin secretion
(Beloff-Chain et al., 1983). Finally, the placenta synthesises
large amounts of POMC but its role remains uncertain (Krieger et
al., 1980).
1.3 Glucocorticoids
1.3.1 Secretion and function of glucocorticoids
In man, dogs and guinea pigs, the main glucocorticoid secreted
is Cortisol while in the rat, mouse and cat, corticosterone is the
predominant glucocorticoid. Glucocorticoids are secreted from the
zona fasciculata and reticularis of the adrenal cortex and have very
diverse functions. They induce enzymes such as tryptophan oxidase,
phenylethanolamine N-methyl transferase, glutamine synthetase and
hepatic cytochrome P-450. Glucocorticoids raise blood glucose by
stimulating hepatic gluconeogenesis, inhibiting glucose uptake in
peripheral tissues, suppressing insulin and stimulating glucagon,
all of which result in increased blood glucose. The increase in
blood glucose is prolonged by the synergistic action of
glucocorticoids with glucagon and adrenaline. Glucocorticoids also
suppress inflammation, the immune response and the activity of
plasminogen activator and other neutral proteinases (Munck et al.,
1984). Glucocorticoids also inhibit the secretion of ACTH and
other derivatives of POMC as part of negative feedback control
(Herbert et al., 1981).
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1.3.2 Functions of glucocorticoids in stress
Almost any kind of threat to homeostasis or stress will cause
plasma glucocorticoid concentrations to rise. The increased
concentrations have traditionally been ascribed the physiological
function of enhancing the organism's resistance to stress, a role
well recognised in glucocorticoid therapy. How the known
physiological and pharmacological effects of glucocorticoids might
accomplish this function has been reviewed by Munck et al. (1984).
Contrary to the traditional view that glucocorticoids enhance
defence mechanisms, it has become increasingly clear that
glucocorticoids at moderate to high concentrations generally
suppress the defence mechanisms. The potent antiinflammatory
action of glucocorticoids, which depends on the ability of these
steroids to suppress the various cellular and humoral defence
systems of the body, would appear to conflict with the role of
glucocorticoids in protecting the organism from stress. Munck et
al. (1984) argue that stress-induced increases in glucocorticoid
concentrations protect not against the source of stress itself but
rather against the body's normal reactions to stress, preventing
these reactions from overshooting and threatening homeostasis.
They support this hypothesis by arguing, for example, that
glucocorticoids can suppress mediators of inflammation and immune
reactions such as immune interferon, lymphocyte activating factor, T
cell growth factor, prostaglandins, leukotrienes, histamine, 5-HT,
bradykinin and neutral proteinases. The glucocorticoid response is
delayed relative to the onset of an immune response, this allows the
immune response to be mounted and then subsequently moderated by
glucocorticoids. In the case of a metabolic challenge, Munck et
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al. (1984) argue that the major metabolic role of glucocorticoids is
to prevent insulin from causing dangerous hypoglycaemia.
Glucocorticoids act synergistically with glucagon and adrenaline in
that the glucocorticoids(which act more slowly) enhance and prolong
the increase in blood glucose initiated by adrenaline and
glucagon. The glucocorticoids raise blood glucose by stimulating
hepatic gluconeogenesis, inhibiting glucose uptake by peripheral
tissues, inhibiting the secretion of insulin and stimulating the
secretion of glucagon.
This hypothesis provides glucocorticoid physiology with a
unified conceptual framework that can accommodate disparate
glucocorticoid effects on carbohydrate metabolism, immune reactions,
water balance, shock and levels of enzymes, though care must be
taken to avoid erroneous generalisations.
1.3.3 Control of ACTH secretion by glucocorticoids
The secretion of ACTH is under negative feedback control of
glucocorticoids. The existence of this negative feedback,
homeostatic system was established in the 19301s and 1940's (Sayers,
1950) and developed into a sophisticated model by Yates and
colleagues (Yates & Brennan, 1967; Yates et al., 1969) which is
illustrated in Fig. 1.5. The amount of ACTH which reaches and acts
on the adrenal cortex depends on the rate of its secretion,
distribution in body compartments and metabolic clearance. This is
further complicated in glucocorticoids as it is generally assumed
that only free glucocorticoid is active in the negative feedback
control of the brain-pituitary component. In man, only 8% of
glucocorticoids are not bound to plasma proteins (Bondy, 1985).
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The glucocorticoid binding proteins serve as a buffer and ensure the
transport of the relatively hydrophobic glucocorticoids to specific
tissue sites; glucocorticoid binding globulin, presumably with
bound steroid, has been shown to enter liver and pituitary cells
(de Kloet & Reul, 1986). The marked changes in plasma Cortisol
during circadian rhythm shows there is rapid and free exchange of
bound and free glucocorticoid.
Corticosteroid feedback inhibition of stress-induced ACTH
secretion has been shown to operate in at least three time domains:
fast feedback (within seconds to minutes), intermediate (over 2-10h)
and slow (over hours to days). Fast feedback was first postulated
to be rate-sensitive by Dallman & Yates (1969) and was confirmed
experimentally by Jones et al. (1972) and by Abe & Critchlow
(1977). Both groups found that rapid inhibition of stress-induced
ACTH secretion occurred during the period of increasing plasma
corticosteroid concentrations and that the inhibition had
disappeared by 30 min after injection. There then followed a
'silent period' during which no inhibition of adrenocortical
response to stress is observed (Dallman & Yates, 1969).
Intermediate feedback occurs 90-120 min after the rise in
corticosteroids. Takebe et al. (1971) and Jones et al. (1974) have
shown the degree and duration of intermediate inhibition depends on
the total dose of steroid administered and that maximal inhibition
of adrenocortical responses occur between 2h and 4h after the
administration of a single dose of corticosterone. Intermediate
feedback is followed by slow feedback, sustained elevation of
corticosteroids for one or more days abolishes the capacity of the
adrenocortical system to respond to most stimuli (Buckingham &
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Hodges, 1974). Slow feedback, however, would be expected to occur
only in pathological conditions or after pharmacological treatment
with corticosteroids when increases in plasma corticosteroids are
prolonged for days.
Studies on basal release of ACTH suggest basal ACTH release is
less sensitive to corticosteroid feedback inhibition. In studies
designed to examine rapid inhibition of ACTH by glucocorticoids in
vitro no inhibition was observed unless the pituitary was stimulated
(Widmaier & Dallman, 1983). Inhibition of basal ACTH release in
vivo by glucocorticoids has been demonstrated during the 'silent
period1 (Zimmerman & Critchlow, 1972). Basal ACTH release is
suppressed 20 min after administration of glucocorticoids in dogs
and after 45 min in man. It appears, therefore, that basal ACTH
secretion in normal animals is inhibited by corticosteroids and that
the temporal pattern for inhibition of this secretion is different
in rats and man than that for inhibition of stimulus-induced
secretion.
1.4 Feedback control of the ACTH-glucocorticoid circadian rhythm
The circadian rhythm in basal secretion of glucocorticoids and
ACTH is a predominant characteristic of the adrenocortical system.
With the exception of dogs, circadian rhythms in plasma ACTH have
been reported in all species studied (Gallagher et al., 1973;
Krieger et al., 1971; Rees et al., 1971). Peak activity of the
system occurs at the onset of the daily activity cycle, for example,
in man the peak is between 0500-0800h and in nocturnal animals such
as the rat, the rhythm is reversed with the peak occurring towards
the end of the light phase (Chiappa & Fink, 1977). There is
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evidence that at the time of the daily adrenocortical minimum,
pituitary ACTH secretion does not require input from the brain.
Lesions placed in the medial basal hypothalamus of the rat, which
prevented stimulus-induced ACTH secretion, had no effect on normal
resting ACTH levels in the morning, but prevented the increase in
ACTH secretion normally seen towards the end of the light phase
(Kaneko et al., 1980). Studies in experimental animals and man
show that the rhythm is driven by a central neural mechanism of
which the main components are the suprachiasmatic nuclei (SCN)
(Moore, 1979; Krieger, 1979a). That is, the SCN generate a rhythm
which approximates to 24h and this rhythm is transduced into a
circadian rhythm of the release of CRF's which, in turn, results in
a 24h rhythm in the release of ACTH and consequently glucocorticoids.
There are several factors which entrain the
hypothalamic-pituitary-adrenocortical rhythm, of which light is the
most prominent (Moore, 1979; Krieger, 1979a), but it remains to be
determined precisely how the circadian rhythm is generated and how
signals are transmitted from the SCN to CRF neurones. The SCN
receive prominent projections from the midbrain raphe nuclei in
which 5-HT is the neurotransmitter. The SCN also has prominent
reciprocal connections with the ventral division of the lateral
geniculate nuclei (VLGN). The functions of the connections between
the SCN and the raphe nuclei and VLGN are not known, but the SCN,
VLGN and hippocampus, all of which have a relatively dense 5-HT
innervation, show circadian changes in the electrophysiological
response to 5-HT (Mason, 1986). Lesions of the raphe nuclei do not
alter the frequency but reduce by about 50% the amplitude of the
ACTH circadian rhythm (Szatarczyk et al., 1980). This suggests
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that the raphe nuclei alter the magnitude but not the frequency of
the signal generated by the SCN.
The technical problems of measuring CRH in hypophysial portal
blood make it difficult to prove that the circadian rhythm of ACTH
and corticosterone is in fact driven by brain derived CRH However,
changes in CRF activity (as determined by bioassay) of hypothalamic
extracts are consistent with a neural drive for the circadian rhythm
which is mediated by way of CRF1 s (Chiappa & Fink, 1977).
1.4.1 Receptors for corticosteroids
Most of the actions of glucocorticoids are thought to be genomic
and depend on the binding on the steroid with a cytosolic receptor
and the movement of the steroid receptor complex to the nucleus
where it binds to chromatin and either promotes or suppresses gene
expression (Miesfeld et al., 1986). There are two types of
glucocorticoid receptors in the rat (de Kloet &. Reul, 1986).
Type 1 (first described by McEwan et al., 1968) bind
3 3
H-corticosterone and H-aldosterone and are concentrated in CA1
and CA2 regions of the hippocampus and other areas of the limbic
system. There are only a few type 1 receptors in the hypothalamus
or pituitary gland and this is surprising given the presumption that
feedback of glucocorticoids is exerted at the level of the
hypothalamic-pituitary systems. However, type 2 receptors bind
^H-dexamethasone and ^H-RU28362 (a synthetic ligand for
glucocorticoid receptors), are similar to the liver glucocorticoid
receptor as identified by monoclonal antibodies (Fuxe et al., 1985)
and are widely distributed in neurones and glial cells all over the
telecephalon, diencephalon and anterior pituitary gland.
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Concentration of these receptors, as assessed by
immunocytochemistry, is not high, except in the PVN, the anterior
periventricular nuclei, the ventral mediobasal hypothalamus and CA1
and CA2 region of the hippocampus. Overlap of glucocorticoid
receptor density and immunoreactivity in hypothalamic areas has been
proposed as evidence that glucocorticoids play a role in the
secretion of CRH, TRH and somatostatin (Fuxe et al., 1985).
The differentiation of receptor systems for glucocorticoids
suggest a dual role of the naturally occurring hormone,
corticosterone, in the control of brain function. Type 2 receptors
have been shown to become occupied with rising plasma concentrations
of corticosterone after stress. This implies that Type 2 receptors
mediate the feedback action of glucocorticoids aimed to turn off
stress-activated brain mechanisms. The negative feedback role is
supported by high concentrations of Type 2 receptors in the anterior
pituitary gland and in the hypothalamus. Type 1 receptors are
concentrated mainly in the limbic system and corticosterone action
on Type 1 receptors may be associated with cognitive functions
ascribed to the limbic system. Differential function of the two
receptor types requires proof that both receptors recognise the
naturally occurring corticosterone equally.
1.5 Aims of this Thesis
There were two main aims of this thesis. First, I wished to
examine, with the aid of the technique of hypophysial portal blood
collection, the interplay between and the relative importance of the
various CRF's in stimulating ACTH in vivo. Specifically, direct
measurements of CRH, AVP and OT release into hypophysial portal
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blood were made to examine (i) the role of CRH and AVP in
mediating ACTH secretion in response to electrical stimulation of
the amygdala, hippocampus, median eminence and PVN, (ii) the site
of action of glucocorticoids in mediating their negative feedback
action, (iii) the role of endogenous opioid peptides in inhibiting
release of AVP and OT into portal blood during electrical
stimulation of the median eminence and iv) the effect of the
presumed absence of AVP in the Brattleboro rat on CRH and OT release
into portal blood and on ACTH release from the anterior pituitary
gland. Secondly, I wished to investigate the factors that affect
the synthesis of POMC and related peptides by measuring the content
of POMC mRNA in the anterior pituitary gland in response to low and
high concentrations of corticosterone, in response to electrical
stimulation of CRH release into hypophysial portal blood and in the
Brattleboro rat which is genetically deficient in AVP.
CHAPTER 2
MATERIALS AND GENERAL METHODS
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2.1 ANIMALS
Animals used in this study were adult female Wistar cobs
(caesarean-originated barrier7sustained) and adult female Long-Evans
rats purchased from Charles River UK Ltd. (Margate, Kent). Female
homozygous and heterozygous Brattleboro rats were bred in the
Department of Pharmacology, Edinburgh. Animals were housed in
cages of four under controlled lighting (lights on 05.00-19.OOh) and
temperature (22°C) and had free access to food (Diet 41B; Oxoid,
Basingstoke) and tap water. All animals subjected to surgery and
maintained alive for more than 48h had access to drinking water
supplemented with aureomycin (50mg/litre) (Chlortetracycline
hydrochloride; Cynamid G.B. Ltd., Gosport). Long-term
adrenalectomised animals received 0.9% saline supplemented with
glucose (250mg/1itre) and aureomycin instead of tap water.
Brattleboro rats were caged singly in metabolic cages to measure
urine output in a 24h period. A homozygous Brattleboro rat was
defined as an animal which passed urine equal to or greater than 75%
of body weight during the 24h collection period. Animals passing
less than this were classed as heterozygous Brattleboro rats.
2.2 SURGICAL AND EXPERIMENTAL PROCEDURES
2.2.1 Anaesthetics
The following anaesthetics were used:
1) Ethyl carbamate (urethane; Sigma Chemical Co. Ltd., Poole,
Dorset). A 10% (w/v) solution was prepared in 0.9% saline and
administered by intraperitoneal (i.p.) injection at a dose of
1.0—1.2g/kg body weight.
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2) Sodium pentobarbitone (sagatal; May & Baker Ltd., Dagenham).
Purchased as 60mg/mi sodium pentobarbitone in alcohol:
propylene glycol vehicle (10:20 v/v), diluted 1:10 in 0.9%
saline and injected i.p. at a dose of 36-40mg/kg body weight.
3) 9 mg/ml alphaxalone (3a-hydroxy-5a-pregnane-ll,20-dione and
3 mg/ml pregnane-11, 20-dione) solubilised in saline by 20%
(w/v) polyoxyethylated castor oil (saffan; Glaxovet Ltd.,
Uxbridge). Administered i.p. at a dose of lml/lOOg body
weight.
4) 2,2,2-tribromoethanol (Aldrich Chemical Co. Gillingham, Kent) in
amylene hydrate (tetr. amyl alcohol; BDH, Poole, Dorset)
lg/ml; 2ml of the stock solution were diluted with 8ml absolute
alcohol and 90ml 0.9% saline solution. The dose used was
l.Oml/lOOg body weight administered by i.p. injection.
5) Anaesthetic ether (McFarlane Smith Ltd., Edinburgh).
2.2.2 Drugs
1. Dexamethasone (Sigma Chemical Co. Ltd.). a stock solution of
0.9mg/ml in ethanol was diluted 1:10 (v/v) with 0.9% saline
solution immediately before use and injected i.p. at a dose of
0.5mg/kg body weight.
2. [l-deamino-8-D-arginine]-vasopressin: dDAVP (Ferring, Malmo,
Sweden). Stock solution of 10pg/ml injected i.p. at a dose of
lOyg/lOOg body weight.
2.2.3 Hypothalamus and Pituitary Dissection
Rats were decapitated and brains quickly removed and placed on
ice ventral side uppermost. The optic nerves were removed at the
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1 eve 1 of the optic chiasm with fine forceps before the hypothalamus
was dissected out. A block of tissue about 2-3mm deep was removed
extending rostro-caudally from the pre-optic area to just caudal to
the mamillary bodies and laterally 1mm on either side of the median
eminence. The block of tissue generally weighed between 28 and
35mg.
The pituitary gland was separated into anterior lobes and
neurointermediate lobes in situ with the aid of watchmaker forceps
and under a dissecting microscope.
2.2.4 Adrenalectomy
Female Wistar cobs (200-250g body weight) were adrenalectomised
in two stages. The second adrenal gland was removed 7-10 days
after the first gland. The survival rate using this approach was
higher than immediate bilateral adrenalectomy.
On day 1, animals were anaesthetised with tribromoethanol and an
incision made along the right costal margin. The right kidney was
exposed and the adrenal gland excised. Bleeding was stopped by
gentle pressure with a gauze swab and the incision was sutured. On
day 7-10, animals were anaesthetised as before and the left adrenal
gland removed in the same manner as the right gland. The animals
were left to recover for the requisite post-operative period.
Whether or not adrenalectomy had been completed was checked by
measurement of plasma corticosterone concentrations and by
inspection for possible adrenal remnants at autopsy.
2.2.5 Treatment of Blood Samples
Blood was collected with heparinised syringes (1000 I.U./ml
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saline) into small plastic tubes (L.P.2: Luckham Ltd., Sussex) and
kept on ice. Aprotinin (Trasylol, Beyer, Newbury, Berkshire) was
added to samples at 1000 Kallikrein Inactivator Units (KIU)/ml
blood. Samples were centrifuged at 1,720 x £ for 20 min at 4°C,
plasma was removed with a Pasteur pipette into plastic storage tubes
(PT0944; Luckham Ltd.) and stored at -40°C.
2.2.6 Collection of Hypophysial Portal Blood
Hypophysial portal blood was collected according to the method
of Worthington (1966) as used in this laboratory by Fink & Jamieson
(1976) with some modifications.
The animal was anaesthetised with either urethane or sagatal and
immobilised supine on an operating board. General anaesthesia was
supplemented with 2% xylocaine (w/v) (Astra Pharmaceuticals,
Watford, Herts) injected into the skin and muscle of the lower
jaw. A midline incision was made in the skin of the lower jaw,
extending caudally from the lower lip for 4-5cm. The muscles
overlying the trachea were exposed by gentle retraction of skin and
subcutaneous tissue. The trachea was exposed by making a 1cm
longitudinal midline incision in the overlying muscles. A silk
suture was passed beneath the trachea and a small transverse
incision (rostral to the thread) was made in the trachea to allow
the insertion of a piece of polythene tubing approximately 1.5cm in
length (2.08mm o.d., 1.57mm i.d.). The tubing was secured by the
silk suture. Gentle traction was applied to the tongue by passing
a long silk Guy suture through the tip. Ligatures were placed
round each mandibular ramus to prevent bleeding from branches of the
lingual arteries taking care not to damage the tongue. The lower
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jaw and floor of the mouth were then divided with a midline
incision. The incision was extended through the muscles of the
mouth floor parallel to each side of the mandible. The fauces were
then cut in order to mobilise the tongue. Long sutures were placed
through each of the flaps of the divided lower lip and were used for
lateral retraction of the two sides of the jaw, the tongue was
gently retracted using the Guy suture to reveal the soft palate and
epiglottis. The tongue was then fixed over the chest under gentle
traction. Sterilised cellulose gauze (Ethicon, Edinburgh) was used
to prevent capillary and small vessel haemorrhage. All further
manipulations were carried out under a Zeiss binocular operating
microscope.
The soft palate was incised longitudinally along the midline
with an iris electrocautery (Weiss & Son, London) from the posterior
edge of the hard palate to 1mm anterior to the epiglottis and
laterally to the pterygoid processes of the sphenoid bone. This
exposed the mucosa overlying the basosphenoid which was then removed
with cotton wool.
Using a dental drill, a hole was drilled in the outer table of
the basisphenoid bone from the occipito-sphenoid suture to the
basisphenoido-presphenoid suture anteriorly. Throughout the
drilling procedure, the drill hole was packed with bone wax,
(Ethicon Ltd., Edinburgh) especially in the area of the transverse
venous sinus in the sphenoid bone. The exposed inner table was
gently eburnated until it yielded to gentle pressure from either a
fine drill or a pair of watchmaker forceps. The thin bone layer
remaining was removed with watch maker's forceps revealing the dura
mater overlying the median eminence and pituitary gland. A piece
-29-
of razor blade held in a pin chuck was used to make a "V" shaped cut
in the dura mater. The base of the "V" was over the pituitary
gland and the apex just rostral to the median eminence.
Cerebrospinal fluid appearing at this stage was removed with cotton
wool. The flap of cut dura was retracted caudally exposing the
median eminence and rostral part of the anterior pituitary gland.
Animals were then injected with 2500IU heparin (heparin sodium
5000 IU/ml; Weddel Pharmaceuticals Ltd., London) into the external
jugular vein. The pituitary stalk was cut transversely using fine
iridectomy scissors (Weiss & Son, London) at its junction with the
pituitary gland. Blood was allowed to flow into the drilled trough
and was collected using a glass pasteur pipette. Fluid collected
during the first 5 min was discarded to allow removal of tissue
debris, bone wax or cerebrospinal fluid. Blood was then collected
into ice cooled plastic tubes containing Trasylol. Peripheral
samples were taken from the external jugular vein at the beginning
of the collection period. Plasma was stored at -40°C until
required for assay.
2.2.7 Median Eminence Stimulation
Animals were prepared as for collection of hypohysial portal
blood until the median eminence and pituitary gland were exposed.
Unipolar electrodes were made according to Jamieson <5, Fink (1976) in
the Department of Pharmacology workshop. A 13mm piece of platinum
wire (0.125mm diameter) was insulated with glass tubing to within
0.3mm of the tip and soldered to a length of copper wire. The
whole assembly was mounted in a Teflon jig and fixed in place with
acrylic cement (Simplex; Dental Fillings Ltd., London). The
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electrode was lowered into position on the median eminence with the
aid of a dissecting microscope and a micromanipulator. The
electrode was placed on the median eminence, the portal vessels were
cut and blood collected as described. Electrical stimulation was
applied during the second half of the collecting period, using a
constant current generator (Digitimer - Neurolog; Welwyn Garden
City) based on parameters described by Jamieson & Fink (1976). The
stimulus consisted of accurately balanced biphasic rectangular waves
with a frequency of 50Hz, pulse width 1msec and amplitude of 1mA.
The stimulus was applied in trains of 30 sec on and 30 sec off for a
period of 30 min and were monitored on a calibrated oscilloscope.
2.2.8 Electrode Implantation
Bipolar electrodes were constructed as described in 2.2.7 with
electrode tips separated by 1.0mm.
For implantation of stimulating electrodes, female rats
(200-250g body weight) were anaethetised with tribromoethanol and
positioned with the head immobilised in a stereotaxic frame. A
midline incision was made in the scalp to expose the frontal and
parietal bones, the periosteum was scraped off and a hole (4 x 4mm)
drilled in the frontal bones immediately anterior to the bregma in
order to expose the dura mater. Care was taken to avoid damage to
the superior sagittal sinus. Bleeding during any point of the
operation procedure was controlled with gentle pressure with cotton
wool soaked in 0.9% saline solution. Three small stainless steel
screws (approximately 1.5mm in diameter) were driven into small
drill holes made around the outside margin of the exposed area.
The dura mater was carefully incised in a longitudinal direction and
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the electrode implanted according to the co-ordinates of de Groot
(1959) and with the aid of a triplanar manipulator (Prior U.K.).
Co-ordinates used are shown in Table 2.1.
Table 2.1
Area to be Co-ordinates Used (mm)
Stimulated Lateral Anteroposterior Ventral
PVN 0 6.4 3.4 - 3.8
Amygdala 4-4.5 5.4 2.5
Ventral Hippocampus 3.5 - 4.5 3.0 1.8
The electrode assembly was secured to the skull using dental
cement which was carefully applied round the electrode hub and the
screws. Once the cement had firmly set, the animal was removed
from the stereotaxic frame and the scalp sutured. Animals were
used for portal blood collection 7-10 days after the electrodes had
been implanted. Parameters for electrical stimulation were as for
median eminence stimulation (2.2.7).
2.3 RADIOIMMUNOASSAY OF CORTIC0TR0PHIN-RELEASING HORMONE
2.3.1 Introduction
Techniques for the measurement of physiological concentrations
of biologically active substances require accurate and precise
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quantitation of picomole (10 mole) amounts of these compounds
in biological fluids. The technique of radioimmunoassay (RIA),
first described by Yalow (1959), is one of the most satisfactory
methods of detection. Radioimmunoassay is highly sensitive,
relatively simple and depending on the antiserum, highly specific.
-32-
The principles of RIA have been discussed in numerous reviews
(Kirkham & Hunter, 1971; Yalow & Bersan, 1971; Jaffe & Behrman,
1979; Yalow, 1980). Briefly, a fixed concentration of labelled
antigen is incubated with a constant dilution of antiserum such that
the concentration of antigen binding sites on the antibody is
limiting; for example, only 30% of the total label concentration
may be bound by the antibody. If unlabelled antigen is added to
the system, there is competition for the constant and limited number
of binding sites on the antibody. As the concentration of
unlabelled antigen increases, the amount of labelled antigen bound
will decrease. After equilibration between bound and free antigen
has been achieved, the amount of antigen bound can be measured by
separating antibody bound from free label by double antibody
precipitation and counting. A standard curve is set up with
increasing concentrations of standard unlabelled antigen and by
comparison of displacement of labelled antigen, the amount of
antigen in unknown samples can be calculated.
Each standard curve contains tubes with only labelled antigen
(total counts, T.C.) and tubes without antiserum to assess
non-specific binding (NSB), the number of counts trapped
nonspecifically in the precipitate. The total bound (Bo) is the
amount of labelled antigen which binds at a given concentration of
antiserum when no unlabelled antigen is present.
Many radioimmunoassays have been described for ovine-CRH (Gibbs
& Vale, 1982; Linton & Lowry, 1982) and used to determine
concentrations of rat and human CRH in plasma and hypothalamic
samples. However, the isolation and characterisation of a 41 amino
acid rat hypothalamic peptide with potent corticotropin releasing
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factor activity (Rivier et al. 1983a) has made it possible to
develop a more specific RIA for the measurement of CRH in rat
samples.
2.3.2 Preparation of Antiserum to CRH
Antiserum is prepared by injecting the antigen, usually in an
oil/water emulsion containing an adjuvant into a suitable animal.
This is usually a rabbit, although sheep, guinea pigs or donkeys are
sometimes used.
300yg of rat CRH (Peninsula) was dissolved in 0.5ml of saline
and emulsified with an equal volume of Freunds1 complete adjuvent.
The immunogen was administered by multiple intradermal injections
into three New Zealand white rabbits. At the same time, the
animals were given a single subcutaneous injection of 0.5ml
B. pertussis vaccine (Difco, Detroit, MI). At six week intervals,
the animals were boosted with further injections of 200vig of the
immunogen in Freund's complete adjuvant and bled from the ear vein
at 10-14 day intervals after each booster injection. The antiserum
used for radioimmunoassay was obtained from a single rabbit 10 days
after the fourth booster dose of rCRH was administered and will be
referred to as 6F 22*4.
At about the same time, a commercial antiserum to human CRH
(rabbit anti rCRH) became available and was purchased from IgG
Corporation (Nashville, TN). IgG antisera was also tested in the
RIA for rCRH. The antisera, purchased for 1,000 tubes, was




A variety of methods are available for the radioiodination of
peptides and proteins. Iodination methods can be broadly divided,
125
direct methods in which I is directly incorporated into
tyrosine and/or histidine residues, and conjugation methods in which
a radioiodinated moiety is conjugated to a specific side chain,
mostly NH^ groups on side chains and at the N-terminus.
Conjugation methods are more complex but can be used to label
peptides that do not contain tyrosine.
The most widely used method of iodination is the chloramine-T
125
oxidation of Na I in the presence of the protein or peptide to
be labelled (Hunter & Greenwood, 1962). This results in
125
incorporation of I into the tyrosine residues in high yield.
Excess chloramine-T is reduced by the addition of a reducing agent
such as sodium metabisulphite. In order to overcome the problems
of peptide damage caused by soluble oxidising agents such as
chloramine-T, Fraker & Speck (1978), examined the use of the
insoluble oxidising agent l,3,4,6-tetrachloro-3a,
6a-diphenylglycoturi1 (Iodogen). Iodogen is coated onto the
surface of the reaction vessel and iodination effected by the
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addition of Na I and peptide solution. A gentle method for
the iodination of peptides using the enzyme 1actoperoxidase to
catalyse the oxidation of iodide in the presence of small amounts of
hydrogen peroxidase was first described by Marchaloanis (1969).
The reaction is initiated by the addition of hydrogen peroxide and
terminated by the addition of cysteine or by dilution.




The most commonly used conjugation reagent is N-succinimidyl
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3-(4-hydroxy 5-[ I] iodophenyl) proprionate (Bolton & Hunter
reagent; Bolton & Hunter, 1973) and was, therefore, used to
iodinate CRH. The reagent is conjugated to CRH under slightly
alkaline conditions.
The reagents were:
r-CRH 5yg/10yl 0.1M Borate Buffer pH 8.5
Bolton Hunter Reagent lmCi Amersham 1M 5861
Glycine 0.2M in 0.1M Borate Buffer pH 8.5
Trifluoroacetic acid/ lOmg ml-''" KI in 0.2% (v/v) TFA
Potassium Iodide (TFA/KI)
Method: lmCi Bolton Hunter reagent was dried down under nitrogen
and 5yg r-CRH was added. After 15 min on ice, 500yl glycine was
added and left for 5 min on ice before the reaction was terminated








0.2mg ml-"'" in 0.05N HC1
40yg ml-"'' dichloromethane
Amersham IM530: 3.7 G Bq ml-''"
lOmg ml-1 KI in 0.2% (v/v) TFA
Method: 50yl of the stock solution of Iodogen was evaporated to
dryness under nitrogen in a polypropylene tube. 2yg Tyr^-CRH,
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20y1 0.5M phosphate buffer and 10yl (lmCi) Na I were added
together and incubated for 10 min at room temperature. The
reaction was terminated by the addition of 200yl 0.5M phosphate









0.2mg ml * in 0.05N HC1
-1
Amersham IMS 30: 3.7 G Bq Ml'
1 mi~l in 0.05M phosphate buffer
0.03% solution
lOmg ml-1 KI in 0.2% (v/v) TFA.
Method: The peptide was placed in a polypropylene tube together
1 9C
with 25y 1 0.5M phosphate buffer, 10yl Na I (lmCi) and 10yl of
stock lactoperoxidase. The reaction was initiated by the addition
of 5yl 0.03% H202 and incubated for 120 sec at room
temperature. The reaction was terminated by addition of lOOyl








Method: 10yl Tyr^-CRH was placed in a polypropylene tube and 10yl
125
0.25M phosphate buffer, 10yl Na I and 10yg of chloramine-T were
added. After 20 sec the reaction was terminated by the addition of
25yg sodium metabisulphite, 180yl 0.25M phosphate buffer and 620yl
TFA/KI.
0.2mg ml-''' in 0.05N HC1
Amersham IMS 30: 3.7 G B& ml-'"
lmg ml-'' in 0.05M phosphate buffer
2.5mg ml-'' in 0.05M phosphate buffer
lOmg ml-1 KI in 0.2% (v/v) TFA
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The four crude iodination mixtures were purified as described
below and tested in the assay for binding to antisera (Bo) and
non-specific binding (NSB).
2.3.3.5 Purification of Labelled Antigen
Methods describing the purification of ^I-Tyr^-CRH from
free label by reverse phase high performance liquid chromatography
(HPLC) (Gibbs & Vale, 1982; Linton & Lowry, 1982) have been
described. In this study ^I-Tyr^-CRH was purified from the
crude iodination mixtures by HPLC (Harmar & Rosie, 1984). This
system consists of a two-channel mini-pump (Milton Roy Co., Riviera
Beach, FL) connected in series to a three way valve, a sample
injection valve with a 1ml loop (Rheadyne Berkeley, LA) and a guard
column holder (Brownlee MPLC cartridge system! Brownlee Labs, Santa
Clara, CA) containing a disposable cartridge of bonded phase silica,
3cm x 0.46cm (Spheri 5 cyano: Brownlee Labs). The two channels of
the pumps were primed respectively with (a) 0.2% (v/v) aqueous
trifluoroacetic acid (TFA) and (b) 0.2% (v/v) TFA in methanol.
After equilibration of the column in aqueous TFA, the reaction
mixture was injected and eluted with a stepwise gradient of
methanol/TFA in increments of 10% from 50-100%B. The flow rate was
lml min-''" and six fractions of 1ml were collected at each step in
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the gradient. Free Na I passed unretarded through the column
and was eluted first. This method was used to purify crude
mixtures from all four iodination methods.
2.3.3.6 Comparison of Results
The sequence of rat-CRH contains no tyrosine residues and,
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therefore, initially conjugation to Bolton Hunter reagent was
used. Purification of the labelled antigen resolved three peaks,
only one of which was immunogenic. This label gave low total
binding (Bo) and high NSB values, suggesting the antigen may be
damaged. Tyr^-CRH then became available commercially (Peninsula
Laboratores Inc. CA) and more direct methods of iodination were
accessible. Gentle methods of direct iodination, Iodogen and
lactoperoxidase were found to be inconsistent in their incorporation
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of I. Purification of the label resolved peaks in the same
way as Bolton Hunter iodination with one peak being immunogenic.
Again NSB values were high and Bo's quite low and, therefore,
chloramine-T iodination was used. Gibbs & Vale (1982) have
described the use of chloramine-T to iodinate ovine-CRH and this
method was found to be very successful in the iodination of rCRH.
Immunogenic, labelled CRH was eluted in 70% methanol/TFA with a
specific activity of 250pCi/yg CRH, an elution profile is shown in
Fig. 2.1. Non-specific binding was less than 2% and total binding
was greater than those with other labels and was therefore the
iodination method used in this study.
Labelled Tyr-CRH can be stored at -70°C for up to four weeks
without decrease in immunogenicity. After this period, total
binding is reduced and non-specific binding is increased. The
addition of 2-mercaptoethanol did not increase the length of time
over which the label retained its immunogenicity.
2.3.4 Optimisation of Assay Conditions
In order to determine suitable antisera dilutions to give
maximum sensitivity, antiserum dilution curves were set up (Fig.













2.2) with dilutions ranging from 1:25 to 1:200 for IgG anti-CRH and
from 1:200 to 1:16,000 for GF22*4 anti CRH. Antiserum dilutions of
1:90 (final dilution 1:270) for IgG antiserum and 1:4,000 (final
dilution 1:12,000) for GF22*4 gave total binding (Bo) values of
20-25% and were used in all further studies.
It is well established that different buffers, separation
techniques and time course can be altered to optimise conditions for
RIA. In the present study, these conditions were altered to
increase sensitivity of the assay.
The optimum pH for antisera binding in RIA is generally 7-7.5
and, therefore, all buffers tested, were in this range. Triton
X-100 was added to some buffers to reduce adsorption of CRH to assay
tubes and, therefore, reduce non-specific binding. Different
incubation times were also tested for binding of antibody,
non-specific binding and sensitivity of the assay.
2.3.4.1 Buffers
Composition of standard buffers is in Appendix I. The buffers
tested were:
(1) RIA Standard Diluent
a) Phosphate-EDTA pH 7.4 + 0.1% Triton X-100
b) Phosphate-EDTA pH 7.4 + 1% BSA + 0.1% Triton X-100
c) Phosphate-EDTA pH 7.4 + 0.03% Triton X-100
d) Phosphate-EDTA pH 7.4 + 0.03% Triton X-100 + 1% BSA
Antiserum Buffer
All the above buffers were 1% (v/v) with Normal Rabbit
Serum (NRS) and were used in the assay with their respective RIA
standard diluent.
100-1
1^5 -^50 ^200 1//looo ^Aooo /fiooo 1/|16ooo
Antisera dilution
Figure 2.2 Binding of ^^I-TyrQ-CRH at
increasing antisera dilutions
1251—TyrO_CRH binding was reduced as the
dilution of IgG anti CRH serum (•) and GF22*4
anti CRH serum ( ▲ ) was reduced. 20-25%
binding was obtained at a dilution of 1:90 for
IgG antiserum and 1:4000 for GF22*4 antiserum.
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2. RIA Standard Diluent
PBS pH 7.4 + 1% BSA + 200 KlU/ml Trasylol
Antiserum Buffer
a) PBS/NRS + 200 KlU/ml Trasylol
b) PBS/NRS + 2000 KlU/ml/Trasylol
Both antiserum buffers were used in conjunction with RIA
standard diluent (2)
All the buffers were initially tested for NSB and Bo values.
Buffers la), lc) and 2b) gave similar binding which were 2- to
4-fold greater than the other buffers. The reduction from 0.1 to
0.03% in Triton X-100 in buffer lc) did not affect the NSB values
and made the pellet more stable, therefore, decreasing assay
variability. Buffers lc), and 2b) were then tested in a standard
curve to establish which one gave the most sensitive assay.
Standard curves were constructed using rat-CRH (Peninsula Labs
Inc.). A stock solution at lpg/yl in 0.05N HC1 was diluted in the
different buffers and in stripped plasma to concentrations of 10,
20, 50, 100, 200, 500 and lOOOpg/ml. Aliquots of lOOyl were used
and stored at -40°C until required. Both buffer standard curves
were tested with the two antisera 1) IgG anti-CRH at an initial
dilution of 1/90 and 2) GF22*4 at an initial dilution of
1/4,000. As can be seen in Fig. 2.3, buffer lc) gave a standard
curve that was 2-fold more sensitive than the buffer 2b) curve using
IgG antiserum and 4-fold more sensitive when using GF22*4
antiserum. Therefore, IgG antiserum was used routinely with buffer
lc) in the RIA for rat CRH.
CRH pg ml"1
Figure 2.3 Standard curves for CRH
"using different buffers and
antisera
Standard curves were set up with
standards of rCRH ranging from lO-lOOOpg
mi-1 in lOOyl of RIA standard diluent.
The buffers tested were phosphate-EDTA
pH 7.4 + 0.03% Triton X-100 (closed symbols)
and PBS + 1% BSA + 200 KlU/ml Trasylol (open
symbols). Both buffers were tested with




The most common method of separation of antibody bound label
from unbound label and standard unlabelled material is by
precipitation with an antibody against gamma globulins, in this
case, Donkey anti-rabbit gamma globulins (ARGG). Following
incubation with ARGG, the double antibody complex is
precipitated. Separation can also be achieved by dextran-coated
charcoal, alcohol precipitation or precipitation with Staphylococcus
aureus. In this study, different concentrations of ARGG (SAPU)
were examined for levels of binding (Bo) and variability. Final
dilutions of ARGG tested were 1/30, 1/60 and 1/120. Pellet
stability was further increased by the addition of 1.6ml washing
buffer (Phosphate-EDTA pH 7.4 + 2.5% BSA) before centrifugation.
ARGG concentration % Binding ± S.E. (n = 6)
1:30 35.5 ± 7.3
1:60 38.8 ± 4.7
1:120 5.2 ± 24.2
Optimum conditions for precipitation were obtained with ARGG in
a final dilution of 1:60.
2.3.4.3 Time Course
Incubation conditions were checked in order to establish the
optimum time course for maximum sensitivity. Standard curves were
set up for three different time courses and the incubation times
were as described below. All incubations were at 4°C.
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1 2 3
Day 1 Antibody + Label Antibody Antibody
2 ARGG
3 Wash + spin Label
4 ARGG Label
5 Wash + spin
6 ARGG
7 Wash + spin
Standard curves obtained are shown in Fig. 2.4. From these, it
can be seen that an increase in the incubation time of antiserum
with standard antigen increased the sensitivity of the assay.
Therefore, the seven day assay was used routinely for rat CRH.
2.3.4.4 Optimal Conditions for RIA of r-CRH
On the basis of these results, the optimal conditions for RIA of
rCRH were as follows:
1) Assay Buffer: Phosphate-EDTA pH 7.4 + 0.03% Triton X-100
2) Antiserum Buffer: Assay Buffer + 1% NRS containing IgG
antiserum at an initial dilution of 1:90
3) Double antibody: Assay Buffer + ARGG (SAPU) at 1:15
initial dilution
4) Incubation: 7 day assay
These conditions gave an RIA for CRH with a sensitivity of 2-4pg
per tube.
2.3.5 Plasma Extraction
CRH is present in very low concentrations in plasma,




Figure 2.4 Standard curves for CRH with
different incubation time"?
Standard curves were set up with
standards of rCRH using three different
incubation times (♦) - 3 day (□) - 5 day and
(•) - 7 day assay as described in 2.3.4.4.
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detection of CRH present. However, the introduction of plasma to
the assay reduced total binding (Bo) and construction of a standard
curve was impossible. It was necessary to extract CRH from large
volumes of plasma by removing plasma proteins and salt thereby
making the sample suitable for RIA.
Many methods extract CRH from plasma by adsorption onto silicic
acid. This method relies on the hydrophobic properties of peptides
such as CRH. Plasma proteins and salts are washed off the silicic
acid by a water-based solvent and the peptide eluted with an organic
solvent. Silicic acid is available as ODS silica cartridges (Bond
Elut, Scotlab, Carluke) or as 100-200 mesh silicic acid (Sigma
Chemicals). A simpler method of extraction of peptides from plasma
is the precipitation of plasma proteins by methanol leaving peptides
in the supernatant. These three methods of extraction were tested
for recovery of rCRH from plasma samples.
2.3.5.1 Silicic Acid Extraction
Plasma samples of 2.4ml (or samples made up to 2.4ml with
hormone free plasma) were mixed with 1ml of silicicacid slurry
(200mg/ml) in phosphate-EDTA buffer. The samples were then mixed,
end over end, at room temperature for 30 min and centrifuged at
1720 x £ for 10 min. The resultant pellet was resuspended in 2.5ml
H^O by vortexing and the sample centrifuged as before. The
supernatant was discarded and peptides eluted from the silicic acid
pellet with a solution of acetone:acetic acid:water in a ratio of
20:1:79. The pellet was resuspended in 2.5ml of elution solvent
and mixed, end over end, for 30 min before centrifuging as above.
The supernatant was collected and the elution procedure repeated.
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The resulting 5m1 of supernatant was freeze dried and then
resuspended in assay buffer. Standards and blanks were made up in
plasma and extracted as described above.
2.3.5.2 OPS Si 1ica Cartridges
"Bond Elute" cartridges (lOOmg sorbent, 1ml reservoir: Scotlab,
Carluke) were prepared by washing with 2ml methanol/1% (v/v) HC1,
solvent (A) followed by 2ml 1% (v/v) HC1, solvent (B). Plasma
samples were acidified with 5 volumes of solvent (A) and applied to
the cartridges. After two 1ml washes with solvent (A), peptides
were eluted with two applications of 1ml solvent (B). The eluate
was evaporated to dryness under vacuum and the extract was
reconstituted in assay buffer. Plasma standard curves for CRH and
hormone free plasma were extracted as above. The same system was
also used with different solvents (A) 75% acetonitrile, 25% 50mM
Triethylammoniurn formate (TEAF) pH 3.0 (B) TEAF pH 3.0.
2.3.5.3 Methanol
Plasma proteins were precipitated in plasma samples and
standards by addition of ice-cold methanol to a final concentration
of 85% methanol. The samples were mixed and left on ice for 10 min.
Proteins were precipitated by centrifugation at 4°C, 1,720 x £ for
20 min. Supernatants were dried under vacuum, the extracts
reconstituted in assay buffer and transferred to fresh assay tubes.
2.3.5.4 Comparison of Methods
Recovery of CRH from ODS silica cartridges was not consistent
and calculation of a standard curve impossible. Standard curves
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from methanol extraction and silicic acid extraction are shown in
Fig. 2.5. Both extraction techniques gave standard curves that
were parallel with the unextracted buffer curve but the recovery of
standard was greater from methanol extraction. Detection limits
for methanol and silicic acid were 2-4 and 6-8pg per tube,
respectively. The large volumes of plasma required for silicic
acid extraction made it impractical for the small volumes of portal
blood available for assay. Therefore, the recovery, adaptability
and simplicity of the methanol extraction made it the extraction
method used for all plasma samples to be assayed for CRH.
2.3.6 Assay Operation
2.3.6.1 Sample Preparation
Plasma samples (25-100yl) were extracted with 85% methanol as
described in 2.3.5, dried down overnight and reconstituted in lOOyl
assay buffer. The samples were transferred to fresh tubes for RIA.
Tissue samples were homogenised in 5-10 volumes of 2M acetic
acid, diluted in 2M acetic acid and an aliquot taken for RIA. Each
aliquot was dried down and reconstituted in lOOyl assay buffer.
Inhibition of binding by serial dilution of portal plasma extracts
was parallel with the standard curve for CRH (Fig. 2.6).
2.3.6.2 Assay Conditions used in Experimental Studies
The following assay procedure was used, all incubations were at
4°C.
CRH pg ml
Figure 2.5 Comparison of methods for the
extraction of rCRH from plasma
Standard curves for rCRH were set up in RIA
standard diluent (#) and compared with plasma
standard curves for rCRH that had been extracted
with 85% methanol (A) and with silicic acid (O).
10 20 50 100 200
C R H pg ml"'
500 1000
Figure 2.6 Comparison of displacement
curves produced by synthetic
rCRH and dilutions of
extracted hypophysial portal
plasma
Extracted plasma standard curves were set
up (#) and compared with the displacement
curve produced by extracts of 25-200yl
hypophysial portal plasma (A). Extracts of
rat portal plasma showed parallelism with
standard rCRH.
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Day 0 Plasma samples, standards and pools were extracted with
85% methanol and the supernatants evaporated under
vacuum overnight. Standards, NSBs, Bo and pools were
extracted in triplicate.
Day 1 The samples were reconstituted in lOOyl assay buffer
(phosphate-EDTA pH 7.4 + 0.03% Triton X-100), T.C., NSB,
Bo and standards were made up in triplicate. All assay
tubes except TC and NSB tubes were mixed with lOOyl
antiserum buffer (assay buffer + 1% NRS) containing
IgG-anti CRH at an initial dilution of 1:90.
Day 4 100p1 assay buffer containing 5,000cpm
125i_jyr0_cRH, iodinated by chloramine-T and
purified by HPLC was added to the tubes and the tubes
were mixed.
Day 6 100yl assay buffer containing 1:15 ARGG (SAPU) was added
to the tubes and mixed.
Day 7 The tubes were washed with 1.6ml phosphate-EDTA pH 7.4 +
2.5% (w/v) BSA.
All tubes except T.C. were spun for 30 min at 4°C, 1,720 x £.
Supernatants were aspirated and pellets counted for 3 min in a
Berthold gamma counter (MAG 315). The data were analysed by an
on-line computer which constructed a standard curve using a log logit
transformation and also gave the concentrations of CRH in unknown
samples. The assay cut off point was at 10% and 90% B/Bo.
2.3.6.3 Quality Control
Pools of r-CRH in rat plasma at low and high concentrations were
stored in aliquots of 100yl at -40°C. Both low and high pools were
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included in the extraction procedure for each assay. Intra-assay
variability for low and high pools were 10.9% and 3.4%
respectively. Inter-assay variability for low and high pools were
13.5% and 9.4% respectively.
2.3.6.4 Hormonal Specificity
Various peptide hormones were tested to determine antibody
specificity for both antisera used. Dynorphin, B-endorphin,
luteinising hormone releasing hormone, somatostatin-14,
adrenocorticotrophin hormone (ACTH), thyrotrophin releasing hormone,
sauvagine and ovine-CRH were tested in the assay, crossreactivity at
concentrations of up to lug/ml is shown in Fig. 2.7. Neither of
the two antisera crossreacted more than 0.1% with any of the
peptides.
2.3.6.5 Comparison with Other Assays
The assay for rCRH developed here for buffer and extracted
plasma samples has a sensitivity of approximately 2-4pg/tube at the
90% B/Bo cut off point. These detection limits compare favourably
with rCRH assays developed by Sasaki et al. (1984) and by Gibbs &
Vale (1983) who report sensitivities of 3.5 and lOpg/tube
respectively. Both these groups also found it necessary to extract
large volumes of plasma to measure concentrations of CRH.
Inhibition of binding by dilutions of plasma extracts was parallel
with standard curves for rCRH.
CRH pg ml"
Figure 2.7 Crossreactivity of peptides with
IgG CRH antiserum
Displacement curves for rCRH and other
peptides are shown. No peptides other than
rCRH crossreacted with the antiserum.
(•) rCRH
(♦) dynorphin, e-endorphin, luteinising hormone
releasing hormone, somatostatin-14, ACTH,
thyrotrophin releasing hormone, sauvagine and
ovine-CRH.
-48-
2.4 RADIOIMMUNOASSAY FOR ACTH
2.4.1 RIA Standard Diluent
RIA standard diluent consisted of ACTH RIA buffer (Appendix I)
made with 3.5% (w/v) BSA. The buffer was then extracted with
silicic acid. Silicic acid (SIL-A-200, 50-200 mesh screen, Sigma)
was added to RIA standard diluent at lOOmg ml-''" and mixed end over
end for 30 min at room temperature. The buffer was then
centrifuged at 1,720 x £ for 10 min and the supernatant removed and
frozen at -40°C until required. Immediately before use, the buffer
was thawed and Trasylol (250KIU/ml) and 0.03% (v/v) Triton X-100
were added.
2.4.2 Reference Standard
A standard curve was constructed using human ACTH (NIADDK) made
up to 5, 10, 20, 50, 100, 200 and 500pg/ml in RIA standard
diluent. The standards were stored at -40°C in lOOyl aliquots
until required.
2.4.3 First Antibody
IgG-ACTH-l^(IgG Corporation, Nashville, TN) was diluted 1:10,000








Amersham IMS 30: 3.7 GBq ml ""
0.2mg ml-1 in 0.01M HC1
lmg ml-"" in 0.05M Phosphate buffer
2.5mg ml-"" in 0.05M Phosphate buffer
lOmg ml ^ KI in 0.2% (v/v) TFA
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Method: 10yl human ACTH was placed in a polypropylene tube and 10yl
125
0.25M phosphate buffer, 10yl Na I and 10yl chloramine-T were
added. After 20 sec, the reaction was terminated by the addition
of 10yl sodium metabisulphite, 180y1 0.25M phosphate buffer and
620yl KI/TFA. Purification of labelled antigen from the crude
iodination mixture was carried out as described in 2.3.3. Labelled
immunoreactive ACTH eluted in 60% methanol and was stored at -70°C
for up to four weeks.
2.4.5 Second Antibody
Donkey ARGG (SAPU) was diluted 1:5 in RIA standard diluent.
2.4.6 Separation Buffer
The separation buffer used was ACTH RIA Buffer containing 2.5%
(w/v) BSA.
2.4.7 Assay Procedure
The following assay procedure was used:
Day 1 lOOyl of standard or sample was added to lOOyl
IgG-ACTH-1 diluted 1:10,000 in standard diluent.
The tubes were mixed and incubated overnight at
room temperature.
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Day 2 a.m. lOOyl -I-ACTH-containing 10,000cpm in standard
diluent was added and the tubes were mixed and left
at room temperature for 8h.
p.m. lOOyl ARGG 1:5 in standard diluent was added. The
tubes were mixed and incubated overnight at 4°C.
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Day 3 1.6ml of separation buffer was added to each tube
and the tubes immediately centrifuged at 1,720 x £
for 30 min at 4°C. The supernatant was aspirated
and the pellet counted. A standard curve was
calculated as described in 2.3.6.2 and a
representative curve is shown in Fig. 2.8.
2.4.8 Quality Control
Pools of ACTH in rat plasma were stored in aliquots of lOOyl at
-40°C and were included in each assay. Intra- and inter-assay
variation were 13.4% and 5.4% respectively.
2.5 RADIOIMMUNOASSAY FOR CORTICOSTERONE
2.5.1 Radioimmunoassay Buffer
The buffer used in this assay was PBS 0.1% Gelatin pH 7.0
2.5.2 Purification of [1,2,6,7^H] Corticosterone
3
lOOyl (ll.lyCi) of stock [1,2,6,7, H] corticosterone was
evaporated to dryness under nitrogen and redissolved in 40yl of
dichloromethane. This was spotted onto Instant Thin Layer
Chromatography S.A.F. paper (Gelman, Hexely) and run against 5yg
chloroform
cold corticosterone, the solvent used was eight parts A to one
part acetone y^g position of the cold corticosterone was detected
by spraying the paper with 2,4—DNPH/HC1 which turns yellow/orange on
contact with ketones. The corresponding area for the labelled
antigen was excised and eluted with 5mls acetone After
ACTH pg ml
Figure 2.8 Standard curve for ACTH
Standard curve from a representative assay for
adrenocorticotrophin (ACTH). Each point represents
the mean of three replicates.
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evaporation under vacuum, the label was dissolved in 1ml
toluene/ethanol 9:1 and stored at -40°C.
2.5.3 Extraction of plasma
3
500cpm of H-corticosterone in lOOylMeOH was added to each
glass tube used for extraction and evaporated to dryness. 20pl
distilled water
plasma + 80yl A for each sample was added, vortexed and left at
room temperature for 10 min. Corticosterone was extracted by
addition of 1ml ether, vortexed and left for 10 min at room
temperature. The phases were separated by freezing in a solid
COg ethanol bath. The combined extracts were evaporated to
dryness and reconstituted in 2m1 methanol. 500^1 was taken from
each sample and counted for recovery of corticosterone. The
percentage recovery was estimated per sample by multiplying recovery
cpm by 4 and dividing by total counts. Samples were assayed in
duplicate by aliquoting 2 x lOOyl of the extract into LP3 tubes and
evaporating to dryness.
2.5.4 Standards
A stock solution of corticosterone at 20.34mg/ml in ethanol,
stored at -40°C was diluted immediately before use in methanol to
give standards, in duplicate, of 20.3, 40.6, 81.2, 162.4, 324.8,
649.6 and 1299pg/tube. The standards were evaporated to dryness
before inclusion in the assay.
2.5.5 Assay Procedure
The following procedure was used, all incubations were carried out
at 4°C.
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Day 1 Samples and standards reconstituted in lOOyl assay
buffer and lOOyl assay buffer containing 5,OOOcpm
3
H-Corticosterone was added, followed by 500yl
assay buffer containing 1:5000 dilution of
anti-corticosterone serum.
Day 2 200yl assay buffer containing 0.5% (w/v) activated
charcoal and 0.05% (w/v) Dextran T70 was added and
left on ice for 20 min. The tubes were then
centrifuged at 1,720 x £, 4°C for 20 min.
Aliquots of 500y1 were put into liquid scintillant
and counted by a Packard liquid scintillation
analyses.
A standard curve was calculated as described in
2.3.6.2 and a representative curve is shown in Fig.
2.9.
2.6 RADIOIMMUNOASSAY FOR VASOPRESSIN (AVP) AND OXYTOCIN (OT) (based
on the method of Robinson, 1980)
2.6.1 Radioimmunoassay Buffer
The standard assay buffer used was 0.1M Tris containing 3% (w/v)
BSA.
2.6.2 Iodination
The reagents used were:
Columns: For both VP and OT: A 20cm x 1cm Sephadex
A-25 column, eluted with 0.1M Tris/3% BSA.
Corticosterone pg/tube
Figure 2.9 Standard curve for corticosterone
Standard curve from a representative assay for
corticosterone. Each point represents the mean
of two replicates.
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Hormones: Oxytocin (4401U/mg; Dr. H. Vilhardt, Ferring,
Sweden): 250yg ml-''' 0.2M phosphate buffer,
20y1 aliquots were stored at -20°C until required.
Vasopressin (400IU mg-''" Batch No. 770110;
Ferring, Sweden): 250yg ml-"' 0.2M phosphate
buffer, 20y1 aliquots were stored at -20°C until
required.
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Na I: lmCi in 10y1 for each assay.
Iodogen: 2.5yg, deposited in a small glass tube.
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Method: 5yg of the hormone was added together with Na I to a
tube containing Iodogen and incubated at room temperature for
20 min. The reaction mixture was transferred to a column and
eluted with assay buffer and 1ml fractions were collected. The
iodinated peptide appears as a single broad peak, this peak was
rechromatographed on a 1 x 10cm sephadex A-25 column and the
fractions tested for binding to excess antibody. The fraction
showing best immunoreactivity was divided into lyCi aliquots and
stored at -20°C.
2.6.3 Standards
A standard curve for oxytocin was constructed using the IVth
International Standard for OT (NIB$f ) and for vasopressin using the
1st International standard for AVP (NIBS*). Standards were made up
to 1.0, 2.0, 4.0, 8.0, 16.0, 32.0, 64.0, 128.0, 256.0 pg/tube
immediately before use by doubling dilutions in 10% (v/v) cleared
dog plasma in assay buffer from a stock solution of 5ng/ml stored at
-20°C.
* NIBS - National Institute of Biological Standards
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2.6.4 Assay Procedure for AVP
The following assay protocol was used, all incubations were
carried out at 4°C.
Day 1 10yl samples and 90yl assay buffer or lOOyl standards
were added to LP3 tubes followed by 200yl assay buffer
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containing 3,000cpm I-AVP and 1:5000 specific
anti-AVP serum. The tubes were mixed and incubated
overnight.
Day 2 900yl absolute alcohol was added to each tube and
centrifuged at 3000 x £ for 10 min at 4°C. The
supernatant was aspirated and the pellet counted.
Standard curve was calculated as described in 2.3.6.2 and
a representative curve is shown in Fig. 2.10.
2.6.5 Assay Procedure for OT
The following assay protocol was used, all incubations were
carried out at 4°C.
Day 1 10yl samples and 90yl assay buffer or lOOyl standards
were added to LP3 tubes followed by 200yl assay buffer
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containing 3,000cpm I-OT and 1:225,000 specific
anti-OT-serum. The tubes were mixed and incubated
overnight.
Day 2 900yl absolute alcohol was added to each tube and
centrifuged at 3,000 x £ for 10 min at 4°C. The
supernatant was aspirated and the pellet counted. A
standard curve was calculated as described in 2.3.6.2 and
a representative curve is shown in Fig. 2.11.
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Figure 2.10 Standard curve for vasopressin
Standard curve from a representative assay for
vasopressin (AVP) as described in section 2.6. Each
point represents the mean of two replicates.
Oxytocin pg/tube
Figure 2.11 Standard curve for oxytocin
Standard curve from a representative assay for
oxytocin. Each point represents the mean of two
replicates.
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2.7 RADIOIMMUNOASSAY FOR VASOPRESSIN
2.7.1 Radioimmunoassay Standard Diluent
RIA standard diluent consisted of RIA Buffer pH 7.4 + 0.1%
Triton X-100 (see Appendix I)
2.7.2 Reference Standard
Standard curves were constructed using arginine vasopressin
(Cambridge Research Biochemicals); 5, 10, 20, 50, 100, 200 and
500pg/ml were made up in RIA buffer containing 10% rat plasma and
stored in lOOyl aliquots at -40°C.
2.7.3 Antiserum
g
Rabbit anti-Arginine vasopressin (RAS 8103) was obtained from
Peninsula Labs Inc. and diluted 1:4 in RIA standard diluent from the
stock provided by Peninsula. This dilution gave total binding (Bo)
of approximately 25% of the total counts.
2.7.4 Labelled Antigen
Vasopressin was iodinated as described in 2.6.2 with the
exception that iodinated vasopressin was separated from the crude
reaction mix by HPLC as described in 2.3.3. Labelled vasopressin
was stored at -70°C for up to three months.
2.7.5 Separation
Separation was by the double antibody technique. ARGG (SAPU)
was diluted 1:10 in RIA buffer and NRS diluted 1:100 in RIA
buffer. NRS and ARGG were added separately to each tube.
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2.7.6 Assay Procedure
The following assay procedure was used, all incubations were at
4°C.
Day 1 lOOyl of standard or sample made up to lOOyl in standard
diluent was mixed with lOOyl anti-AVP serum diluted in
standard diluent.
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Day 2 100y1 of I-AVP containing 10,000cpm in standard
diluent was added and the tubes were mixed.
Day 3 350yl NRS 1:100 in RIA buffer and 350yl ARGG 1:10 in RIA
buffer were added and the tubes mixed.
Day 4 1ml ice cold phosphate buffered saline was added before
centrifuging at 4°C, 1,720 x £ for 30 min. The
supernatant was aspirated and the pellet counted. A
standard curve was calculated as described in 2.3.6.2 and
a representative curve is shown in Fig. 2.12.
AVP pg ml 1
Figure 2.12 Standard curve for vasopressin
Standard curve from a representative assay
for vasopressin as described in section 2.7.
Each point represents the mean of three
replicates.
CHAPTER 3
EFFECTS OF ENDOCRINE MANIPULATIONS ON THE CONTENT
OF PROOPIOMELANOCORTIN mRNA IN THE ANTERIOR PITUITARY
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3.1 INTRODUCTION
The gene encoding the protein pro-opiomelanocortin (POMC) in the
mammalian neuroendocrine system is under complex hormonal control
and is expressed in a tissue specific manner (Herbert et al., 1980;
Vale et al., 1981; Rosa et al., 1980; Roberts et al., 1982). In
the corticotrophic cells of the anterior pituitary, POMC is
processed to form ACTH, s-1ipotrophin and amino terminal peptide
(Roberts et al., 1978; Hinman & Herbert, 1980). The POMC gene is
also expressed in the neurointermediate lobe (NIL) of the pituitary
gland and at low levels in the hypothalamus (Civelli et al., 1982;
Roberts et al., 1982). However, different post-translational
processing results in the secretion of different sets of hormones:
ACTH in the NIL is further processed to a-MSH and CLIP (Eipper &
Mains, 1980) and in the arcuate region of the hypothalamus, a
mixture of ACTH, a-MSH and CLIP is produced (Krieger & Liotta, 1979).
Secretion of ACTH from the corticotroph cells of the anterior
pituitary is stimulated by CRH (Vale et al., 1981; Yates & Maran,
1974; Rivier et al., 1982) and this action of CRH is potentiated by
AVP (Vale et al., 1981; Gillies et al., 1982; Yasuda et al.,
1982). Corticosteroids are secreted from the adrenal gland
primarily in response to ACTH (Jones et al., 1976) and
glucocorticoids produce inhibitory effects ('negative feedback1) on
the CRF activity of the hypothalamus (Buckingham, 1979) and on the
secretion and content of pituitary ACTH (Dallman et al., 1972;
Sayers & Portanova, 1974). In contrast, glucocorticoids have no
influence on the secretion or content of POMC derived peptides in
the NIL (Roberts et al., 1982). However, dopamine agonists have
been shown to inhibit the release and content of a-MSH and
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s-endorphin from the NIL (Vermes et al., 1980; Farah et al., 1982;
Lepine & Dupont, 1981), while dopamine antagonists have a
stimulatory effect (Hoi It et al., 1982). Dopaminergic compounds
have not been shown to affect POMC peptide secretion from the
anterior pituitary (Rosa et al., 1980). While much is known about
factors modulating POMC peptide secretion from the pituitary, less
is known about the regulation of gene expression, although
differential regulation in the different pituitary lobes is
suggested by the alternate processing pathways. The introduction
of recombinant DNA technology has resulted in reliable assays for
#■
the measurement of specific mRNA levels. Measurement of POMC mRNA
content by Herbert et al. (1981) in separated pituitary lobes after
adrenalectomy showed progressively increasing content in the
anterior pituitary after an initial lag period of 6h until they were
10-fold higher than control values; no change in POMC mRNA content
was found in the NIL. Dexamethasone treatment decreased POMC mRNA
content 30- to 50-fold in adrenalectomised animals. Administration
of glucocorticoids produces a dramatic reduction in POMC gene
transcription which can be detected 15 min after the injection.
This shows that the inhibitary actions of glucocorticoids on POMC
mRNA are due, at least in part, to an inhibition in POMC mRNA
synthesis (Eberwine & Roberts, 1984).
The importance of normal PVN function on the response of
corticotrophs to adrenalectomy has been suggested by results which
showed that the high levels of POMC mRNA in corticotrophs after
adrenalectomy decrease after the PVN is lesioned (Bruhn et al.,
1984). The increase in POMC synthesis after adrenalectomy may be
accounted for largely by the removal of corticosteroids. However,
* For details of 'Northern' blotting see Appendix II.
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in the absence of hypothalamic releasing factors due to hypothalamic
deafferentation, no increase in POMC mRNA after adrenalectomy is
observed (Dallman et al., 1985).
Long-term exposure of cultured adenohypophysial cells to
ovine-CRH increases the cellular content and secretion of ACTH (Vale
et al., 1983b) and also increases the content of POMC mRNA in
corticotrophs (Bruhn et al., 1984). Long-term administration of
ovine CRH j_n vivo increased POMC mRNA content in the anterior
pituitary gland and this increase was reversed by injection of
dexamethasone (Bruhn et al., 1984). Little is known of the effect,
if any, of AVP on ACTH synthesis.
The aims of the present study were to measure POMC mRNA content
in the anterior pituitary gland and examine the effects on POMC gene
expression (i) of high and low concentrations of glucocorticoids
in plasma and (ii) increased CRH release into hypophysial blood by
electrical stimulation of the hypothalamus, and (iii) to determine
the importance of normal vasopressin levels in the brain on POMC
gene expression. Conditions of low plasma glucocorticoid
concentration were produced by adrenalectomy and high plasma
glucocorticoid concentrations were produced by ether stress. It is
well established that a variety of stressors cause release of ACTH
from the anterior pituitary gland and glucocorticoids and
catecholamines from the adrenal gland, but there are few data on the
effects of stress on the biosynthesis of POMC. In order to
investigate whether POMC gene expression can be increased by an
increased release of endogenous CRH into portal blood, anterior
pituitary contents of POMC mRNA after electrical stimulation of the
PVN were compared with those after electrical stimulation of the
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amygdala. The PVN were stimulated because they contain the highest
concentration of CRH and because stimulation of the PVN results in
increased CRH release in portal blood (see Chapter 7). Control
animals with electrode implants in the amygdala, were used to
determine whether changes, if any, in POMC gene expression were due
simply to the stress of implantation of electrodes. The dependance
of POMC gene transcription and translation on normal hypothalamic
AVP levels was determined by measuring the content of POMC mRNA in
the anterior pituitary gland in Brattleboro rats (as defined in
section 2.1) which are genetically deficient in AVP due to a single
expressed in magnocellular neurones
base deletion of the geneA(Schmale & Richter, 1984). Lack of AVP
results in diabetes insipidus and Brattleboro rats are continuously
searching for water. The effect of replacing AVP in the
Brattleboro rat with the synthetic analogue, dDAVP, on POMC mRNA
content in the anterior pituitary gland was also examined.
3.2 MATERIALS AND METHODS
3.2.1 Animals
Adult female Wistar COB rats (200-250g body weight) purchased
from Charles River U.K. Ltd. (Margate, Kent) were used for
adrenalectomy, control and stress experiments. Homozygous or
heterozygous Brattleboro rats (200-250g body weight) were bred in
the Department of Pharmacology. Adult female Long Evans rats were
used as controls and were purchased from Charles River U.K. Ltd.
The animals were maintained under controlled lighting (lights on
0500-1900h) and temperature (22°C) and had free access to Diet 41B
(Oxoid, Basingstoke, Hants) and tap water. Animals that had been
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operated on drank 0.9% (w/v) NaCl solution containing 40mg/l
chlortetracycline hydrochloride.
Brattleboro rats were caged singly in metabolic cages to measure
urine output. A homozygous Brattleboro rat was defined as an
animal which passed urine equal to or greater than 75% of body
weight during a 24h collection period. Brattleboro rats passing
less than this were classed as heterozygous.
Ether stress was applied to female Wister COB rats by placing
until the animals were unconscious
them in a chamber permeated with ether vapour for 5 mir^, Trunk
blood was collected from rats killed without ether stress (cont),
immediately after (Oh), and 6h and 24h after the stress. There
were five animals in each of the four groups. The animals were
rapidly decapitated and the blood was collected in chilled
polypropylene tubes washed with 1000U heparin in 0.9% saline.
Trasylol, 1000 KlU/ml blood was added immediately and samples
mixed. Plasma was stored at -40°C.
3.2.2 RNA Extraction
The pituitary gland was quickly removed and the anterior and
neurointermediate lobes were separated using watchmaker forceps.
RNA was extracted according to Chirgwin et al. (1979). Freshly
dissected tissues were immediately homogenised in 10 volumes of 4M
guanidinium thiocynate and 1M mercaptoethanol pH 5.0 and left at
room temperature for 2h. The homogenate was loaded onto a 5.7M
ceasium chloride cushion and centrifuged at 138,900 x £ for 20h at
room temperature. The resultant pellet was dissolved in lOOmM Tris
acetate/lOOmM sodium acetate pH 9.0 and the RNA precipitated with
10% (v/v) 2M potassium acetate pH 5.5 and 10 volumes ethanol. The
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amount of RNA in the pellet was determined by dissolving the pellet
in water and measuring uv absorbance at 260nm. RNA was stored at
2.5pg/yl at -70°C.
3.2.3 Isolation and in vitro translation of mRNA
Poly (A+) RNA was prepared from total RNA by chromatography on
an oligo (dT) cellulose column a.s described by Aviv & Leder
(1972). RNA was bound to the oligo (dT) cellulose in high salt
binding buffer (0.5M NaCl, ImM EDTA, lOmM Tris pH 7.5) and eluted
from the column with low salt buffer (ImM EDTA, lOmM Tris pH 7.5).
0.7ml fractions were collected and those containing Poly (A ) RNA,
as shown by uv absorbance at 260nm, were pooled and precipitated.
Poly (A+) RNA was stored at lpg/yl at -70°C.
The activity of Poly (A+) RNA isolated in this manner was
checked by inclusion into a cell free rabbit reticulocyte-lysate.
Isolated Poly (A+) RNA added to the reticulocyte lysate system
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increased incorporation of S-methionine into precipitating
proteins 10-fold over control values. Thus the mRNA was judged to
be intact and capable of being translated.
3.2.4 Isolation of Recombinant Plasmid DNA
A 550 base pair cDNA complementary to the ACTH and b-LPH
sequence of the rat POMC mRNA was inserted into pBR322 at the Pst 1
site (Drouin & Goodman, 1980). Bacterial growth and plasmid
preparation were as previously described (Clewell & Helinski,
1972). Cells were centrifuged, lysed and the plasmid concentrated
by centrifugation in ceasium chloride. The plasmid was then
purified by gel filtration chromatography on a Sephadex G50 column
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equilibrated in Buffer H (lOmM Tris, lOOmM NaCl, ImM EDTA, 0.1%
(w/v) SOS pH 7.6).
For Northern Blot analysis the unrestricted plasrnid was labelled
10
with [a P] dCTP by nick translation (Amersham Nick Translation
Kit Nl50) to a specific activity of 10® cpm/yg DNA. The labelled
32
plasmid was separated from free [a P]-dCTP by precipitation with
2.5M ammonium acetate using tRNA as a carrier.
3.2.5 Preparation of Markers
Plasmids pBR322 and pAT153 were restricted with enzymes Alu and
Pst 1 and Bam HI respectively and heat inactivated at 65°C for
10 min. The reactions were mixed giving restriction fragments of
2525, 1131, 910, 657/655, 521, 403 and 281 base pairs. The POMC
cDNA probe is inserted into pBR322 and, therefore, the nick
translated plasmid will hybridise with markers derived from
pBR322. Markers were run with each set of samples.
3.2.6 Detection of POMC mRNA
3.2.6.1 Preparation of RNA sample for Nothern Blot
The RNA was dissolved in 4.4yl H2O and 2.0pl 10 x MEA (running
buffer) was added to give a final concentration of 1 x MEA. The
sample was then denatured by the addition of 3.6y1 formaldehyde and
lO.Oyl formamide and further denatured by heating at 60°C for
15 min. Samples and markers were treated the same way.
3.2.6.2 RNA Separation
RNA samples and markers were separated by electrophoresis on a
-64-
1.1% agarose gel containing 6.7% Formaldehyde and 1 x MEA buffer.
Bromophenol blue was added to the markers as a front indicator.
The gel was run at 150V, 60-80mA, in 1 x MEA until the front was 1cm
from the end of the gel.
3.2.6.3 Hybridisation of Probe
The RNA from the gel was transferred on to presoaked
nitrocellulose sheets according to Thomas (1980). The blots were
then baked at 80°C for 4 hrs and prehybridised in a sealed plastic
bag for 4 hrs at 42°C containing 20mls prehybridisation buffer (50mM
Tris-HCl pH 7.6, 1M NaCl, 0.1% tetrasodium pyrophosphate, 50pg
ml ^ denatured single strand salmon sperm DNA, 10 x denhardt's
reagent, 50% formamide). The buffer was then replaced with 10ml
prehybridisation buffer containing 5% (w/v) dextran sulphate (Sigma
Chemicals) and nick translated rat POMC cDNA (section 3.2.4) after
heat denaturing for 5 min. Hybridisation was carried out at 42°C
in a shaking water bath for 16-20 hrs. Excess probe was removed
from the blot with repeated washing with 5mM Tris HC1 pH 7.5, 25mM
NaCl, 0.1% SDS, ImM EDTA at 52°C for 2h. The nitrocellulose was
dried and autoradiographed with the aid of intensifier screens.
3.2.7 Quantitation of POMC mRNA
Amounts of RNA loaded onto gels and then subsequently
transferred onto nitrocellulose are not always consistent and,
therefore, an internal control was used to standardise the
samples. Each blot was probed with POMC cDNA and then the
procedure repeated with mouse 7SL cDNA as the probe (Balmain et al.
1982). In some cases, both probes were added together. The
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proportion of 7SL RNA in a given cell population will be constant
and, therefore, changes in POMC mRNA levels can be related to it.
Autoradiographs were obtained for POMC and 7SL and the intensity of
and integration of the peak
the bands determined quantitatively by scanning densitometry.
Results are expressed as a ratio of POMC mRNA/7SL RNA.
3.3 RESULTS
3.3.1 Detection of POMC mRNA in total and Poly (A ) RNA extracts
Amounts of Poly (A+) and total RNA extracts from the anterior
pituitary gland of female Wistar COB rats (200-250g body weight)
were size-fractionated on an agarose gel. The resulting Northern
blot was then hybridised with the specific POMC cDNA probe and with
a specific 7SL cDNA probe. Figure 3.1 shows a very strong signal
from the Poly (A+) enriched RNA extract corresponding to a size of
approximately 1000 bases and a weaker one from the total RNA. As
expected only total RNA tracks gave a signal for 7SL RNA.
Figure 3.1 shows that POMC mRNA can be detected in total RNA
extracts and also that 7SL RNA content can be used as an internal
standard. Amounts of RNA loaded onto the gel were routinely within
10% of each other.
3.3.2 Glucocorticoid Effect on POMC mRNA Levels
Total RNA was extracted from anterior pituitaries of adult
female Wister COBS and from female Wistar COBS that had been
adrenalectomised three weeks previously. Adrenalectomy was
validated by the presence of very low plasma corticosterone
concentrations and by inspection for possible adrenal remnants at
Molecular weight
markers (base pai
1 2 3 4 5
Figure 3.1 Detection of POMC mRNA in total and Poly (A+) RNA
extracts from the anterior pituitary gland
Northern blot analysis of Poly (A+) RNA (lanes 1-3) and total
RNA (lanes 4-5) isolated from the rat anterior pituitary gland
hybridized with 7SL cDNA and POMC cDNA Probes. The amount applied
was 0.5yg (lane 1), l.Oyg (lane 2), 2.0yg (lane 3), 5yg (lane 4) and
10yg (lane 5).
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autopsy. POMC mRNA levels were determined as described and
quantitated with respect to 7SL RNA levels. Figures 3.2 and 3.3
show that adrenalectomy increased the content of POMC mRNA in the
anterior pituitary gland 10-fold over the control values.
3.3.3 Effect of Stress on POMC mRNA Levels
The three groups of five animals were stressed with ether as
described in section 3.2.1 and decapitated 0, 6 and 24h after the
stress together with a control, non-stressed group. Total RNA was
extracted from the anterior pituitary glands of these animals and
trunk blood was collected and assayed for ACTH and corticosterone.
Figure 3.4 shows that immediately after stress, plasma ACTH
concentrations had increased approximately 10-fold over control
animals with a 3-fold increase in corticosterone. Six hours after
stress, plasma ACTH concentrations had dropped, but were still
5-fold greater than control values. Twenty-four hours after the
stress, the plasma ACTH concentrations were similar to those in
control animals. POMC mRNA levels were determined in the three
groups as described and were quantitated with respect to 7SL RNA
levels. Figures 3.5 and 3.5 show POMC mRNA content in the anterior
pituitary gland had increased 2-fold 6h after stress and had
returned to control values 24h after the stress.
3.3.4 Effect of Electrical Stimulation on POMC mRNA Levels
Electrodes were implanted as described (2.2.8) and seven days
later, the animals were anaesthetised with sagatal and stimulated
for 30 min as described in 2.2.7. A control group of animals with





Figure 3.2 POMC mRNA content in the anterior pituitary gland of
adrenalectomized rats
Northern blot analysis of total RNA isolated from the rat
anterior pituitary gland from control female Wistar rats (lanes 3
and 4) and in female Wistar rats that had been adrenalectomised for
three weeks (lanes 1 & 2) hybridised with a POMC cDNA probe. The
amount applied was 5yg (lane 1), 10yg (lane 2), 5ug (lane 3) and
10yg (1 ane 4).
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Figure 3.3 7SL RNA content in the anterior pituitary gland of
adrenalectomised animals
Northern blot analysis of total RNA isolated from
the rat anterior pituitary gland from control female Wistar rats
(lanes 3 and 4) and in female Wistar rats that had been
adrenalectomised for three weeks (lanes 1 & 2) hybridised with a
7SL cDNA probe. The amount applied was 5ug (lane 1),
10pg (lane 2), 5yg (lane 3) and 10yg (lane 4).
Figure 3.4 Effect of ether stress on ACTH and corticosterone
concentrations
Mean (± S.E.M.; n = 6) concentrations of ACTH (pg ml_l) and
corticosterone (pg/100ml) in peripheral plasma from intact female
Wistar rats before and after a 5 min period of ether stress. Trunk
blood samples were taken immediately after decapitation before































Figure 3.5 The effect of ether stress on POMC mRNA content in
the anterior pituitary gland
Northern blot analysis of 10pg total RNA extracted from the
anterior pituitary gland of female Wistar rats immediately after 5
min ether stress (lane 1), 6h after ether stress (lane 2) and 24h








of 7SL RNA In the anterior pituitary gland
- stressed rats
Northern blot analysis of 10yg total RNA extracted from the
anterior pituitary gland of female Wistar rats immediately after 5
min ether stress (lane 1), 6h after ether stress (lane 2) and 24h
after stress (lane 3) hybridised with a 7SL RNA probe.
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stimulus was applied. Six hours after stimulation, the animals
were decapitated and the anterior pituitary glands removed.
Pituitary POMC mRNA contents were determined. Figure 3.7 shows
that there was no detectable difference in POMC mRNA content between
the stimulated and the non-stimulated animals.
3.3.5 POMC mRNA Levels in the Brattleboro Rat
RNA was extracted from the anterior pituitary of female Long
Evans rats and female homozygous and heterozygous Brattleboro rats
(as defined in 2.1) and POMC mRNA levels determined. Fig. 3.8
shows that the pituitary content of POMC mRNA in both homozygous and
heterozygous Brattleboro rats was 2-fold higher than the content in
the anterior pituitary glands from the Long Evans rats.
In order to establish whether this increase in POMC mRNA content
in Brattleboro rats could be reversed by treatment with a AVP
analogue, groups of heterozygous and homozygous Brattleboro rats
were given lOpg/lOOg body weight dDAVP (Ferring) i.p. 24h and lh
before decapitation. Control Long Evans and Brattleboro rats were
also decapitated at the same time after injection with lml/lOOg body
weight 0.9% saline. RNA was extracted from the anterior pituitary
glands and POMC mRNA content determined. Figure 3.9 shows that no
difference in POMC mRNA content was detectable between the treated
and non-treated Brattleboro rats.
3.4 DISCUSSION
These results confirm that POMC mRNA can be detected in total
RNA extracts from the anterior lobe of the pituitary by Northern







Figure 3.7 Effect of electrical stimulation of the brain on
POMC mRNA content in the anterior pituitary g1 and
Northern blot analysis of 10yg total RNA extracted from the
anterior pituitary gland of female Wistar rats 6h after electrical
stimulation, hybridised with 7SL cDNA and POMC cDNA probes. In
control animals (lane 1) electrodes were implanted in the amygdala
but no stimulation was applied, electrical stimulation was applied
to the amygdala (lane 2) and the PVN (lane 3) for 30 min (30s on,









Figure 3.8 POMC mRNA content in the anterior pituitary gland of
Brattleboro rats"
Northern blot analysis of total RNA extracted from the anterior
pituitary gland of Long Evans rats (lanes 1 & 2), heterozygous (lane
3) and homozygous (lane 4) Brattleboro rats hybridized with POMC
cDNA and 7SL cDNA probes. The amounts applied were 5pg (lane 1),






Figure 3.9 The effect of dDAVP on POMC mRNA content in the
anterior pituitary gland of Brattleboro rats
Northern blot analysis of 10yg total RNA extracted from the
anterior pituitary gland of Long Evans rats (lanes 1 & 2),
heterozygous Brattleboro rats (lane 3), heterozygous Brattleboro
rats injected with dDAVP (10ng/100g body weight) 24h and lh before
decapitation (lane 4), homozygous Brattleboro rats (lane 5) and
homozygous Brattleboro rats injected with dDAVP as above (lane 6).
The Northern blot was hybridised with POMC cDNA and 7SL cDNA probes.
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quantitated with respect to content of 7SL RNA. POMC mRNA detected
in this way has a mobility corresponding to an RNA of approximately
1000 bases which is in agreement with Civelli et al. (1981). Some
higher molecular weight bands were detected and presumably
correspond to larger, immature forms of the mRNA. Identification
of specific POMC mRNA was further confirmed by the large increase in
mRNA levels measured after bilateral adrenalectomy: three weeks
after adrenalectomy, a 10-fold increase was found which corresponds
well with other reports (Herbert et al., 1980; Bruhn et al.,
1984). The increase in steady state mRNA content has been shown to
be due to an increase in POMC gene expression lh after adrenalectomy
which can be reversed by administration of dexamethasone (Birnberg
et al., 1983; Eberwine & Roberts, 1983). mRNA content continued
to rise up till day 18 after adrenalectomy although the increase in
transcription rates had reached a plateau by 14 days. This
continued increase in mRNA content is unusual and is probably due to
the complex effect of adrenalectomy on corticotroph cells. Five
days after adrenalectomy, POMC-containing cells in the anterior lobe
of the pituitary gland increased in size and number (Chi Ids et al.,
1982). In situ hybridisation has shown that after adrenalectomy in
the rat there is a 2-fold increase in POMC mRNA density in
corticotroph cells and a 3-fold increase in the number of cells in
the anterior pituitary that express POMC mRNA (Gee et al., 1983).
The plateau reached in the increase in transcription rates of the
POMC gene by day 14 is likely due to the cell mass not increasing
any further. The increase in POMC gene expression after removal of
glucocorticoid by adrenalectomy suggests that in the intact animal,
POMC gene expression is partially repressed by the presence of
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endogenous glucocorticoids. However, Dallman et al. (1985) have
shown that in the absence of endogenous drive from the hypothalamus,
the corticotroph does not have the capacity to respond to
adrenalectomy and that in the absence of drive from external
sources, the corticotroph has no autonomy.
The results of the present studies suggest that three
conclusions may be drawn about the regulation of the adrenocortical
system: (1) acute stress which causes a discharge of ACTH from the
pituitary gland is accompanied by an increase in POMC mRNA content
in the anterior pituitary gland (2) stimulation of the PVN which
leads to a short-term increase in exposure of the corticotrophs to
CRH does not appear to affect the synthesis of ACTH in the anterior
pituitary gland (3) lack of AVP in the Brattleboro rat is
associated with results in an increased content of POMC mRNA in the
anterior pituitary gland which is not affected by treatment with
dDAVP.
Acute stress in the rat, elevated the levels of POMC mRNA in the
anterior pituitary and this was associated with an increase in the
plasma concentration of the POMC derived peptide, ACTH, and with an
increase in the release of corticosterone from the adrenal gland.
These results show that both the biosynthetic and secretory
activities of the anterior pituitary are enhanced 6h after ether
stress. Ho 111 et al. (1986) have reported an increase in POMC mRNA
content in the anterior pituitary gland after footshock applied
twice daily for up to seven days; the increase was already
established by day one and diminished by day seven. The magnitude
of the increase in POMC mRNA content seen after repeated footshock
over seven days was similar to that found after infusion of CRH by
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way of osmotic minipumps over a period of 4-8 days (Bruhn et al.,
1984). This suggests that long-term exposure of POMC cells to
endogenous CRH during long-term stress might be a factor in
induction of POMC gene expression. The present study shows that
the elevation of plasma ACTH concentration after application of a
stress persists for over 6h and that this is sufficient to stimulate
induction of POMC gene expression. The mechanism by which stress
induces POMC mRNA changes is unknown but alterations may reflect
changes in mRNA formation (e.g. transcription, RNA processing and/or
RNA degradation). There are preliminary indications that stress
may cause an increase in the j_n vitro transcription rate of the POMC
gene (Eberwine & Roberts, 1984). Plasma concentrations of ACTH at
6h after stress may have been reduced by negative feedback effects
of high circulating corticosterone. A number of workers have shown
that the inhibition of adrenocortical responses is maximal 2-4h
after administration of a single dose of corticosterone (Keller-Wood
& Dallman, 1974; Kendall, 1971). POMC gene transcription rates
have been shown to change 15 min after glucocorticoid
administration, but changes in POMC mRNA content are not detected
until much later (Eberwine & Roberts, 1984).
Stimulation of the PVN for 30 min resulted in a smaller
elevation of plasma ACTH concentration than ether stress
(5- compared with 10-fold, see Fig. 7.7) and the present results
suggest that this stimulus is not sufficient to induce changes in
POMC mRNA content in the anterior pituitary gland. The PVN
contains CRH and AVP cell bodies that project to the median eminence
(Tilders et al., 1982; Merchenthaler et al., 1984) where they
release their neuropeptides into the hypophysial portal blood
vessels (Horn et al., 1985) and, therefore, stimulation of the PVN
should increase the release of CRH and AVP into portal blood. Both
CRH and AVP have been demonstrated to stimulate ACTH secretion and
it has been reported that long-term administration of ovine CRH can
increase the anterior pituitary gland content of POMC mRNA in vivo
(Bruhn et al., 1984). The increase in POMC mRNA content in the
anterior pituitary gland 6h after ether stress followed a 10-fold
increase in ACTH secretion. Electrical stimulation of the PVN for
30 min produced a 5-fold increase in ACTH secretion and did not
increase POMC mRNA content; unfortunately the high mortality rate
of the animals prevented longer stimulation of the PVN.
The Brattleboro rat has been shown to have a 2-fold increase in
POMC mRNA content in both genotypes over the isogenic control the
Long Evans strain of rats. This was a surprising result given that
the ACTH secretogogue, AVP, is thought to be reduced in the
heterozygous and absent in the homozygous Brattleboro. However,
plasma ACTH and corticosterone concentrations are reduced in
Brattleboro rats but this was only significant in the heterozygous
Brattleboro rat (see Chapter 5). Lack of AVP results also in
diabetes insipidus and Brattleboro rats are continuously searching
for water and this could perhaps be regarded as a continuous stress
which affects or involves the hypothalamo-pituitary-adrenal system
and thereby elevates POMC mRNA content above the values in the Long
Evans rats. Injection of dDAVP has been shown to restore urine
output in DI rats to control values (e.g. Valtin et al., 1975;
Sutherland et al., 1985). Whether dDAVP has 'CRF activity' is not
clear. Some groups have reported that dDAVP stimulates ACTH
secretion (Pearlmutter et al., 1974; Aizawa et al., 1982) while
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others report that dDAVP has no CRF activity (Andersson et al.,
1972; Lazlo et al., 1981). After injection with dDAVP in the
present study, peripheral plasma concentrations of ACTH and
corticosterone were significantly increase in homozygous and
heterozygous Braccleboro rats (Chapter 5) and POMC mRNA content was
unchanged in both Brattleboro genotypes, suggesting stress caused by
water seeking was not responsible for elevated POMC mRNA content in
the anterior pituitary gland. These results suggest that dDAVP
does indeed have 'CRF activity1 but does not affect the synthesis of
ACTH. The implications of the elevated POMC mRNA content in
Brattleboro rats in relation to control of ACTH and corticosterone
release will be further discussed in Chapter 5.
CHAPTER 4
REGULATION OF ACTH SECRETION BY GLUCOCORTICOIDS
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4.1 INTRODUCTION
The key role played by the hypothalamus in the regulation of
ACTH secretion has been well established (for review, see Chapter
1). The isolation and characterisation of a peptide with potent
corticotropin-releasing activity (Vale et a 1., 1981) and the
demonstration of its presence in hypophysial portal blood (Gibbs &
Vale, 1982) ended controversy as to whether AVP might have the
additional role of the principal CRF of the hypothalamus.
Nevertheless, it is clear that both AVP and oxytocin (OT), which are
themselves weak ACTH secretagogues, have the ability to potentiate
the effect of CRH on the release of ACTH from the anterior pituitary
(Gillies et al., 1982; Vale et al., 1983; Gibbs et al., 1984).
At concentrations of CRH above which no further increase in ACTH
secretion is observed, addition of AVP or OT further elevates ACTH
secretion from anterior pituitary cells in culture. This
potentiation is observed at concentrations of AVP and OT that are in
the range of those found in portal blood (Horn et al., 1985;
Zimmerman et al., 1973) and, therefore, it is possible that
interactions between AVP or OT and CRH may play a physiological role.
The origin of CRH, AVP and OT and physiology of release have not
been clearly defined. Anatomical studies indicate that neurones
delivering CRH to hypophysial portal vessels in the median eminence
are concentrated in a discrete zone of the parvocellular division of
the PVN (Bloom et al., 1982; Merchanthaler et al., 1983; Swanson
et al., 1983). In contrast, most OT- and AVP-containing neurones
are concentrated in an anatomically distinct magnocel1ular division
that projects to the pars nervosa (Sawchenko & Swanson, 1982;
Rhodes et al., 1981), though cells of each type are scattered
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through the parvocellular division and project to the external layer
of the median eminence (Zimmerman et a 1., 1977). In colchicine
treated animals, a small number of neurones in the magnocel1ular
division of the PVN jointly expressed CRH and OT immunoreactivity,
while a very small number of neurones in the parvocellular division
stain for both CRH and AVP or OT. This expression of two peptides
in individual parvocellular neurones suggests that these peptides
may interact in the control of ACTH secretion (Sawchenko et al.,
1984b).
Removal of the negative feedback effect of glucocorticoids by
adrenalectomy results in marked increases in the transcription of
the ACTH gene (Eberwine & Roberts, 1984) and in the synthesis and
secretion of ACTH (Birnberg et al., 1983; Dallman et al., 1972)
which can be reversed by glucocorticoid treatment. Glucocorticoids
have been shown to inhibit ACTH synthesis and secretion by an action
at the level of the corticotroph itself (Sayers & Portanova, 1974;
Widmaier & Dallman, 1984) and also at the level of the
hypothalamus. Several groups have reported that adrenalectomy
markedly enhances CRH immunostaining in the PVN (Swanson et al.,
1983; Merchenthaler et al., 1983). Vasopressinergic, and to a
lesser extent oxytocinergic projections to the median eminence show
an enhanced immunoreactivity after adrenalectomy which is reversed
by dexamethasone (Stillman et al., 1977). Immunohistochemical
double staining techniques have shown adrenalectomy greatly
increases the number of neurones in which CRH and AVP are
co-localised. Within neurones of the parvocellular region of the
PVN more than 70% of CRH cells stained positively for AVP. The
distribution of OT-stained cells was unaffected by adrenalectomy
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(Sawchenko et al., 1984b). The increase in the number of neurones
in which CRH and AVP are co-localised is presumably due to removal
of glucocorticoids and, therefore, the presence of AVP in
parvocel1u1ar neurones in the PVN is presumably affected by the
withdrawal of adrenal steroids. The dependence of AVP expression
in parvocellular neurones on adrenal steroid withdrawal has been
further confirmed by in situ hybridisation studies which showed that
the density of specific AVP mRNA increased in the magnocel1ular
portion of the PVN after adrenalectomy and that the distribution of
AVP mRNA expanded into the parvocellular region of the PVN. AVP
mRNA could be detected in CRH immunoreactive neurones after
adrenalectomy but not in control animals. The changes in AVP mRNA
content and distribution were prevented by dexamethasone treatment
(Davies et al., 1986).
These data suggest that in addition to its neurosecretory role
in the neural lobe, AVP may be involved in the regulation of
adenohypophysial function after adrenalectomy and, therefore, in the
negative feedback control of ACTH secretion. The aim of the
present study was to determine the mechanism of negative feedback of
glucocorticoids by examining the effect of adrenalectomy on the
release of CRH, AVP and OT into hypophysial portal blood and
pituitary responsiveness to CRH. In preparation for this study,
it was necessary to determine the effect of three different
anaesthetics on the elevation of ACTH and corticosterone
concentrations during surgery and whether anaesthesia would allow
the circadian rhythm of ACTH and corticosterone to be maintained.
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4.2 MATERIALS AND METHODS
4.2 1 Animals and Surgery
Adult female Wistar COB rats (200-250g body weight) purchased
from Charles River U.K. Ltd. (Margate, Kent) were maintained under
controlled lighting (light on 0500-1900h) and temperature (22°C) and
allowed free access to diet 41B (Oxoid, Basingstoke, Hants) and tap
water. Adrenalectomy was carried out under tribromoethanol in two
stages as described in 2.2.4. Animals that had undergone
adrenalectomy drank 0.9% (w/v) NaCl solution containing 2% glucose
and 40mg 1" chlortetracycline hydrochloride. A three week
period of recovery was allowed before the animals were used.
from anaesthetised animals
Peripheral blood samples were takenAwith heparinised syringes
from the external jugular vein. The samples were immediately mixed
with 2000KIU Trasylol/ml blood in chilled plastic tubes before
spinning at 1,720 x £ for 20 min. Plasma was stored at -40°C for
assay. Hypophysial portal blood was collected as described in
2.2.6 during two consecutive 30 min periods. Blood samples were
immediately mixed with Trasylol lOOOKIU/ml blood in chilled plastic
tubes before spinning at 1,720 x £ for 20 min and the plasma was
stored at -40°C for assay. Hypothalami and anterior pituitary
glands were dissected out as described in 2.2.3 and tissue samples
were homogenised in 5-10 volumes 2M acetic acid.
4.2.2 Anaesthetics and Drugs
Surgery was carried out under one of the following anaesthetics,
all given intraperitoneally:
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i) Urethane: Ethyl Carbamate (Sigma Chemicals); lg kg^ body
weight dissolved 1:10 in saline,
ii) Sagatal: Sodium pentobarbitone (May & Baker Ltd.); 36mg
kg ^ body weight, diluted 1:10 with saline,
iii) Althesin: (Glaxovet Ltd., Uxbridge); 1.0ml lOOg ^ body
weight.
Dexamethasone (9a-fluro-16a methyl prednisolone) supplied by
Sigma, was stored as a stock solution of 0.9mg ml-''' ethanol and
diluted 1:10 with saline immediately before use.
Rat corticotrophin-releasing hormone (Peninsula Labs) was dissolved
in 0.05N HC1 and stored at O.lmg ml ^ and diluted before use in
0.9% (w/v) saline containing Img ml-'" ascorbic acid and lOmg
ml-'" bovine serum albumin.
4.2.3 Assays
The concentrations of CRH in plasma and hypothalamic tissue
samples were determined as described in 2.3.6. Plasma samples of
25—100y1 were extracted with 85% methanol and set up in single
aliquots while standards and pools were set up in duplicate. The
lower limit of sensitivity ranged from 2—5pg per tube. Tissue
samples were homogenised in 200yl Acetic acid and diluted 1:100 in
2M acetic acid. lOOyl aliquots were evaporated to dryness,
reconstituted in assay buffer and assayed as described in 2.3.6.
OT and AVP concentrations were determined as described in 2.6.
Plasma samples of 10pl were set up in single aliquots and standards
in duplicate. The lower limit of sensitivity ranged from 4-6pg per
tube for OT and 2—3pg per tube for AVP.
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Concentrations of ACTH in plasma and anterior pituitary tissue
samples were determined as described in 2.4. Plasma samples of
10—50p1 were set up in duplicate and standards and pools in
triplicate. The lower limit of sensitivity ranged from 5-10pg
ml-''". Pituitary samples were homogenised in lOOyl 2M acetic acid
and then diluted 1:20,000 in 2M acetic acid. Aliquots from the
diluted extract of 10 and 25yl were taken in duplicate, evaporated
to dryness and assayed as above.
Corticosterone concentrations were measured as described in
2.5. Single samples of peripheral plasma (20-50yl volume) were
extracted with ether and aliquots of the extract dried down and set
up in duplicate in the assay. Standards were diluted in methanol
dried down and set up in duplicate in the assay. Crossreactivity
of the antiserum to dexamethasone was less than 0.1%.
4.3 RESULTS
4.3.1 Anaesthetics
Six groups of six female Wistar rats were anaethetised with
either urethane. saqatal or althesin and peripheral blood collected
1 h after induction of anaesthesia
from the external juqular veirw SamDles were taken at 20 min
in a second group of animals
intervals between 09UU-1000h andAbetween 1700-1800h and assayed for
ACTH and corticosterone. Figure 4.1 shows ACTH and corticosterone
concentrations at both time points under the three anaesthetics,
taking the late afternoon peak and the lowest morning values for
each anaesthetic. The circadian rhythm of ACTH and corticosterone
was maintained under anaesthesia with althesin; plasma
concentrations of ACTH increased 4-fold and corticosterone 2-fold in
Figure 4.1 Effect of anaesthesia on the circadian rhythm of
ACTH and corticosterone in plasmaT
Mean (± S.E.M.; n = 6) concentrations of ACTH (pg ml~l) and
corticosterone (yg.100ml) in peripheral plasma from female Wistar
rats at 09.20h and 17.40h (1 and 2 respectively) under anaesthesia
with althesin (Alt), sagatal (Sag) and urethane (Ure). Blood
samples were withdrawn from the external jugular vein. *p < 0.01


































the afternoon compared with the morning although the difference in
corticosterone concentration was not significant. Similar results
were obtained with sagatal; plasma ACTH concentrations increased
3-fold and corticosterone 2-fold with only the difference in
corticosterone concentrations being significant. The plasma
concentrations of ACTH were considerably higher under urethane
anaesthesia compared with the values in animals under the other
anaesthetics and the circadian rhythm of ACTH was abolished under
urethane anaesthesia. Although ACTH concentrations under sagatal
anaesthesia were elevated above those with althesin anaesthesia,
sagatal was chosen as the anaesthetic for the remainder of
experiments because the survival rate was much higher with sagatal
compared with althesin anaesthesia.
4.3.2 Hypophysial blood collection
Results are expressed as the concentration of CRH, AVP and OT in
hypophysial portal plasma and also as content (concentration x
volume in 30 min) of CRH, AVP and OT in hypophysial portal plasma.
Expression as content allows for correction of different volumes of
plasma collected and is the total amount of hormone
secreted into portal blood during the 30 min collection period (Fink
& Jameson, 1976).
4.3.3 Effect of Adrenalectomy on ACTH and corticosterone
concentrations in peripheral plasma and the anterior
pituitary gland
Peripheral concentrations of ACTH and corticosterone were
measured in control female Wister COB rats and in female Wister COB
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total
rats three weeks afterAadrenalectomy. Animals were anaesthetised
with sagatal, the pituitary stalk exposed and peripheral samples
taken from the external jugular vein immediately before cutting the
pituitary stalk. Fig. 4.2 shows that adrenalectomy significantly
increased the concentration of ACTH 4-fold. Whether adrenalectomy
was complete was confirmed by the low concentrations of
corticosterone in plasma and by the absence of adrenal tissue at
autopsy. The anterior pituitary content of ACTH was significantly
reduced (p < 0.001; n = 5) from 11.5 ± l.lug per pituitary to 5.83
± 0.8yg per pituitary by adrenalectomy. In adrenalectomised
animals injected with dexamethasone, 0.5mg kg-''' body weight 2.5h
before blood collection, the ACTH concentration was decreased 2-fold
(Fig. 4.2). The pituitary content of ACTH in adrenalectomised rats
treated with dexamethasone was 13.6 ± 0.9yg/pituitary gland which is
significantly greater (p < 0.001; n = 5) than the value of 5.83 ±
0.8ug/pituitary gland in untreated adrenalectomised rats.
4.3.4 Effect of adrenalectomy on concentrations of CRH, AVP and
OT in hypophysial portal plasma
Fig 4.3 shows that adrenalectomy three weeks before collection
of hypophysial portal blood produced a significant 5-fold increase
in the CRH content in portal plasma when compared with the content
of CRH in portal plasma of intact control animals. Dexamethasone
injection had no significant effect on the concentration or content
of CRH in portal plasma in adrenalectomised animals when compared
with the values in untreated adrenalectomised animals (Fig. 4.3).
The concentrations and contents of AVP in hypophysial portal
plasma were significantly increased in adrenalectomised rats when
Figure4.2
Effectofadr nalectomyplasmaACTHandcorticosteroneconcentr tions
Mean(±S.E.M.;n=10)co centrationfa)ACTHa db)corti steroneinperipheralplasm
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compared with the values in control animals. AVP content and
concentration were, respectively, 4- and 5-fold greater in
adrenalectomised than in control rats (Fig. 4.4). Dexamethasone
injection resulted in a 2-fold decrease in concentration and content
of AVP when compared with the values in untreated adrenalectomised
rats although the concentrations did not return to the values in
intact control rats (Fig. 4.4).
There was no significant difference between the concentration
and content of OT in hypophysial portal blood in adrenalectomised
rats when compared with control rats (Fig. 4.5). Dexamethasone
injection also had no significant effect on OT release into
hypophysial portal blood.
4.3.5 Pituitary responsiveness to CRH after adrenalectomy
Female Wistar COB rats, adrenalectomised three weeks previously,
were injected with either saline or 0.5mg kg-^ body weight
dexamethasone and anaesthetised with sagatal. Three hours after
injection, the external jugular vein was exposed and an initial
peripheral blood sample collected. This was followed by
intravenous injection of either saline, O.lyg CRH or 3pg CRH and
blood samples collected 5, 15 and 60 min after injection. Fig 4.6
shows injection of O.lpg CRH to saline treated animals produced a
2-fold increase in the plasma ACTH concentration above the initial
ACTH concentration when compared with injection of saline which
increased ACTH concentrations above control values by 20%.
Injection of 3yg CRH produced a 4-fold increase in the plasma ACTH
concentrations. Dexamethasone injection decreased initial plasma
ACTH concentrations 10-fold and significantly reduced the ACTH
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Figure 4.6 Pituitary responsiveness to CRH after adrenalectomy
Mean (± S.E.M.; n = 5) concentration of ACTH (pg/ml) in
peripheral plasma from adrenalectomised female Wistar rats. Rats
were injected with either dexamethasone (Dexa) or saline 3h before
blood samples were withdrawn from the external jugular vein
(time 0). Immediately after this, the rats were challenged with
either saline, O.lyg CRH or 3yg CRH and blood samples collected 5,
15 and 60 min after the challenge.
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response to injections of either 0.1 or 3.0yg CRH. Due to the
substantial differences in baseline ACTH concentrations between the
dexamethasone and the saline treated rats, the results are expressed
in Fig. 4.7 as a percentage increase above the initial plasma ACTH
concentration. Figure 4.7 shows that there was a dose response
effect to CRH in saline-treated adrenalectomised rats and that while
the dexamethasone treated adrenalectomised rats did respond to 3yg
CRH, the response was significantly lower than in the saline-treated
adrenalectomised rats.
4.4 DISCUSSION
The choice of anaesthetic has been shown previously to have
important consequences. For example, althesin anaesthesia does not
block the spontaneous ovulatory surge of LH or the associated surge
of LHRH, in contrast, sagatal and urethane anaesthesia block both
these surges (Sarkar et al ., 1976; Fink & Jamieson, 1976; Sherwood
et al., 1980). Urethane has been shown to elevate SS in portal
blood compared with sagatal or althesin anaesthesia (Chihara et al.,
1976). Also, the release of TRH into portal blood during the
afternoon of pro-oestrous was higher with althesin than with sagatal
or urethane (Fink et al., 1982). ACTH and corticosterone are
secreted in a circadian fashion (Chiappa & Fink, 1977). It was
necessary to use an anaesthetic that would not substantially
elevate the secretion of these hormones or abolish the circadian
rhythm, otherwise changes in the release of these hormones and of
their hypothalamic releasing factors could be masked. In the
present study, urethane anaesthesia elevated plasma ACTH and



















Figure 4.7 Pituitary responsiveness to CRH after adrenalectomy
Mean (± S.E.M.; n = 5) of the percentage increase over time 0
in plasma concentrations of ACTH 60 min after the challenge of saline,
0.1 pg CRH or 3 pg CRH. Female Wistar rats that had been adrenal-
ectomised for three weeks were pretreated 3 h before blood collection
with either saline or dexamethasone (DEXA). *P < 0.05 when compared
to the dexamethasone treated rats (Student's t-test).
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levels and abolished the circadian rhythm ACTH. These results
agree with the work of Hamstra et al. (1984). Hamstra proposed
that urethane was stimulating the cholinergic system as the
increased secretion of corticosterone could be reversed by
atropine. The present study demonstrates that the circadian rhythm
of corticosterone is maintained with sagatal anaesthesia but not
with althesin, this is in agreement with Honma et al. (1984) and
Dunn & Doray (1984). However, the opposite applies to the ACTH
rhythm with althesin and not sagatal maintaining the circadian
rhythm. From these results, there was very little difference
between althesin and sagatal anaesthesia as neither anaesthetic
substantially elevated the secretion of ACTH and corticosterone.
Sagatal was used routinely as it gave a higher survival rate than
althesin.
These results, using sagatal anaesthesia, show that interruption
of the negative feedback effect of glucocorticoids by adrenalectomy
results in a significant increase in both CRH and AVP release into
hypophysial portal blood. The increased release of AVP, but not
CRH, can be significantly reduced by dexamethasone injection.
Adrenalectomy resulted in a marked increase in ACTH synthesis as
shown by increased content of POMC mRNA in the anterior pituitary
(see Chapter 3). Secretion was reduced to that in intact rats by
dexamethasone administration 2.5h before blood collection and this
finding agrees with that of other reports (Eberwine & Roberts,
1984; Birnberg et al., 1983). However, after three weeks of
adrenalectomy, the anterior pituitary content of ACTH was
significantly reduced when compared with the values in control
animals. The finding of reduced pituitary ACTH content differs
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from the findings of Buckingham & Hodges (1974) and Dallman et al.
(1972), who found an increase in pituitary content three weeks after
adrenalectomy. The pituitary ACTH contents in the present study
suggest that the increase in the synthesis of ACTH in the anterior
pituitary gland after adrenalectomy (as discussed in chapter 3) does
not compensate for the increased secretion of ACTH into peripheral
plasma and, therefore, results in a depletion of the content of ACTH
in the anterior pituitary gland.
The mechanism by which the corticotroph responds to
adrenalectomy has been the focus of many recent studies. Dallman
et al. (1985) have shown that in animals in which anterolateral
hypothalamic deafferentation has been carried out, the corticotroph
was unable to respond to adrenalectomy by increasing ACTH synthesis
and secretion. The findings of Dallman et al. (1985) suggest that
hypothalamic drive plays an important role in glucocorticoid control
of ACTH secretion. Wynn et al. (1985) have demonstrated a
down-regulation of receptors for CRH in the anterior pituitary gland
after adrenalectomy which was accompanied by a comparable decrease
in CRH stimulated adenylate cyclase activity in the anterior
pituitary gland. The ability of the corticotroph to maintain
increased ACTH release in spite of down-regulation of the CRH
receptors indicates that elevated ACTH secretion can be maintained
by occupancy and activation of a small number of CRH receptors and
also suggests that synergistic interactions between CRH and other
regulators of ACTH release may contribute to the substantial
increase in ACTH secretion that follows adrenalectomy. The
interactions between CRH and other peptides in the regulation of
ACTH secretion has been confirmed by the present study, in that
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increased release of CRH and AVP into hypophysial portal blood was
found to correlate with increased plasma concentrations of ACTH.
OT release remained unaffected by adrenalectomy and this is in
agreement with the immunohistochemical studies which showed that no
increase in the distribution or density of OT staining occurred
after adrenalectomy (Sawchenko et al., 1984a). The ratio of
CRH:AVP in hypophysial portal blood after adrenalectomy was the same
as in control animals; that is, the portal blood content of both
peptides increased 5-fold, suggesting that both peptides are of
similar importance in controlling the ACTH response to
adrenalectomy. The present result differs from that of Holmes et
al. (1986) who found that vasopressin release from the median
eminence in vitro increased 3- to 4-fold more than CRH release after
adrenalectomy. Holmes et al., (1986) suggested that AVP was the
predominant ACTH releasing stimulus in adrenalectomised rats.
However, the results of Holmes et al. (1986) were based on
experiments on tissue containing nerve terminals isolated from their
cell bodies and are therefore unlikely to represent the situation in
vivo and are difficult to compare with the present in vivo studies.
Previous reports have found CRH-like activity in the
hypothalamus, as measured by bioassay (Krieger et al., 1977) or
radioimmunoassay (Suda et al., 1983), increases after adrenalectomy
and the increase in CRH-like activity is consistent with the present
data. On the other hand, the effects of replacement with
glucocorticoids at the pituitary and hypothalamic level have been
less consistent. There are known to be at least three distinct
time domains in which negative feedback by glucocorticoids on ACTH
secretion are exerted: fast (within seconds to minutes),
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intermediate (over 2-10h) and slow (over hours to days, for details
see section 1.3.3). Thus, interpretation of results of an in vivo
experiment are dependent on the timing of the experiment relative to
the glucocorticoid signal. In the present study, the timing of
corticosteroid treatment represents an intermediate level of
feedback. Administration of dexamethasone 2.5—3h before blood
collection was chosen because a number of studies have indicated
that maximal inhibition of adrenocortical function occurs between 2h
and 4h after administration of a single dose of dexamethasone
(Takebe et al., 1971; Jones et al., 1974a). Replacement of
glucocorticoids in adrenalectomised animals with dexamethasone in
the present study did not reverse the increase observed in CRH
release into portal blood but did decrease the release of AVP.
This is contrary to what has been reported by other groups who have
found that an intermediate level of feedback decreases the release
and synthesis of CRF (Vermes et al., 1977; Hillhouse & Jones,
1976; Jones & Hillhouse, 1976). However, these discrepancies can
be explained, in part, by their use of bioassay to determine changes
in CRF release. Bioassay would be unable to differentiate between
CRH and AVP, thereby masking the differential regulation of the two
peptides.
The effect of long-term glucocorticoid feedback on specific CRH
mRNA and specific AVP mRNA in the hypothalamus has been examined by
Northern blot analysis of hypothalamic mRNA seven days after the
removal of glucocorticoids by adrenalectomy. Hypothalamic content
of both CRH mRNA (Jungami et al., 1985) and AVP mRNA (Davies et al.,
1986) were found to be increased seven days after adrenalectomy
suggesting that the increased release of CRH and AVP into portal
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blood observed in the present study is the result of increased
synthesis of the precursor proteins. Replacement of
glucocorticoids in adrenalectomised rats by injection of
dexamethasone for seven days reversed the increase observed after
adrenalectomy in hypothalamic content of both CRH mRNA (Jungami et
al., 1985) and AVP mRNA (Davies et al., 1985) However, in the
present study, restoration of 'intermediate' feedback in
adrenalectomised rats reduced the release of AVP into portal blood
but had no effect on the release of CRH into portal blood when
compared to untreated adrenalectomised rats, suggesting that at the
intermediate level of feedback, there is differential regulation of
AVP and CRH release by glucocorticoids. Differential regulation of
AVP and CRH has also been observed in response to insulin-induced
hypoglycemia where the AVP, but not the CRH concentration, increases
in portal blood (Plotsky et al., 1985c) and in the response to
haemorrhage, where CRH acts as the predominant regulatory agent
(PIotsky et al., 1985b).
As mentioned above, after adrenalectomy, CRH and AVP are
co-localised in the parvocellular division of the PVN and,
therefore, it seems reasonable to suggest that the AVP and CRH
released into portal blood after adrenalectomy originate from the
same nerve terminals. However, the differential regulation of CRH
and AVP release by glucocorticoids would argue against this. In
the parvocel1ular region of the PVN only 70% of CRH cells stain for
AVP after adrenalectomy and, therefore, it appears that the two CRH
cell types in the parvocel 1 ul ar region are differentially regulated
by glucocorticoids.
In adrenalectomised animals the secretion of CRH is not reduced
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by restoration of glucocorticoid feedback for 3h, however, the
effectiveness of CRH in stimulating ACTH secretion from the anterior
pituitary gland is dramatically reduced. The results obtained in
the present study show that the administration of glucocorticoids to
adrenalectomised rats 3h previously, drastically reduced the
responsiveness of the pituitary gland to exogenous synthetic CRH and
this is in agreement with the results obtained by Rivier et al.
(1982) in the intact rat.
In conclusion, removal of the negative feedback of
glucocorticoids by adrenalectomy results in an increase in ACTH
secretion from the anterior pituitary gland which is a result of an
increase in the release of CRH and AVP into hypophysial portal
blood. Restoration of glucocorticoid feedback for an
'intermediate' time period reduced ACTH secretion into peripheral
plasma by a combination of two factors (1) a reduction in the
release of AVP into portal blood and (2) reduced pituitary
responsiveness to CRH. The results of the present study indicate
that glucocorticoid feedback acts both at the hypothalamic and at
the pituitary level to influence ACTH secretion.
CHAPTER 5




The defect in the hormone secretion of the Brattleboro rat was
first discovered when it was noted that Brattleboro rats had a urine
output each day that was equivalent to greater than 70% of its body
weight, compared to 3% in the Long Evans strain, the strain from
which Brattleboro rats are derived. The abnormality in
heterozygous Brattleboro rats is intermediate between that of
homozygous Brattleboro rats and the normal, Long-Evans rats. The
first and major endocrine abnormality to be described in the
Brattleboro rat was its deficiency in the neurohypophysial
peptides. The lack of AVP results in diabetes insipidus and
Brattleboro rats are constantly searching for water. Not only was
AVP found to be absent in the posterior pituitary gland of
homozygous Brattleboro rat but the posterior pituitary content of 0T
was also less in Brattleboro rats than in control Long-Evans rats
(SokoU Valtin, 1965; Valtin et al., 1965). However, peripheral
plasma concentrations of 0T were shown to be higher in homozygous
Brattleboro rats than in control rats suggesting reduced pituitary
content was a result of increased secretion (Edwards et al.,
1982). A partial AVP deficiency was reported in heterozygous
Brattleboro rats in posterior pituitary lobe content and peripheral
plasma concentrations (Sokol & Valtin, 1965; Moses & Miller,
1970). Analysis of the pedigree of these Brattleboro rats led to
the conclusion that the defect in the Brattleboro rat strain is
inherited as an autosomal semirecessive trait at a single gene locus
(Valtin et al., 1975). Horn et al. (1985) found that AVP was
undetectable in hypophysial portal plasma from the homozygous
Brattleboro while heterozygous Brattleboro rats had reduced
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concentrations of AVP in portal blood when compared to the Wistar.
Concentrations of 0T in portal blood were significantly higher in
both strains of Brattleboro than in the Wistar rat (Horn et al.,
1985). The AVP deficit in Brattleboro rats appears to be due to a
single base deletion in exon B of the protein coding region of the
AVP precursor (Schmale & Richter, 1984). The deletion leads to an
'out-of-frame' reading sequence and loss of both the glycosylation
site and the normal temination site with the possible consequence of
impeded AVP-mRNA translation (Schmale & Richter, 1984). However,
in the homozygous Brattleboro rat, immunoreactive AVP has been
demonstrated in the ovaries (Lim et al., 1984) and in the adrenal
gland (Nussey et al., 1984) suggesting that the homozygous
Brattleboro is not entirely deficient in AVP. Very low
concentrations of immunoreactive AVP have also been found in the
anterior pituitary gland and hypothalamus of the homozygous
Brattleboro rat (Nussey et al., 1984; Lolait et al., 1986), and
Mezey et al. (1986) have shown AVP and C-terminal propressophysin
immunoreactivity in the PVN, supraoptic nuclei and in the posterior
pituitary of homozygous Brattleboro rats suggesting that homozygous
Brattleboro rats make small amounts of the normal AVP precursor.
AVP and possibly 0T are weak ACTH secretagogues and also have
the ability to potentiate the effect of CRH on the release of ACTH
from the anterior pituitary gland (see Chapter 1).
Immunocytochemical staining has shown that CRH is located in the
PVN, supraoptic nuclei, median eminence and in the posterior
pituitary gland of both Long-Evans and homozygous Brattleboro
rats. Hypothalamic staining for CRH in the Brattleboro rat was
weaker than in the Long Evans rat (Burlet et al., 1983).
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Therefore, many groups have examined the effect of the Brattleboro
rats hormonal deficiencies on ACTH and corticosterone concentrations
in peripheral plasma. Plasma ACTH and corticosterone
concentrations in homozygous Brattleboro rats have been reported to
be similar, higher and lower than those in Long Evans rats (Arimura
et al., 1967; Allen et al., 1982; Ixart et al., 1982; Buckingham,
1982; Conte-Devolx et al., 1982; Laulin et al., 1985). These
conflicting results may be due, in part, to differences in resting
conditions and treatment of the animals.
The aim of the present study was to measure the release of ACTH
secretagogues, CRH, AVP and OT into hypophysial portal blood in Long
Evans, Wistar and Brattleboro rats. The release of CRH, AVP and OT
was correlated with peripheral plasma concentrations of ACTH and
corticosterone. In Brattleboro rats, the adrenocortical response
to injection of the AVP analogue, dDAVP was also examined.
5.2. MATERIALS AND METHODS
5.2.1 Animals and Surgery
Adult female Wistar COB and Long Evans rats purchased from
Charles River U.K. ltd. (Margate, Kent) and Brattleboro rats, bred
in the Department of Pharmacology (200-250g body weight), were all
maintained under controlled lighting (lights on 0500-1900h) and
temperature (22°C) and allowed free access to diet 41B (Oxoid,
Basingstoke, Hants) and tap water. Brattleboro rats were housed
singly in metabolic cages and urine output was measured over a 24h
period. Animals that passed an amount of urine equal or greater
than 75% of their body weight were classified as homozygous and
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those that passed less than 75%, as heterozygous Brattleboro rats.
Confirmation of hormonal phenotype was confirmed at the end of the
experiment when the pituitary gland was removed and assayed for AVP.
Rats were removed individually from their cages and decapitated
within 1 min. Trunk blood was collected into chilled heparinised
plastic tubes containing Trasylol 200KIU/ml blood. Tubes were
mixed before spinning at 1,720 x £ for 20 min. Plasma was stored
at -40°C before assay. Hypophysial portal blood was collected,
under anaesthesia with sagatal as described in 2.2.6, over two
consecutive 30 min periods. Blood samples were immediately mixed
with Trasylol (lOOOKIU/ml blood) in chilled plastic tubes before
spinning at 1,720 x £ for 20 min at 4°C, plasma was stored at
-40°C. Hypothalamic and anterior pituitary glands were dissected
out as described in 2.2.3 and tissue samples homogenised in 5-10
volumes of 2M acetic acid.
dDAVP (10yg/ml saline) was administered by i.p. injection at a
dose of lOpg/lOOg body weight 24h and lh before decapitation.
Control animals were injected with saline at a dose of lml/lOOg body
weight 24h and lh before decapitation.
5.2.2 Assays
Concentrations of CRH in plasma and hypothalamic tissue samples
were determined as described in 2.3.6. Plasma samples of 25-50yl
were extracted with 85% methanol and set up in single aliquots while
standards and control pool samples were set up in duplicate. The
lower limit of sensitivity ranged from 2-4pg per tube. Tissue
samples were homogenised in 200yl 2M acetic acid and diluted 1:100
in 2M acetic acid, 100yl aliquots were evaporated to dryness,
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reconstituted in assay buffer and assayed as described.
Oxytocin concentrations were determined as described in 2.6.
Plasma samples of 10y1 were assayed in single aliquots and standards
in duplicate. The lower limit of sensitivity ranged from 4-6pg per
tube.
Vasopressin concentrations were determined as described in
2.7. Plasma samples of 10yl and standards were assayed in
duplicate. The lower limit of sensitivity ranged from l-2pg per
tube. Pituitary and hypothalamic tissue samples were homogenised
in lOOpl and 200pl 2M Acetic acid respectively and then diluted from
1:100 to 1:64000 in assay buffer. Aliquots of lOOyl were assayed
in duplicate.
The presence of AVP immunoreactivity in hypophysial portal blood
was further examined by high performance liquid chromatography by
Dr. I.C.A.F. Robinson as described in Robinson & Jones (1983). In
brief, the portal blood sample was loaded onto a Nucleophil 5ym
column with Cg packing. The peptides were eluted at a flow rate
of lml/min with a linear gradient from solvent A [0.1% v/v) TFA in
water] to solvent B [(0.1% v/v) TFA in 60% acetonitrile] from 10-40%
B over 30 min. The fractions collected were than analysed for AVP
immunoreactivity by RIA as described in 2.6.
Concentrations of ACTH in plasma and anterior pituitary tissue
samples were determined as described in 2.4. Plasma samples of
25—50y 1 were set up in duplicate and standards and pools in
triplicate. The lower limit of sensitivity ranged from 5-10pg/ml.
Corticosterone concentrations were measured as described in
2.5. Single samples of peripheral plasma (20-50yl volume) were
extracted with ether and aliquots of the extract dried down and set
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up, with standards, in duplicate.
5.3 RESULTS
5.3.1 Peripheral plasma concentrations of ACTH and corticosterone
Trunk blood was collected from groups of six female Wistar, Long
Evans homozygous and heterozygous Brattleboro rats. Figure 5.1 and
5.2 show that in the Wistar rat, concentrations of ACTH and
corticosterone were significantly lower than in the Long Evans
rat. There was no significant difference in the plasma ACTH and
corticosterone concentrations between the homozygous Brattleboro and
Long Evans rats but the concentrations of ACTH and corticosterone in
the heterozygous Brattleboro rat were significantly lower than in
the Long Evans (Fig. 5.1 and 5.2).
Injection of the vasopressin analogue, dDAVP, 24h and lh before
decapitation to heterozygous Brattleboro rats significantly
increased ACTH and corticosterone concentrations 3- and 2-fold
respectively, when compared with animals injected with saline alone
(Fig. 5.1 and 5.2). In the homozygous Brattleboro rat, the
increases in plasma ACTH and corticosterone concentrations after
dDAVP injection were not significant when compared to homozygous
rats injected with saline alone.
5.3.2 Concentrations of CRH, AVP and OT in hypophysial portal plasma
There was a significant difference in the concentration
(Fig. 5.3) and content (Fig. 5.4) of CRH between the Wistar and the
Long Evans rats. The concentration and content of CRH in the Long
Evans rats was approximately 2-fold greater than in the Wistar
























Figure 5.2 Peripheral plasma concentrations
Evansin Wistar, Long and
of corticosterone
Brattleboro rats
Mean (± S.E.M.; n = 6) concentration (yg 100ml-l) of
corticosterone in peripheral plasma from female Wistar (WIS),
heterozygous Brattleboro (HET), homozygous Brattleboro (HOM) and
Long Evans (LE) rats. Rats were injected with either saline or
dDAVP (+ dDAVP) 24h and lh before decapitation. *p < 0.001,
**p < 0.05 when compared with Long Evans rats. ***p < 0.01 when
compared with the saline treated Brattleboro rats (Student's t-test)




















CRH content (pg )
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rats. The concentrations and contents of CRH in the Long Evans
control rats and homozygous or heterozygous Brattleboro rat were not
significantly different (Fig. 5.3 and 5.4). The hypothalamic
content of CRH in the Long Evans rat (31.8 ± 4.6ng/hypothalamus) did
not differ significantly from the CRH content in the heterozygous
Brattleboro (32.8 ± 2.4ng/hypothalamus) or in the homozygous
Brattleboro rats (31.0 ± 4.0ng/hypothalamus).
Figures 5.5 and 5.6 show that there were no differences in the
concentrations and contents of AVP in portal blood between the Wistar and
Long Evans rats. There were no significant differences in the AVP
concentrations or contents between the Long Evans control and
heterozygous Brattleboro rats. AVP was consistently found in
hypophysial portal blood from homozygous Brattleboro rats, in three
separate experiments and using two different assay systems, at
approximately 50% of the concentration and content found in Long
Evans rats. The posterior pituitary content of AVP in the Long
Evans rat was 582 ± 117ng/lobe and this was significantly higher
than the heterozygous Brattleboro rat, 12 ± 2ng AVP/posterior lobe
(p < 0.001; n = 6). AVP was undetectable in the posterior
pituitary lobe and hypothalamus of the homozygous Brattleboro rat
and hypothalamic AVP was detectable only in the Long Evans rats
(21.6 ± 3.4ng/hypothalamus). AVP was undetectable in the anterior
pituitary gland of Long Evans rats and was present in very low
amounts in the heterozygous Brattleboro (0.1 ± 0.05ng/anterior
pituitary) and in the homozygous Brattleboro rat (0.3 ±
O.lng/anterior pituitary).
There was no significant difference in 0T concentration (Fig.
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Figure 5.5 Concentration of Vasopressin (AVP) in hypophysial
portal plasma of Wistar, Long Evans and Brattleboro
rats
Mean (± S.E.M.; n = 8) concentration of AVP (ng ml~l) in
hypophysial portal plasma from female Wistar (WIS), heterozygous
Brattleboro (HET), homozygous Brattleboro (HOM) and Long Evans rats
(LE). Hypophysial portal blood was collected during two
























Figure 5.6 Content of Vasopressin (AVP) in hypophysial portal
plasma of Wistar, Long Evans and Brattleboro rats
Mean (± S.E.M.; n = 8) content of AVP (ng/30 min) in
hypophysial portal plasma from female Wistar (WIS), heterozygous
Brattleboro (HET), homozygous Brattleboro (HOM) and Long Evans rats
(LE). Hypophysial portal blood was collected during two





















Figure 5.7 Concentration of Oxytocin (OT) in hypophysial portal
plasma of Wistar, Long Evans and Brattleboro rats
Mean (± S.E.M.; n = 8) concentration of OT (ng ml-1) in
hypophysial portal plasma from female Wistar (WIS), heterozygous
Brattleboro (HET), homozygous Brattleboro (HOM) and Long Evans rats
(LE). Hypophysial portal blood was collected during two
consecutive 30 min periods (1 and 2).
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Figure 5.8 Content of Oxytocin (OT) in hypophysial portal
plasma of Wistar, Long Evans and Brattleboro rats
Mean (± S.E.M.; n = 8) content of OT (ng/30 min) in hypophysial
portal plasma from female Wistar (WIS), heterozygous Brattleboro
(HET), homozygous Brattleboro (HOM) and Long Evans rats (LE).
Hypophysial portal blood was collected during two consecutive 30 min
periods (1 and 2).
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between Wistar and Long Evans rats.
Hypophysial portal blood extracts from homozygous Brattleboro
rats and from Long Evans rats were examined by high performance
liquid chromatography by Dr. I.C.A.F. Robinson. The AVP
immunoreactivity from homozygous Brattleboro rats co-eluted with
authentic from the Long Evans rats. The amount of AVP in the
Brattleboro rat portal blood extract was approximately 33% of the
amount found in the extract from Long Evans rats (Fig. 5.9).
5.4 DISCUSSION
These results show that there is a strain difference between
Wistar and Long Evans rats in peripheral plasma concentrations of
ACTH and corticosterone and that this difference can be attributed
to a significantly lower concentration of CRH
in portal blood in Wistar rats. The strain
differences found between Long Evans and Wistar rats in ACTH and
corticosterone concentrations demonstrates the importance of using
the isogenic control for the Brattleboro rat. Surprisingly, the
homozygous Brattleboro rat was repeatedly found to have vasopressin
present in portal blood at concentrations of about 50% of those
found in heterozygous rats and control Long Evans rats. There was
no significant difference in CRH or OT concentrations in portal
blood between either Brattleboro or Long Evans rats. ACTH and
corticosterone concentrations in peripheral blood were lower in
Brattleboro rats compared with the concentration in Long Evans rats
but the difference was significant only in the heterozygous rat.
Injection of dDAVP to homozygous and heterozygous Brattleboro rats
















Figure 5.9 HPLC analysis of hypophysial portal plasma from Long
Evans and Brattleboro rats
Hypophysial portal plasma was collected from Long Evans and
homozygous Brattleboro rats and analysed by HPLC. Thirty-five 1ml
fractions were collected and assayed for AVP by RIA. Results are
expressed as vasopressin pg/tube.
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heterozygous Brattleboro rat.
Immunoreactive AVP was found present in portal blood of
homozygous Brattleboro rats. Classification of Brattleboro rats as
homozygous was based on their urine output in a 24h period was equal
to or greater than 75% of their body weight and by the absence of
immunoreactive AVP in the posterior lobe of the pituitary gland.
Chromatographically, the immunoreactive AVP in portal blood was
identical to authentic AVP from Long Evans rats. The presence of
AVP in portal blood in homozygous Brattleboro rats is not in
agreement with Horn et al. (1985) who found AVP was undetectable in
portal blood in homozygous Brattleboro rats. Although in the
present study, AVP was not detectable in hypothalamic extracts from
Brattleboro rats, the dilution factor was too great to measure the
low amounts of AVP reported by other groups. Many groups have
reported low concentrations of AVP in the hypothalamus of the
homozygous Brattleboro rat (Lolait et al., 1986; Brownstein et al.,
1980; Russell et al., 1980) thus providing a source for the AVP
found in the portal blood from homozygous Brattleboro rats. Higher
hypothalamic content of AVP has been shown in Long Evans rats (this
study and Lolait et al., 1986) and this is reflected in the higher
content of AVP in portal blood and in the posterior lobe of the
pituitary gland. The heterozygous Brattleboro portal blood content
of AVP was not significantly different from the Long Evans though
hypothalamic and posterior pituitary content of AVP were
substantially lower in the heterozygous Brattleboro rat.
The presence of AVP in hypophysial portal blood from homozygous
Brattleboro rats is supported by the work of Mezey et al. (1986) who
have shown AVP and C-terminal propressophysin immunoreactivity in
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the PVN, supraoptic nuclei and in the posterior pituitary of
homozygous Brattleboro rats. From these results, Mezey et al.
(1986) suggest that homozygous Brattleboro rats make small amounts
of the normal AVP precursor. The results of the present study and
also Mezey's results are, at first sight, difficult to reconcile
with the results of Schmale & Richter (1984), who have shown a
genetic deficit in the Brattleboro rat which leads to an alteration
in the AVP precursor. The presence of AVP in portal blood from
homozygous Brattleboro rats suggests that (1) that the faulty AVP
precursor is extracellularly processed after release; this would
require the processing enzymes to work rapidly and efficiently to
process the AVP after release and before collection of portal blood
and is, therefore, unlikely (2) that the defect in the Brattleboro
rats in the present study is not the same as the defect reported by
Schmale & Richter (1984) or (3) the defect reported by Schmale &
Richter (1984) would result in an alteration in the sequence of the
C-terminus of the AVP precursor. It is possible that in the ovary,
the adrenal gland and also in parvocellular neurones, the C-terminal
component of the AVP precursor is not required for the processing of
AVP, thereby explaining the tissue-specific distribution of AVP in
the Brattleboro rat. However, the presence of C-terminal
immunoreactivity in the adrenal gland, the testis and in the
supraoptic and PVN of homozygous Brattleboro rats (Mezey et al.,
1986) suggests this is not the case or (4) that Brattleboro and
normal rats have more than one AVP gene. There is preliminary
evidence to support the latter hypothesis as there appear to be more
than two rat genes which hybridise to a neurophysin probe (Mezey et
al., 1986). Processing of the different AVP genes in a tissue
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specific manner could result in the high concentration of AVP in
portal blood but very little AVP in the posterior pituitary gland.
Hypothalamic content of CRH and portal blood concentrations of
CRH and OT were not significantly different in the three groups.
ACTH and corticosterone concentrations in the homozygous Brattleboro
rats were not significantly lower than control animals.
It would perhaps be expected, given
the synergistic relationship between AVP and CRH in stimulating ACTH
release, that such a reduced secretion of AVP would result in a much
greater deficit in ACTH release. Results in chapter 3 indicate
that in both genotypes of the Brattleboro rat, the mRNA encoding for
the ACTH precursor (POMC) is 2-fold more abundant than in control
Long Evans rats. It is, therefore, possible that the
adrenocortical feedback system has a different set point in
Brattleboro rats, the reduced concentration of corticosterone having
less feedback effect on the anterior pituitary. Thus, in relation
to Long Evans rats, POMC mRNA synthesis and ACTH release is
increased in Brattleboro rats.
Laulin et al. (1985) have postulated that ACTH and
corticosterone concentrations are higher than expected in
Brattleboro rats due to the stress of water deprivation. In the
present study, replacement of AVP with the synthetic analogue dDAVP
in Brattleboro rats significantly increased the secretion of ACTH
and corticosterone, but had no effect on POMC specific mRNA levels
(Chapter 3). The present data is in agreement with Aizawa et al.
(1981) who found ACTH secretion increased after injection with
-100-
dDAVP. The site of action of dDAVP appears to be on the pituitary
since dDAVP also stimulates the secretion of ACTH from the isolated
anterior pituitary (Pearlmutter et al., 1974). However, there is
also a report by Andersson et al. (1972) that dDAVP, at doses much
lower than used in this study, did not stimulate ACTH secretion in
healthy male human subjects. In homozygous Brattleboro rats,
administration of dDAVP has been shown to enhance hypothalamic
staining for CRH (Burlet et al., 1983). Therefore, it is possible
that dDAVP acts at the level of the hypothalamus to increase CRH
release and also directly on the anterior pituitary gland to
increase ACTH secretion without having an effect on POMC gene
expression.
In conclusion, the homozygous Brattleboro rat has been shown to
have AVP present in hypophysial portal blood at concentrations of
approximately 50% of those found in Long Evans rats. The reduction
in AVP in portal blood does not appear to affect ACTH release. The
presence of AVP in portal blood in Brattleboro rats and the absence
of AVP from the posterior pituitary gland suggests that (1)
parvocel1ular neurones do not require the C-terminal component of
the AVP precursor for the correct formation of AVP or (2) there
may be more than one AVP gene, tissue specific processing of the
different genes could result in AVP in portal blood being derived
from a different AVP precursor to the precursor that supplies the
neurones that project to the posterior pituitary gland.
CHAPTER 6
EFFECT OF ELECTRICAL STIMULATION OF THE MEDIAN EMINENCE




For many years, AVP and OT were thought to be located
exclusively in the posterior pituitary gland with projections coming
from magnocellular neurones in the hypothalamus. More recently,
immunohistochemical evidence has shown an OT- and AVP-containing
pathway in mammals in the external layer of the median eminence with
endings on the capillaries of the hypophysial portal system
(Zimmerman, 1977). This pathway has also been demonstrated in
birds using Gomori staining (Oksche et a 1., 1974). Further studies
have shown that the origin of this AVP and OT is in parvocel1ular
neurones of the PVN (Swanson et al., 1983; Merchanthaler et al.,
1983), suggesting that there are two distinct systems involved in
the secretion OT and AVP. One system which originates in
parvocellular neurones, terminates in the external layer of the
median eminence and releases OT and AVP into portal blood and
another system which originates in the magnocellular neurones and
terminates with the release of OT and AVP from the posterior
pituitary gland. AVP can be released from median eminence in vitro
(Beny & Baertschi, 1981) and release ran be increased by stimulation
with depolarising concentrations of potassium (Holmes et al.,
1986). Both AVP and OT have been found in high concentrations in
hypophysial portal blood at concentrations approximately
10- to 20-fold greater than the values in peripheral blood
(Zimmerman et al., 1973; Recht et al., 1981; Gibbs, 1984; Horn et
al., 1985).
Electrical stimulation of the median eminence in vivo increased
AVP and OT release into peripheral blood but not into hypophysial
portal blood (Horn et al., 1985). The possible explanations
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offered by Horn et al. (1985) were that the frequency of stimulation
used may have been too high or that the neurones were fatigued by
the frequency or by the length of pulse trains. However, both
these explanations were unlikely as the same frequency and length of
stimulation caused a significant release of AVP and 0T into
peripheral blood in intact animals. The third, and most likely
explanation, was that exposure and subsequent cutting of the stalk
somehow leads to maximal activity of the VP and 0T neurones so that
release of these peptides cannot be increased by stimulation. The
study by Horn et al. in 1985 was carried out under urethane
anaesthesia which has been shown, in Chapter 4, to substantially
elevate ACTH and corticosterone concentrations. The choice of
anaesthesia may account for the fact that Horn et al. (1985) found
that electrical stimulation of the median eminence did not increase
AVP and 0T release into portal blood although other explanations
cannot be excluded. Endogenous opioids may regulate 0T and AVP
release from the posterior pituitary. Opioid peptides are present
both within (Martin & Voight, 1981; Weber & Barchas, 1983; Zamir
et al., 1985) and around (Van Leeuwen et al., 1983) magnocellular
neurones in the supraoptic and paraventricular nuclei that
synthesise AVP or 0T. Metenkephalin has been found to be
co-localised with oxytocin and dynorphin and related peptides
co-localised with vasopressin. In addition, opiate receptors are
present in the neural lobe of the pituitary and in the supraoptic
and paraventricular nuclei of the hypothalamus of the monkey
(Womsley et al., 1982). In the isolated neurohypophysis, reports
on the effect of opioid agonists and antagonists on electrically
stimulated AVP release have been variable with both inhibition of
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AVP release by opioid agonists (Iversen et al., 1980; Lightman et
al., 1982) and no effect of opioid agonists (Bicknell et al., 1985b)
being reported. Data on the effect of opioid antagonists on
electrical stimulation of AVP from the neurohypophysis are also
conflicting. Maysinger et al. (1984) and Knepel & Meyer (1983)
have reported that naloxone increases the electrically stimulated
release of AVP from the neurohypophysis while Bicknell & Leng (1982)
and Bicknell et al. (1985a) found no effect of opioid antagonists on
stimulated AVP release. The inhibitory effect of endogenous opioid
peptides on electrically stimulated 0T release from the
neurohypophysis in vitro has been demonstrated by the work of many
groups, showing that naloxone infusion markedly increased the
secretion of OT in response to electrical stimulation of the
neurohypophysis (Clarke et al., 1979; Bicknell & Leng, 1982;
Maysinger et al., 1984).
These data demonstrate that an opioid ligand is released within
the posterior pituitary gland together with AVP and OT and acts to
inhibit OT and possibly AVP secretion. The aims of the present
study were to examine the effect of anaesthesia on release of AVP
and OT and to establish whether endogenous opioid peptides inhibit
OT and AVP release into hypophysial portal blood during electrical
stimulation of the median eminence.
6.2 MATERIALS AND METHODS
6.2.1 Animals and Surgery
Female COB Wistar rats (200-250g body weight), purchased from
Charles River U.K. Ltd. (Margate, Kent), were maintained under
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controlled lighting (lights on 0500-1900h) and temperature (22°C)
and allowed free access to diet 41B (Oxoid, Basingstoke, Hants) and
tap water.
Anaesthesia was induced with either urethane (ethyl carbamate lg
kg""'" body weight) or sagatal (sodium pentobarbitone 36mg kg-''"
body weight). One group of animals was anaesthetised with urethane
20 min after anaesthesia was induced
and/\given an i.v. loading dose of lmg naloxone hydrochloride (Sigma
Chemicals) in 0.5ml 0.9% saline via the external jugular vein lh
before blood collection. Circulating concentrations of naloxone
were kept constant during blood collection by infusion of naloxone
1.55mg ml ^ at a rate of 0.54ml h-"" into the external jugular
vein. A control group of animals received an infusion of saline
instead of naloxone.
The method of collection of hypophysial portal blood and
electrical stimulation of the median eminence were as described in
2.2.6 and 2.2.7. Hypophysial portal blood was collected into
chilled plastic tubes containing Trasylol 1000 KIU /ml blood.
Blood was collected during two consecutive 30 min periods with
electrical stimulation applied to the median eminence of some
animals during the second collection period. The electrical
stimulus was generated by a Neurolog constant current stimulator
(Digitimer, Welwyn Garden City, Herts) and a stimulus of biphasic
rectangular waves with parameters of frequency 50Hz, pulse width
lms, amplitude of 1mA, was applied in trains of 30 sec on and 30 sec
off.
6.2.2 Assays
Oxytocin and Vasopressin concentrations in portal and peripheral
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plasma were determined as described in 2.6. Plasma samples of lOpl
were set up in single aliquots and standards in duplicate. The
lower limit of sensitivity for oxytocin ranged from 4-6pg/tube and
for vasopressin from 2-3pg/tube.
6.3 RESULTS
6.3.1 Volume of hypophysial portal plasma collected
Table 1 shows that the volumes of hypophysial portal plasma
collected in the first 30 min in the groups infused continuously
either with saline or naloxone, were significantly greater than the
volumes collected in the groups not infused with saline. The volume
of plasma collected during stimulation of the median eminence in the
non-infused group was significantly greater than the volume
collected before application of the stimulus. Because of these
differences in volumes of portal plasma, the values of 0T and AVP in
portal plasma are expressed as content (concentrations x volume of
plasma collected) as well as concentration.
6.3.2 Stimulation of 0T and AVP into hypophysial portal blood
Hypophysial blood was collected under anaesthesia with Sagatal
and stimulation was applied during the second 30 min collection
period to one group. Peripheral blood samples were withdrawn from
the external jugular vein immediately before sectioning of the stalk
and at the end of collection of portal blood. Fig. 6.1 and 6.2
show respectively that there was no significant increase in either
the concentration or content of AVP or 0T during the second 30 min
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* Peripheral plasma concentrations of OT and AVP
Control group; 0.25 ± 0.19 ng/ml OT, 0.17 ± 0.13 ng/ml AVP.
Stimulated group (prestimulation); 0.3 ± 0.15 ng/ml OT,
0.19 ± 0.16 ng/ml AVP
Saline infused group; 0.3 ± 0.1 ng/ml OT, 0.28 ± 0.19 ng/ml AVP
Naloxone infused group; 0.26 ± 0.15 ng/ml OT, 0.14 ± 0.12 ng/ml AVP
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all the groups, peripheral plasma concentrations of 0T and AVP were
significantly (p < 0.001) lower than these found in portal plasma.
Figs. 6.3 and 6.4. show that continual infusion with either
saline or naloxone to animals anaesthetised with urethane did not
significantly affect concentration or content of either AVP or OT in
hypophysial portal plasma. In all the groups, peripheral plasma
4"
concentrations of AVP and OT were significantly lower (p < 0.001)
than portal plasma concentrations.
6.4 DISCUSSION
These results, which show that 0T and AVP are present in
hypophysial portal plasma in higher concentrations than in
peripheral plasma, are in agreement with previous findings (Oliver
et al., 1977; Recht et al., 1981; Gibbs, 1984; Horn et al.,
1985). Stimulation of the median eminence did not increase release
of 0T or AVP into portal blood, as was the case in the study by Horn
et al. (1985) under urethane anaesthesia. As shown in Chapter 4,
urethane anaesthesia substantially elevates the plasma
concentrations of ACTH and corticosterone. The lack of effect of
median eminence stimulation on AVP and 0T release into portal blood
could be explained by the fact that the anaesthesia and pituitary
stalk section could lead to maximum release of 0T and AVP neurones
so that stimulation could not further increase the release of these
peptides into portal blood. However, this explanation for the lack
of effect of median eminence stimulation on the release of AVP of
maximum output cannot be reconciled easily with the significant
increase in AVP found in adrenalectomised animals. In the present
study, anaesthesia was induced with sagatal which does not elevate
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stress hormones so dramatically (Chapter 4) when compared with
urethane anaesthesia. There was no increase in the release of AVP
or 0T on stimulation of the median eminence with either
anaesthetic. In the present study, comparison between
pre-stimulation amounts of AVP and 0T released under urethane and
sagatal is difficult due to the infusion of saline to the rats
anaesthetised with urethane. It is, therefore, not possible to
ascertain whether urethane anaesthesia increased the release of AVP
and 0T into portal blood to a greater extent than anaesthesia with
sagatal.
The frequency of the electrical stimulus used has produced an
increased release of other peptides into hypophysial portal blood
(Fink & Jamieson, 1976; Sheward et al., 1984) and has also
increased release of AVP and 0T into peripheral blood (Horn et al.,
1985). Endorphins are synthesised in the hypothalamus (Smyth,
1983) and are released into hypophysial portal blood (Wardlaw et
al., 1982; Sakar & Yen, 1985). Therefore, the possibility that
stimulated release of AVP and 0T is inhibited by opioid peptides was
examined by blockade of opioid receptors with naloxone.
Stimulation of the median eminence under infusion with naloxone
failed to increase the release of AVP and 0T into portal blood.
Although there are conflicting views regarding the in vitro effects
of naloxone on AVP secretion from the posterior pituitary, with both
facilitation and lack of effect being reported (Bicknell & Leng,
1982; Maysinger et al., 1984; Bicknell et al., 1985a), the
stimulatory action of naloxone and k-antagonists on in vivo and in
vitro 0T secretion from the posterior pituitary has been well
established (Bicknell & Leng, 1982; Bicknell et al., 1984;
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Bicknell et al., 1985a). Therefore, it is surprising that naloxone
infusion had no effect in the present study on basal or stimulated
release of AVP and OT. B-endorphin has been shown to have a dual
effect on CRF release from the rat hypothalamus in vitro with a
stimulatory response at low concentrations and an inhibitory effect
at higher concentrations (Buckingham, 1986). The stimulatory
effect of B-endorphin on CRF secretion is readily antagonised by
naloxone and has been shown to be mediated by y opioid
receptors while the inhibitory action of 8-endorphin on CRF release
is only antagonised by concentrations of naloxone high enough to
interact with 6 opioid receptors (Buckingham & Cooper, 1986).
Opioid substances normally produce an effect by inhibiting the
release of neurotransmitters and, therefore, the inhibitory action
of B-endorphin may be exerted on 6 receptors on the releasing-factor
different
secreting neurones and on A receptors at the pituitary level. The
different receptor types may explain the difference in the effect of
naloxone at the hypothalamic and pituitary level. The
concentrations of naloxone used in the present study may have been
insufficient to block & receptors and, therefore, the lack of effect
of naloxone cannot rule out the possibility that opioid peptides
prevent an increased release of AVP and OT into hypophysial portal
blood in response to electrical stimulation.
CHAPTER 7
EFFECT OF ELECTRICAL STIMULATION OF THE BRAIN
ON THE HYPOTHALAMO-PITUITARY ADRENOCORTICAL SYSTEM
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7.1 INTRODUCTION
Central neural control of adrenocortical function has been the
subject of numerous studies. However, there is still controversy
regarding the role of various brain structures in the control of
pituitary-adrenal function. The neural apparatus which regulates
adrenocortical function is generally held to have two components; a
medial basal hypothalamic component which maintains a basal level of
secretory activity and a limbic-midbrain component which is involved
in the circadian rhythm and stress induced ACTH release (Yates &
Maran, 1975).
The involvement of the hypothalamus in control of adrenocortical
function is well established. The parvocel1ular region of the
paraventricular nuclei (PVN) of the hypothalamus contains AVP and
CRH neurones that terminate on hypophysial portal vessels in the
median eminence. CRH and AVP are transported to the anterior
pituitary where they stimulate ACTH release, which in turn
stimulates release of corticosterone from the adrenal cortex (for
details see Chapter 1). Glucocorticoid receptor density is high in
the hypothalamus, particularly in the PVN where there is
considerable overlap between cells containing a high concentration
of glucocorticoid receptors and cells containing immunoreactive CRH
(Fuxe et al., 1985). Stimulation of the lateral hypothalamus
resulted in a marked increase in plasma Cortisol in the monkey
(Frankel et al., 1978) and stimulation of the PVN increased the ACTH
concentration in plasma of cats (Dornhorst et al., 1981). The
increase in plasma concentrations of ACTH and corticosterone in
response to hypothalamic stimulation has been suggested to be due to
stimulated release of CRH and/or AVP from the median eminence. CRH
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and AVP release from the isolated median eminence can be stimulated
by depolarising concentrations of potassium (Holmes et a 1., 1986).
However, electrical stimulation of the median eminence or PVN did
not increase the release of AVP from the median eminence into
hypophysial portal blood (Horn et al., 1985). The lack of effect
of electrical stimulation of the median eminence in releasing AVP is
surprising given that the frequency used for stimulation had
resulted in a significant release of AVP and 0T into peripheral
blood in intact animals. Horn et al. (1985) concluded that
exposure and subsequent cutting of the pituitary stalk may lead to
maximum activity of the AVP neurones so that release of the peptide
could not be further increased by stimulation.
Species differences as well as differences in methodology may
account for some discrepancies in changes in plasma corticosterone
following stimulation or lesioning of the amygdala. Increased
adrenocortical activity has been reported to follow bilateral
removal of the amygdaloid and pre-amygdaloid cortex of cats and dogs
(Martin et al., 1958), electrolytic destruction of the amygdala of
rats (Yamada & Greer, 1980) or ablation of the medial amygdala
nuclei in deer mice (Eleftheriou et al., 1966). Decreased activity
followed transection of the stria terminalis and bilateral
amygdalectomy of concious monkeys (Mason, 1959). An increase in
plasma corticosterone concentrations have been reported to follow
electrical stimulation of the amygdala of conscious cats where
pre-stimulation concentrations of corticosterone were low. In the
cat, when corticosterone concentrations were elevated due to
anaesthesia with urethane, stimulation of the corticomedial amygdala
caused inhibition of corticosterone release suggesting that the
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inhibitory effect of stimulation of the amygdala is masked in
animals with low prestimulation concentrations of corticosterone
(Matheson et a 1., 1971). However, plasma corticosterone
concentrations also increased after stimulation of the amygdala in
conscious rats (Carrillo & Dunn, 1977) and in rats anaesthetised
with pentobarbitone (Redgate & Fahringer, 1973). The various
individual nuclei of the amygdala project differently onto the
hypothalamus (Krettek & Price, 1978) and in the anaesthetised rat,
Dunn & Whitener (1986) have shown that stimulation of the different
amygdaloid nuclei have different effects on plasma concentrations of
corticosterone; stimulation of the central and lateral amygdaloid
nuclei produced a decrease in plasma corticosterone concentrations
and stimulation of the basomedial, medial and posterior
corticomedial nuclei resulted in increased plasma corticosterone
concentrations.
The hippocampus has been shown to exert mainly an inhibitory
effect in the regulation of ACTH secretion (Casady & Taylor, 1976;
Mangili et a1., 1966) and also to play a role in maintaining the
circadian rhythm of adrenocortical function (Moberg et al., 1971).
The hippocampus is a main target region for corticosterone (McEwen,
et al., 1979). Type 2 glucocorticoid receptors (as described in
1.4.1) are present in high concentrations in the CA1 and CA2 regions
of the hippocampus (Fuxe et al., 1985). Detailed analysis of
changes in plasma concentrations of corticosterone following
stimulation of the hippocampus has shown that in the anaesthetised
rat, specific changes can be related to distinct sites within the
hippocampus. An increase in plasma corticosterone concentration
was observed following stimulation of the CA1 region. In contrast,
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stimu1 ation of CA3, the dentate gyrus and the subiculum produced
significant decreases in plasma corticosterone concentrations (Dunn
& Orr, 1984).
The aim of the present study was to examine the effect of
stimulation of the limbic and hypothalamic structures presumed to be
involved in adrenocortical function on the release of CRH and AVP
into hypophysial portal blood. The changes in CRH and AVP release
into portal blood were correlated with the changes in plasma
concentrations of ACTH and corticosterone after brain stimulation in
rats in which the pituitary stalk was intact.
7.2 MATERIALS AND METHODS
7.2.1 Animals and Surgery
Adult female Wistar COB rats (200-250g body weight) purchased
from Charles River U.K. Ltd. (Margate, Kent) were maintained under
controlled lighting (lights on 0500h-1900h) and temperature (22°C)
and allowed free access to diet 41B (Oxoid, Basingstoke, Herts) and
tap water. Animals that were subjected to surgery and allowed to
recover had access to drinking water to which had been added
aureomycin (50mg I-''').
The electrodes were implanted according to the co-ordinates of
de Groot (1959) and were as described in section 2.2.8.
Animals were allowed to recover for 7-9 days before the
collection of hypophysial portal blood. Median eminence
stimulation was carried out as described in 2.2.7.
Hypophysial portal blood was collected under anaesthesia with
sagatal over two consecutive 30 min periods as described in 2.2.6.
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Stimulation was applied during the second 30 min period using a
constant current generator and the stimulus was based on the
parameters used by Jamieson & Fink (1976). Hypophysial portal
blood was collected every minute and immediately mixed with Trasylol
lOOOKIU/ml blood in chilled plastic tubes. Peripheral blood
samples were taken from the external jugular vein immediately before
section of the pituitary stalk and mixed with Trasylol, 2000KIU/ml
blood in chilled plastic tubes. All blood samples were spun for
20 min at 1,720 x £ at 4°C and plasma stored at -40°C for assay.
In some animals, electrodes were implanted and anaesthesia
induced with sagatal. The external jugular vein was exposed and
peripheral blood samples taken immediately before and after 30 min
of stimulation as described above.
7.2.2 Localisation of site of stimulation
At the end of each experiment, animals were decapitated and the
head placed in 4% formalin in 0.9% saline for seven days. For the
removal of the electrodes, the skin was cut off from the area
covering the electrodes and the dental cement. The dental cement
was removed by placing the heads, dorsal surface downward and
supported by a piece of aluminium foil, in a glass container filled
with chloroform. After the cement had been dissolved, the
electrodes were gently removed from the brain. The brain was then
removed from the skull and stored in 4% formalin in 0.9% saline
overnight. The tissue was embedded in paraffin wax and serial 10ym
frozen sections of the brain were prepared and stained with thionine
for microscopic assessment of the position in the brain of the
stimulating electrodes. Fig. 7.1 shows representative sections
Figure 7.1 Positioning of stimulating electrodes in rat brain
Representative coronal sections of rat brain stained with
thionine showing the position of the stimulating electrode tips
in A) the amygdala (AMY) B) the ventral hippocampus (HIP) and
C) the paraventricular nuclei (PVN).
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with electrodes positioned in the amygdala, hippocampus and PVN.
7.2.3 Assays
Concentrations of CRH in plasma samples were determined as
described in 2.3.6. Plasma samples of 50-100pl were extracted with
85% methanol and set up in single aliquots due to the small sample
volume while standards and pools were extracted and set up in
duplicate. The lower limit of sensitivity ranged from 2-4pg per
tube.
Vasopressin concentrations were determined as described in
2.7. Plasma samples of 10pl and standards were set up in
duplicate. The lower limit of sensitivity ranged from 1—2pg per
tube.
Concentrations of ACTH in peripheral plasma samples were
determined as described in 2.4. Plasma samples of 20pl were set up
in duplicate with standards and pools in triplicate. The lower
limit of sensitivity ranged from 5-10pg ml .
Corticosterone concentrations were measured as described in
2.5. Single samples of 20yl of peripheral plasma were extracted
with ether, aliquots of the extract dried down and set up in the
assay in duplicate. Standards were made in duplicate in methanol,
dried down and set up in the assay.
7.3 RESULTS
7.3.1 Volume of hypophysial portal plasma collected
The volumes of portal plasma collected during the two collection
periods are shown in Table 7.1. Stimulation of most brain areas
TABLE 7.1
Mean (± S.E.M.) volumes (ul) of hypophysial
portal plasma collected during two consecutive 30 min periods
Number of animals 0-30 min 30-60 min
Experimental group per group
AMY control 6 315 ± 55 298 ± 52
PVN stimulated 17 297 ± 51 591 ± 134*
ME stimulated 8 153 ± 13 198 ± 12*
AMY stimulated 6 248 ± 56 318 ± 79
HIP stimulated 8 190 ± 35 244 ± 44*
*p < 0.05 (paired student's t test) when compared with volume of
plasma collected during the first 30 min collection period.
Stimulation was applied during the second 30 min period. AMY -
amygdaloid; PVN - paraventricular nuclei; ME - median eminence;
HIP - hippocampus.
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significantly increased the volume of plasma collected and,
therefore, the results are expressed as content (concentration x
volume of plasma) as well as concentration.
7.3.2 Stimulation of CRH and AVP into hypophysial portal blood
In 'control' animals in which electrodes had been implanted in
the amygdala but no stimulus applied, there was no significant
difference in content (Fig. 7.2) or concentration (Fig. 7.3) of CRH
in portal plasma during the two collection periods. Stimulation of
the median eminence during the second 30 min period increased the
release of CRH into portal blood but not significantly. However,
stimulation of the amygdala significantly decreased the content
(Fig. 7.2) of CRH and stimulation of the hippocampus significantly
decreased the concentration (Fig. 7.3) of CRH in portal blood by
40-50%. The CRH response to PVN stimulation depended on the
position of the tips of the stimulating electrodes. Individual
values of CRH content before and during stimulation are shown in
Table 7.2. Figure 7.4 shows that in animals in which the electrode
tips were within 0.2mm of the PVN, stimulation produced a
significant release of CRH into portal blood so that CRH content
increased 3-fold relative to that in the 30 min period before the
stimulus was applied (Fig. 7.2). Figures 7.5. and 7.6 show that
neither content or concentration of AVP in portal blood was
significantly affected by stimulation of the various brain areas.
7.3.3 Stimulation of ACTH and corticosterone into peripheral blood
Wistar rats that had been implanted with an electrode were
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Content (pg/30 min) of CRH in hypophysial portal plasma
of individual female Wistar rats with stimulating electrodes
implanted in the PVN. Hypophysial portal blood
was collected during two consecutive 30 min periods
with electrical stimulation applied during the second 30 min period




















Figure 7.4 Positioning of stimulating electrodes in the PVN and
their effectiveness in stimulating CRH release
Schematic coronal section of rat brain redrawn from de Groot
(1959), illustrating the distribution of stimulation sites around
the paraventricular nuclei (PVN). Stimulation of sites marked (#)
increased release of CRH into hypophysial portal plasma and
stimulation of sites marked (O) decreased release of CRH into
portal plasma when compared with the control, non-stimulated release
































the external jugular vein. In the control animals, electrodes were
implanted in the amygdala but no stimulation was applied. Thirty
minutes of sham stimulation did not alter plasma ACTH or
corticosterone concentrations (Fig. 7.7). Stimulation of the
amygdala for 30 min did not significantly alter plasma ACTH or
corticosterone concentrations (Fig. 7.7). In contrast, stimulation
of the PVN in all animals significantly increased both ACTH and
corticosterone concentrations 4-fold relative to that of the
concentrations in plasma before application of the stimulus
(Fig. 7.7).
7.4 DISCUSSION
The present results demonstrate that stimulation of the ventral
hippocampus and amygdala inhibits the release of CRH into
hypophysial portal blood. However, changes in CRH release on
stimulation of the amygdala did not correlate with the peripheral
plasma concentrations of ACTH and corticosterone observed after
stimulation of the amygdala in rats in which the pituitary stalk was
intact. As expected, stimulation of the PVN resulted in a 2- to
3-fold increase in CRH release into portal blood, and this
correlated with a 4-fold increase in the peripheral plasma
concentrations of ACTH and corticosterone produced by PVN
stimulation in rats in which the pituitary stalk was intact.
Stimulation of the median eminence gave variable responses with an
overall increase in CRH release which was not significant. Sham
electrical stimulation did not affect CRH release into portal blood,
or ACTH and corticosterone concentration in peripheral blood.
There was no effect of stimulation on the release of AVP into portal
blood.
Figure 7.7 Effect of electrical stimulation in the intact rat
on ACTH arid corticosterone concentrations in
peripheral plasma
Mean (± S.E.M.; n = 6) concentrations of ACTH (ng ml~l) and
corticosterone (yg/100ml) in peripheral plasma from female rats with
electrode implants before (1) and after (2) 30 min of electrical
stimulation trains (30s on, 30s off) of biphasic rectangular pulses
(50Hz, 1mA peak to peak, 1ms duration). Electrodes were implanted
in the amygdala (AMY) and paraventricular nuclei (PVN), control
animals (CON) had electrodes implanted in the amygdala but no
stimulation was applied. Blood samples were withdrawn from the
external jugular vein immediately before and after the 30 min period
of stimulation. *p < 0.001, ** p < 0.01 when compared with plasma


















Numerous studies have shown that the hippocampus modifies
adrenocortical activity. Stimulation and lesion studies have
demonstrated that the effect of the hippocampus is mainly inhibitory
(Casady & Taylor, 1976; Mangili et al., 1966; Knigge, 1961;
Feldman & Conforti, 1980; Dunn & Orr, 1984) and the present
findings show that this inhibition is mediated by a decrease in
release of CRH into portal blood. However, Dunn & Orr (1984) have
demonstrated an increase in the plasma corticosterone concentrations
following stimulation of the CA1 region of the hippocampus;
stimulation of other regions of the hippocampus decreased
corticosterone concentrations. The present results are consistent
with the findings of Dunn & Orr (1984), as in the present study, the
stimulating electrodes were positioned in the ventral hippocampus,
while the CA1 region is concentrated mainly in the dorsal
hippocampus. Dorsal hippocampectomy significantly reduced the
degree of feedback effect of dexamethasone on the adrenocortical
response to ether stress while ventral hippocampectomy had no such
effect (Feldman & Conforti, 1980). Glucocorticoid receptors are
also present at a higher density in the dorsal hippocampus (Fuxe et
al., 1985), suggesting that the dorsal hippocampal region
participates in the feedback mechanism of glucocorticoids while the
ventral region is involved in mediation of other adrenocortical
responses, such as those that follow somatosensory stimulation
(Conforti & Feldman, 1976).
Stimulation of the amygdala in the anaesthetised intact rat
resulted in a slight but not significant decrease in ACTH
concentrations in peripheral blood.
The effect of stimulation of
on CRH release into portal blood
the amygdaiyyin the present study differs from that in the conscious
rat (Carrillo & Dunn, 1977) and conscious monkey (Mason, 1959;
Frankel et al., 1978) in which stimulation of the amygdala increased
plasma corticosterone concentration. Amygdaloid stimulation was
found to be ineffective in increasing corticosterone concentrations
in rats anaesthetised with pentobarbitone in the study by Carrillo &
Dunn (1977) but stimulation of the amygdala did increase
corticosterone concentrations in the study by Redgate & Fahringer
(1973). The discrepancies in the result of amygdaloid stimulation
on corticosterone concentrations may be due, at least in part, to
the fact that different regions of the amygdala are differentially
involved in adrenocortical function (Dunn & Whitener, 1986) .
Stimulation of the ventral and lateral amygdala decreased plasma
corticosterone concentrations in rats while stimulation of the
medial, basomedial and posterocorticomedial amygdala increased
plasma corticosterone concentrations. Positioning of the
electrodes in the amygdala in the present study would result in all
regions of the amygdala being stimulated and the present results,
therefore, suggest that the amygdala exerts a predominantly
inhibitory effect on CRH release.
For the sake of clarity, only the sites of stimulation close to
the PVN have been included in the statistical analysis of the
changes in CRH release due to electrical stimulation. Jamieson &
Fink (1976) measured the spread of the square wave stimulus used in
the present study by the milk ejection response to stimulation of
the hypothalamo-hypophysial tract in a lactating rat. The
stimulatory effect was found to 'spread' over a distance of no more
than 1.5mm from the electrode tip. In the present study,
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stimulation through electrodes positioned within 0.2mm of the PVN
result in increased release of CRH, whereas stimulation of the PVN
region through electrodes removed by more than 1.5mm from the PVN
did not stimulate release of CRH into portal blood. Stimulation of
the PVN increased the release of CRH into portal blood 4-fold and in
the intact animal, significantly increased ACTH and corticosterone
concentrations in peripheral blood. The ability of electrical
stimulation of the hypothalamus to increase ACTH and corticosterone
concentrations in plasma is in agreement with the findings of
Mason (1959) and Frankel et al. (1978) in the conscious monkey and
with Dornherst et al. (1986) in the anaesthetised cat.
The present and other findings suggest that the projection from
the PVN to the external layer of the median eminence mediates the
release of ACTH. Therefore, it should be possible to stimulate the
release of CRH and AVP by stimulation of the median eminence. The
fact that this was not the case in the present study cannot be due
to maximal release as PVN stimulation increased the release of CRH
into portal blood. The lack of effect of electrical stimulation of
the median eminence was surprising as the parameters used for
stimulation in the present study have been shown previously to cause
increased release of LHRH, SS and SS28^ ^ into portal blood
(Chiappa et al., 1977; Millar et al., 1983; Sheward et al.,
1984). Furthermore, AVP and CRH release from the median eminence
can be stimulated in vitro by depolarising concentrations of
potassium (Holmes et al., 1986) and by low (lCT^M) concentrations
of e-endorphin (Buckingham, 1986). However, higher doses of
B-endorphin reduced not only spontaneous release of CRH but also the
secretion elicited by other neurotransmitters. Stimulation of the
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median eminence in vivo would also stimulate adjacent areas of the
hypothalamus such as the arcuate nucleus. Indeed, Makara et al.
(1972) have demonstrated antidromic invasion of hypothalamicneurones
nucleus
outside the supraoptic^and PVN, (e.g. arcuate and ventromedial
nuclei) following stimulation of the median eminence. The arcuate
nucleus is the source of B-endorphin in portal blood (Wardlaw et
al., 1982; Wehrenberg et al., 1982; Sarkar & Yen, 1985) and,
therefore, one possibleexplanation of the fact that median eminence
stimulation did not produce an increased release of CRH is that
stimulation of the median eminence also releases B-endorphin from
the arcuate nucleus which acts to inhibit CRH release. Renaud
(1978) has demonstrated recurrent inhibition in parvocel1ular
neurosecretory neurones following stimulation of the median
eminence. Renaud suggested that neurosecretory neurones not only
have terminals in the median eminence but also produce axon
collaterals which form part of an inhibitory feedback pathway to the
parent neurone either directly by a synapse on the neurone of origin
or indirectly through a transynaptic excitation of local
interneurones whose axons then terminate on the neurosecretory
cell. Any of these pathways could account for the fact that median
eminence stimulation produced only a small increase in CRH release
compared with that produced by stimulation of the PVN.
In conclusion, electrical stimulation of the amygdala and
hippocampus have an overall inhibitory effect on the release of CRH
into hypophysial portal blood but this did not correlate with a
decrease in the release of ACTH or corticosterone into peripheral
blood. Facilitation of ACTH release by PVN stimulation appears to
be a direct result of increased release of CRH into portal blood.
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However, in the physiological situation, stimulation of ACTH release
by AVP cannot be excluded. From the results of the present study,
the PVN appears to be the major central node controlling the release
of ACTH from the anterior pituitary gland. The different responses
to stimulation in the release of CRH and AVP is also indicative of





The techniques of hypophysial portal blood collection and
radioimmunoassay were used to examine the relative importance and
the relationships between corticotrophin releasing hormone (CRH),
vasopressin (AVP) and oxytocin (OT) in stimulating the secretion of
adrenocorticotrophin (ACTH) in vivo. Factors affecting synthesis
of proopiomelanocortin (POMC), the precursor for ACTH, were examined
by measuring the content of POMC mRNA in the anterior pituitary
gland by Northern blot analysis.
It is well established that the secretion and synthesis of ACTH
is modulated by the negative feedback action of glucocorticoids.
Therefore, to examine the mechanism of negative feedback of
glucocorticoids, the effect of adrenalectomy on the release of CRH,
AVP and OT into portal blood, the pituitary responsiveness to CRH
and on the content of POMC mRNA in the anterior pituitary gland was
examined. Removal of the negative feedback of glucocorticoids by
adrenalectomy increased the content of POMC mRNA in the anterior
pituitary gland and also increased the secretion of ACTH into
peripheral plasma. The increase in the release and synthesis of
ACTH after adrenalectomy is a direct result of the significant
increase observed in the release of CRH and AVP into portal blood
after adrenalectomy. Hypothalamic content of CRH mRNA (Jungami et
al., 1985) and AVP mRNA (Davies et al., 1986) have been shown to
increase after adrenalectomy suggesting that the increase observed
in the present study in the release of CRH and AVP into portal blood
is due, at least in part, to the increased synthesis of the
precursors for CRH and AVP. Replacement of glucocorticoids for an
intermediate time period in adrenalectomised rats decreased the
release of AVP but not CRH into portal blood when compared with
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untreated adrenalectomised rats. These results suggest there is
differential regulation of CRH and AVP release by glucocorticoids at
the intermediate level of feedback. Differential regulation of CRH
and AVP has also been observed in response to haemorrhage (Plotsky
et al., 1985b) and in response to insulin-induced hypoglycemia
(Plotsky et al., 1985c).
Although the release of CRH into portal blood is unaffected by
restoration of negative feedback for 3h, the effectiveness of CRH in
stimulating ACTH secretion is drastically reduced by a reduction in
the responsiveness of the pituitary gland to CRH. These findings
suggest that glucocorticoids exert their action on the hypothalamus
and on the pituitary gland to control ACTH secretion.
A variety of stressors are well known to cause release of ACTH
and glucocorticoids into peripheral plasma. To determine whether a
short-term increase in the demand for ACTH secretion would be
accompanied by an increase in the synthesis of ACTH, the content of
POMC mRNA in the anterior pituitary was measured at various time
points after a 5 min period of ether stress. Ether stress
immediately increased the peripheral plasma concentrations of ACTH
and corticosterone 10- and 3-fold respectively, 6h later, ACTH
concentrations were 5-fold higher than in the control animals.
Twenty-four hours after the stress, plasma concentrations of ACTH
and corticosterone were similar to those in control animals. After
6h, POMC mRNA content in the anterior pituitary gland was 2-fold
greater than in control animals, suggesting that the biosynthetic
and secretory activities of the anterior pituitary gland are coupled
to enable the animal to respond to stress with a dramatic increase
in ACTH release.
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The neural apparatus which regulates adrenocortical function is
generally held to comprise of two components: a hypothalamic
component and a limbic-midbrain component. The effect of
electrical stimulation of the various brain areas implicated in the
regulation of adrenocortical function on the release of CRH and AVP
into hypophysial portal blood was examined. Changes in the release
of these peptides were then compared with the effect of electrical
stimulation on the synthesis of ACTH and on ACTH and corticosterone
concentrations in peripheral plasma in animals in which the
pituitary stalk was intact. The release of CRH into portal blood
was significantly increased during stimulation of the PVN and this
correlated with a significant increase in ACTH and corticosterone in
peripheral plasma following 30 min of PVN stimulation. However,
POMC mRNA content in the anterior pituitary gland was unchanged 6h
after electrical stimulation of the PVN suggesting that the increase
in CRH release was not sufficient to increase transcription of the
POMC gene. Stimulation of the amygdala and the hippocampus reduced
the release of CRH into portal blood. However, the decrease in CRH
release following stimulation of the amygdala did not correlate with
changes in ACTH and corticosterone concentrations in animals in
which the pituitary stalk was intact and there was no change in POMC
mRNA content in the anterior pituitary gland. Stimulation of the
median eminence did not significantly increase the release of CRH.
Release of AVP into portal blood was not altered by stimulation of
any of the brain areas tested. The parvocellular region of the PVN
contains AVP and CRH neurones that terminate on hypophysial portal
blood vessels in the median eminence and, therefore, it could be
expected that stimulation of both the PVN and the median eminence
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would increase the release of CRH and AVP into portal blood.
However, stimulation of the median eminence in vivo would also
undoubtedly stimulate adjacent areas of the hypothalamus such as the
arcuate nucleus, which is the source of B-endorphin in portal blood
(Sarkar & Yen, 1985). Therefore, it is possible that B-endorphin
is also released during stimulation of the median eminence with the
result of inhibiting the release of CRH and AVP into portal blood.
Renaud (1978) has demonstrated recurrent inhibition in parvocel1u1ar
neurosecretory neurones following median eminence stimulation.
Renaud suggested that neurosecretory neurones produce axon
collaterals which form part of an inhibitory feedback pathway to the
parent neurone either directly or indirectly through local
interneurones, whose axons then terminate on the neurosecretory
cell. These pathways could account for the small increase observed
in CRH release into portal blood during stimulation of the median
eminence. These results suggest that the PVN is the major central
mode for regulating adrenocortical function.
The possibility that release of opioid peptides during median
eminence stimulation could inhibit the release of AVP and OT was
examined as it had proved impossible, by electrical stimulation, to
increase the release of these peptides from the median eminence in
vivo. Infusion with naloxone lh before and during electrical
stimulation of the median eminence did not affect the release of AVP
and OT into portal blood. This was surprising, as there are many
reports on the inhibition of OT release and a few reports on
inhibition of AVP release from the neurophysis by opioid peptides.
An inhibitory role for opioid peptides in the control of release of
AVP and OT cannot be ruled out. The inhibitory and stimulatory
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actions of B-endorphin on CRF release have been shown by Buckingham &
Cooper (1986) to be mediated by different opioid receptor types.
The 6 receptors thought to be involved in the inhibitory action of
B-endorphin are not readily antagonised by naloxone. Therefore, in
the present study, the lack of effect of naloxone cannot rule out
the possibility that opioid peptides prevent an increased release of
AVP and OT into hypophysial portal blood in response to electrical
stimulation.
The first, and major, endocrine abnormality to be described in
the homozygous Brattleboro rat was the lack of AVP which results in
diabetes insipidus. Schmale & Richter (1984) have shown that there
is a single base deletion in the protein coding region of the AVP
gene which results in an 'out of frame' reading sequence and,
therefore, impedes AVP mRNA translation. In spite of this, AVP
immunoreactivity has been shown in the ovary, adrenal gland and
anterior pituitary gland of the homozygous Brattleboro rat. In the
present study, AVP immunoreactivity was found in hypophysial portal
blood from homozygous Brattleboro rats at concentrations of
approximately 50% of those found in control Long Evans rats.
Portal blood from homozygous Brattleboro rats was further analysed
by high performance liquid chromatography and the 'AVP' was found to
be identical to authentic AVP. Hypothalamic AVP was undetectable
in homozygous Brattleboro rats and this could be due to the dilution
factor used in the assay being too high or it could reflect a highly
efficient processing of AVP from the hypothalamus, at the level of
the external layer of the median eminence, into portal blood.
These results combined with the evidence of Mezey et al. (1986) that
homozygous Brattleboro rats make small amounts of the normal AVP
-127-
precursor in the PVN and in the posterior pituitary suggests that
the defect in the homozygous Brattleboro rat is not the same as the
defect reported by Schmale & Richter (1984). Alternatively, there
may be more than one AVP gene and they can be processed in a
tissue-specific manner which results in a relatively high
concentration of AVP in portal blood but very little AVP in the
posterior pituitary gland.
There was no significant difference in CRH or OT concentrations
in portal blood between control Long Evans and homozygous or
heterozygous Brattleboro rats. ACTH and corticosterone
concentrations in peripheral blood were lower in Brattleboro rats
compared with Long Evans rats, but the difference was only
significant in the heterozygous Brattleboro rat. The slight
reduction in ACTH and corticosterone in the homozygous Brattleboro
rat may be due to the reduced secretion of AVP into portal blood.
However, given the synergistic relationship of AVP with CRH, a
greater deficit might be expected in ACTH secretion in the
Brattleboro rat. In both genotypes of Brattleboro rat, POMC mRNA
in the anterior pituitary gland is 2-fold more abundant than in
control Long Evans rats. Therefore, it may be possible that the
adrenocortical feedback system has a different set point in
Brattleboro rats, the reduced concentration of corticosterone having
less feedback effect on the anterior pituitary gland, thereby
increasing POMC mRNA synthesis and ACTH release.
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Detection of Specific Nucleic Acid Sequences within Heterogeneous
Populations of Molecules by Gel Transfer Hybridisation
A type of gel transfer hybridisation has been developed to
analyse the distribution of specific RNA sequences within a
population of electrophoretically fractionated RNA molecules. A
solid-phase support is used to bind and immobilise the RNA in the
position to which it has migrated on a gel. This technique is
described as 'Northern' blotting. The support originally used is
paper derivitised with diazobenzyl-oxymethyl groups to which
single-stranded nucleic acid will bind covalently. It has
subsequently been shown that nitrocellulose sheets will bind RNA
that is fully denatured. This is also important to achieve a linear
inverse relationship between the mobility of an RNA molecule and its
molecular length. The gels are therefore run in the presence of
methylmercury, glyoxyl or formaldehyde as denaturing agents.
Following its transfer to diazobenzyl-oxymethyl paper or
nitrocellulose, the immobilized RNA can be hybridised with a
radiolabeled DNA probe. In order to prevent non-specific binding
of the radiolabeled DNA probe, the di azobenzyl-oxymethyl paper or
nitrocellulose is incubated for 2-4 h in a prehybridisation buffer
which contains denature salmon sperm DNA. Hybridisation of the DNA
probe to RNA immobilised on nitrocellulose is carried out for 16 h
at 42°C in a buffer which contains 50% formamide and 5-10% dextran
sulphate. Hybridisation reactions are faster in an aqueous solution
at 68°C but the high temperature presents problems of evaporation
and damage to the nitrocellulose. In the presence of dextran
sulphate, the rate of association of nucleic acids is accelerated
because the nucleic acids are excluded from the volume of the
solution occupied by the polymer. However, the use of dextran
sulphate is not always necessary to detect sequences of interest.
It is also difficult to handle because of its viscosity and it can
sometimes lead to high backgrounds. The DNA probe is added to the
nitrocellulose in as small a volume of hybridisation buffer as
possible. The kinetics of nucleic acid reassociation are faster and
the amount of probe may be reduced. However, it is essential that
sufficient liquid be present for the nitrocellulose to remain at all
times covered by a film of the hybridisation solution. Excess
radiolabeled DNA probe is then washed off the nitrocellulose and
the nitrocellulose autoradiographed with the aid of intensifier
screens.
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